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Evidence suggests that host immunity has an important bearing on
the growth and spread of malignant tumours. Naturally occurring immuno¬
suppressive substances have been demonstrated in the plasma of cancer
patients, but the nature and relevance of such factors to the impaired
immunity of cancer patients and to tumour behaviour are poorly understood.
Cellular immunity is impaired in malnourished subjects also; although
nutritional repletion with fat-free intravenous fluids may improve
nutritional and immunological parameters, the immunological consequences of
using solutions rich in polyunsaturated fatty acids are largely unknown.
The aims of the study were to quantify the lymphocyte suppressive
activity of plasma (plasma suppressive activity, PSA) and to identify
specific substances associated with suppressive activity in plasma from
normal subjects, and patients with benign or malignant diseases and with
various degrees of malnutrition. Also, an attempt was made to correlate
PSA with tumour behaviour in an animal model, firstly by measuring PSA
before, during and after tumour growth, and secondly by observing tumour
growth after artificially increasing PSA. In other studies in vitro
lymphocyte reactivity was measured firstly after incubation with fat
emulsion, and secondly in patients receiving parenteral fat emulsions.
The study found that PSA was low in healthy subjects and patients
with benign disease, and was associated entirely with the plasma protease
inhibitor alpha-2-macroglobulin (A2M). PSA was raised moderately, although
significantly, in malnourished patients with benign disease and correlated
significantly with the extent of nutritional impairment; PSA was associated
mainly with A2M but also with a small molecular weight peptide fraction.
Patients with malignant disease had very high PSA which did not correlate
with nutritional impairment and which was associated mainly with A2M but
also with immune complexes, IgG, Fc fragments and a small molecular weight
peptide fraction. Plasma A2M concentrations did not differ significantly
between subject groups although the amount of suppressive activity
associated with A2M did. PSA increased with tumour growth in the animal
model but returned to pre-tumour levels after complete removal of tumours.
Tumour growth was increased significantly in animals in which PSA was
elevated at the time of tumour transplantation. Intravenous fluids
containing fat significantly depressed in vitro lymphocyte reactivity in
the laboratory and clinical studies.
The study shows that A2M is an important regulator of lymphocyte
reactivity in health and in malignant disease, and demonstrates a mechanism
of immunological evasion by tumours by way of naturally occurring immuno-
regulatory plasma factors.
PGS/ABST/81 Use this side only
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INTRODUCTION
The thesis examines the role of naturally occurring
immunosuppressive substances, mainly in relation to malignant disease but
also in malnutrition. Members of the laboratory in which the work was
performed had undertaken studies of naturally occurring lymphocyte
suppressive activity in relation to organ transplantation and, as the
author had interests in surgical oncology and immunology, attention was
directed towards investigating suppressive substances in cancer patients.
It appeared to the author that a paradox existed in the interaction
of tumours with their hosts. On the one hand, the literature indicated
that an immunologically competent subject could respond specifically to new
or foreign antigenic material and reject it, and that tumour-bearing
patients and experimental animals frequently exhibited specific immune
responses to tumours or tumour extracts. On the other hand, it was obvious
that cancers grew progressively, even in patients in whom specific immune
responses could be demonstrated. Thus, it appeared that tumours had found
a way of evading either detection or destruction by the hosts' immune
responses, a concept known as "immunological escape". This thesis
considers the part played by naturally occurring plasma factors in the
immunological escape of tumours.
The experimental work involved four distinct stages. First,
lymphocyte reactivity and the ability of plasma to suppress lymphocyte
reactivity was measured and quantified in three groups of subjects -
healthy volunteers and hospitalised patients with benign or malignant
disease. The influence of nutritional status had to be taken into account
when the results were analysed. Second, plasma from a small number of
subjects from each of five experimental groups - healthy volunteers, benign
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well nourished, benign malnourished, malignant well nourished and malignant
malnourished subjects - was analysed in detail with the aim of identifying
the substances responsible for suppressive activity and assessing the
relative contribution of each substance. Third* experiments were
undertaken to assess the effects on lymphocyte reactivity of solutions used
for parenteral nutrition in malnourished patients. Fourth, an animal model
was used in an attempt to correlate tumour growth with lymphocyte
suppressive activity in plasma and to observe tumour growth when
suppressive activity was increased by means unrelated to tumour activity.
The thesis is presented in six chapters. The literature review
(Chapter 1) examines the immune response and its control in relation to
anti-tumour mechanisms, and reviews the principal, currently recognised
ways by which tumours evade immune attack. The biological role of the
plasma protease inhibitor alpha-2-macroglobulin as a non-specific
inhibitory substance is reviewed and hypotheses are proposed concerning
alpha-2-macroglobulin in cancer patients. A review of some aspects of the
literature on malnutrition identifies the nutritional deficiencies which
are present in many cancer patients, highlights the wide-ranging
consequences of malnutrition on the immune system and critically assesses
current methods of nutritional assessment. Although the literature
indicates that nutritional repletion of malnourished individuals can
reverse many of their immunological deficiencies, there is very little data
concerning the immunological effects of fluids used for parenteral
nutrition; this lack of information provided the stimulus for studies of
parenteral feeding solutions.
The methods used for the experimental work are presented in chapter
two; they include the Tanned Erythrocyte Electrophoretic Mobility (TEEM)
X
test, gel filtration chromatography, single- and fused-rocket Immuno¬
electrophoresis, immuno-specific affinity chromatography, a polyethylene
glycol precipitation technique and radial immunodiffusion. The background,
development and method of the TEEM test are presented', because the test is
not used widely at present and has been misrepresented and misinterpreted
in the past. The methods of nutritional assessment are presented.
The results are presented in chapters three, four and five. Chapter
three contains the results of studies of lymphocyte reactivity and plasma
suppressive activity, and the influence of nutritional status and the site
and stage of malignant diseases on these two parameters. The results of
experiments with plasma fractions and individual suppressive substances are
also presented. The studies of the effects of nutritional fluids on
lymphocyte reactivity and the results of lymphocyte reactivity in patients
receiving parenteral nutrition are presented in chapter four. The results
of tumour growth studies in animals are given in chapter five.
The results of most of the experiments are discussed individually
within appropriate sections. The experimental work is discussed as a
whole, and in relation to the reviewed literature and the author's
hypotheses, in chapter six. A further mechanism of immunological escape is
proposed and an explanation is offered for the apparent paradox of tumour
growth in the presence of specific anti-tumour immune responses. A list of






It is often thought that cancer is a disease of modern times but
malignant disease has affected mankind from the time of his first
appearance on earth. Pithecanthropus, the Java 'ape-man' discovered in
1891 and believed to be about half a million years old, had a tumourous
growth on his femur. Ancient manuscripts from Egypt and India, written
centuries before Christ, describe ulcerating tumours, and the early Greek
physicians, including Hippocrates, wrote of men being plagued by a variety
of growths with peculiar features. Galen wrote a treatise on tumours and
classified them as benign or malignant. As humans now live considerably
longer than in former times and as malignant disease is generally more
common with increasing age, cancer has now become the second commonest
cause of death in the western world.
Although cancer has been studied extensively, an entirely
satisfactory definition of malignancy has yet to be formulated. Many
'definitions' of cancer are in fact observations or descriptions of the
behaviour of neoplastic cells, either grouped together as solid tumours or
disseminated as haematological malignancies.
Malignant tumours have several characteristic features. Firstly,
the growth of constituent cells is not under the same control as that of
normal tissues, with the result that growth is disorganised and unco¬
ordinated. Secondly, malignant cells have the ability to invade host
tissues by direct extension and dissemination through the circulation,
lymphatic channels and across body cavities to sites unconnected with the
primary growth. Uncontrolled growth and spread impairs normal function of
involved tissues by biochemical or mechanical means and eventually kills
the host.
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1.1.1 TRANSFORMATION AND EVASION
The development and progression of cancer involves two fundamental
processes, namely transformation and evasion. Transformation removes the
growth-limiting restrictions from a cell so that it continues to divide and
produce generations of cells similarly free of growth limitations. If
transformation was all that was required for a cell to grow successfully as
a neoplastic cell then it must be a rare event, considering the rate of
cell turnover in the body in comparison with the incidence of cancer. Cell
marker studies indicate that experimental carcinogens transform normal
cells with a frequency several orders of magnitude higher than the observed
rate of overt tumour development. Thus, it appears that not all
transformed cells survive to produce clinically detectable neoplasms.
One explanation for the discrepancy between rates of transformation
and cancer occurrence is that the human immune system is able to prevent
transformed cells from becoming overt tumours. Burnet^1,2), in 1957,
proposed the concept of "immune surveillance" whereby cells of the host's
immune system detect and destroy 'foreign' malignant cells. Burnet's
theory has been debated intensively by protagonists(3-6) ancj
antagonists^7-11), and has not received universal acceptance. If
transformation is not a rare event, then anti-tumour mechanisms must be
highly effective in eliminating transformed cells early in their natural
history. At present, it is not possible to measure the success of anti-
tumour mechanisms as there is no way of detecting in vivo when the growth
and reproduction of transformed cells is overcome. It is evident that many
transformed cells are not eliminated and undergo the second critical
process of evasion.
Evasion allows transformed cells to resist destruction by immune
responses of the host and, as a consequence, transformed cells continue
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their pattern of abnormal growth and a malignant tumour is formed. In
spite of an enormous amount of study, the precise role of the host's immune
system in the development, control and progression of malignant tumours is
unclear. Many tumours in humans and experimental animals are able to
stimulate specific immune responses within their hosts and, although such
responses may retard the growth and dissemination of the tumour by killing
malignant cells, the tumour is still able to proliferate and overcome the
host.
1.2 THE IMMUNE RESPONSE
The human immune system is a highly complex, integrated homeostatic
mechanism of defence against foreign material which may threaten the
integrity of the host. It has non-specific and specific components. Non¬
specific or innate components include mechanical barriers to pathogens
(skin, mucous membranes), bacteriocidal substances in tissues and body
fluids (lysozyme, complement, basic peptides), and the process of
phagocytosis or entrapment within circulating phagocytic cells (monocytes)
or tissue phagocytes (macrophages). Once a foreign antigen has penetrated
or by-passed these first-line defences it comes into contact with cells of
the immune system, whereupon specific immune responses occur. Two
different specific responses may arise: (a) the humoral response:
production of antibodies by plasma cells derived from bursa-dependent (B)
lymphocytes, and (b) the cell-mediated response: production of specifically
sensitised lymphoid cells processed by or dependent upon the thymus
(T lymphocytes) to become either effector cells of cell-mediated immunity
or regulators of other immune cells.
Initiation of an immune response requires the interaction of
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antigen with an antigen presenting cell (APC) of the macrophage series.
Macrophages act as accessory cells in the immune response and are essential
for the activation of T lymphocytes; their function is initial binding and
presentation of antigen to lymphocytes and regulation of lymphocyte
responsiveness by secretion of suppressive and enhancing factors(12)
Processing of antigens by APC is required for optimal antigenicity
and may influence the nature of the induced immune response^13-15)
Physical interaction between antigen-bearing macrophages and lymphocytes is
required for functional differentiation and maturation of lymphocytes
during an immune response, and requires that the cells have their major
histocompatibility complex (MHC) antigens in common. The APC cell membrane
is a site of expression of histocompatibility linked immune response (Ir)
genes which regulate T cell activity(16*17). Antigens are presented to
T cells in some structural or functional association with antigenic
determinants encoded by Ir genes (la determinants or class II MHC
molecules) on the cell surface of the macrophage. T lymphocytes then
recognise the antigen - la complex by way of antigen-specific membrane
receptors, some of which carry determinants coded by MHC genes(18).
Following antigen recognition, T cells become primed. An antibody response
may occur if B lymphocytes have already bound the antigen to their surface
receptors and have produced the "first signal" which has led to
inactivation of the cell (i.e. tolerance); interaction and co-operation
between primed T cells and B cells produces the "second" or activating
signal^19). After antigenic stimulation, differentiating plasmablasts and
plasma cells appear within lymphoid tissue. Alternatively, a cell-mediated
response occurs if the T cell is activated by interaction with the
macrophage-associated antigen and a signal is passed to the cell nucleus so
that lymphocyte transformation occurs. Although the "two signal"
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model(19-20) js not accepted universally, it serves as a useful schema for
understanding cellular interactions and co-operation in the immune response
to antigen.
Cell-mediated immune responses are brought about by two effector
mechanisms: firstly, by the release from lymphocytes of biologically active
substances called lymphokines,22) which modulate activities of other
cells involved in immune and inflammatory responses, and secondly, by the
generation of lymphoid cells with cytotoxic ability.
1.2.1 LYMPHOKINES
Lymphokines are produced by T and B cells and make an important
contribution to the efferent limb of the immune response by local
amplification of the sequelae of lymphocyte-antigen interaction.
Rocklin^S) has estimated that less than 59s of the cellular infiltrate of a
cutaneous delayed hypersensitivity reaction (CDHR) is sensitised
specifically to the antigen initiating the reaction, the remainder of
infiltrating mononuclear cells being recruited non-specifically by
lymphokines released from sensitised lymphocytes. Lymphokines also
participate in local regulation of immunological responses as some have
helper and suppressor activities and others exert a local negative feedback
effect to prevent excessive production of lymphokines^4)
Plasma protease inhibitors (Section 1.5.8) have an important
in vivo function in the regulation of immune responses by complex
interaction with lymphokines and lymphokine inhibitors(♦26^.
1.2.2 CELL-MEDIATED CYTOTOXICITY
Cell-mediated cytotoxicity refers to lysis of targets by one of
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three mechanisms which involve specialised effector cells: (a) T lymphocyte
cytotoxicity (CTL), (b) antibody-dependent cellular cytotoxicity (ADCC),
and (c) cytotoxicity exhibited by activated macrophages.
Generation of cytotoxic T lymphocytes (CTL) with antigenic
specificity occurs after interaction of a T lymphocyte with an antigenic
determinant associated with MHC antigens^27). Unlike ADCC, target cell
killing by CTL is a cyclic phenomenon in as much as a single CTL has the
capacity to lyse more than one target cell^28). Expression of T cell
cytotoxicity is restricted to lymphocytes bearing MHC antigens shared or
cross-reacting with sensitising cells. CTL can be induced in vitro in
response to viral, xenogeneic and modified "self" antigens recognised in
association with MHC antigens, which provide the primary stimulus for CTL
when complexed with "foreign" antigenic determinants(29).
1.3 REGULATION OF THE IMMUNE RESPONSE
The immune system depends on sophisticated regulatory mechanisms
for maintenance of its functional integrity. The major factors influencing
or regulating immune responses include host genetic factors, lymphocytes
with suppressor functions and anti-idiotypic networks. Non-specific
immunoregulatory factors and changes in antigenicity have an important
bearing on immune responsiveness and are discussed in the section dealing
with the escape of tumours from immune destruction (Section 1.5).
1.3.1 GENETIC CONTROL
Immune responsiveness is controlled by Ir genes, the products of
which act by influencing the size and specificity of an immune response.
Some Ir genes act non-specifically, as if setting the "background tone" of
responsiveness, while others influence the host's response to specific
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antigens^33). Genes controlling antibody responses to a variety of
synthetic and naturally occurring proteins are linked by chromosomal
positioning of genes with the MHC^31). MHC linkage of Ir genes may be.
observed when the dose of stimulating antigen is sufficiently low for only
one imrauno-dominant determinant to be recognised. As the response to each
determinant of a complex antigen is controlled by separate Ir genes, it is
unlikely that the various antigenic determinants would be associated
consistently with either all high or all low responder Ir genes, but rather
a mixture of high and low responses would be expected^3-^) . Therefore,
genetic control becomes an important influence on the host's ability to
launch an effective response against an antigen with multiple epitopes
(such as a tumour cell) if, for example, the individual has predominantly
weak responses to the complex antigen^32).
1.3.2 SUPPRESSOR T LYMPHOCYTES
Human T lymphocytes with a suppressor function (suppressor
T cells - Ts) can be distinguished from other T and B lymphocytes by
surface phenotype and biological properties. Membrane determinants of Ts
include the presence of Fc receptors, and differentiation antigens detected
by monoclonal antibodies (e.g., 0KT8) or heterologous antisera. T cell-
mediated immune suppression performs at two functionally distinct levels:
(a) antigen specific or non-specific suppression, which is dependent on
exposure of host cells to antigens or mitogens respectively, and
(b) idiotypic suppression, which is brought about by interaction of
lymphocytes with idiotypic determinants on antibody molecules formed
specifically in response to antigens. This second suppressive network has
the advantage that the anti-idiotype specific Ts induced by the
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immunoglobulin molecule can still exert control of immune reactivity after
the antigen has been eliminated and after the specific antigen-induced Ts
cell activity has declined.
Long-lived memory suppressor cells are produced in response to
antigen exposure so that subsequent exposure leads to an augmented
suppressor response which is important in the maintenance of tolerance and
immune homeostasis(33). Suppressor T cells are involved in regulation of a
wide range of immune responses including antibody production(34),
expression of delayed hypersensitivity(35), induction of tolerance in
humoral and cell-mediated responses^3®), induction of suppression by the
mitogen Concanavalin A (Con A)(37), suppression of immune responses in
neonates^38) and the elderly^39), and suppression to self antigens^40,41).
Because of the far reaching influences of Ts in immune regulation and
tolerance, it is not surprising that imbalances of Ts activity have been
associated with several disease states. Manipulation of the immune system
through T cell suppression could be a possible mechanism by which a tumour
could evade destruction by the host. The possible role of Ts in tumour
evasion is discussed in Section 6.1.
1.3.3 ANTI-IDIOTYPIC NETWORKS
The network model of anti-idiotype responses as proposed by
Jerne^42) in 1974 provides a theoretical model of immune regulation by
antibody-cell interactions. Following contact with antigen, antibodies are
formed with common specificity but with different antigen binding sites
("idiotypes"). B lymphocyte cell surface receptors have the same idiotype
as the immunoglobulin which they secrete. The network theory states that
the host has the ability to respond to these idiotypes ("auto-anti-
idiotype" responses) and to form antibodies against them ("anti-idiotypic"
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antibodies). Anti-idiotypic antibodies can inhibit formation of antibody-
forming cells and suppress the generation of antibody or cell-mediated
responses. Suppression or enhancement is brought about by binding of the
anti-idiotypic antibody to the antigen-specific cell surface receptor
("idiotype"). Thus, the idiotype can act as either an antibody by
combining with the antigenic determinants of the antigen molecule
("epitope"), or as an antigen by combining with the anti-idiotype.
While there is no doubt that auto-anti-idiotypic responses play a
significant role in immune regulation, tolerance and auto-immunity,
evidence is awaited concerning the role of anti-idiotypic networks in the
development or progression of transformed cells and clinical malignancy.
1.4 THE.. IMMUNFL RESPONSE AOATNST CANCER
1.4.1 TUMOUR ANTIGENS
A tumour antigen is any molecular arrangement present within or on
a malignant cell but not in healthy cells of the same original tissue at
the same stage of development of that tissue. Four different species of
tumour antigens have been classified: (1) tumour specific antigens (TSA),
a rare class of antigens found only on malignant cells, (2) organ specific
antigens (OSA), cross reacting antigens from tumours derived from common
tissues. It is uncertain whether OSA are truly organ specific or are in
fact (3) oncofoetal antigens (OFA), which are synthesised by a limited
number of cells in embryonic tissues and are either absent from healthy
adult cells or present at low concentrations. (4) Tumour associated
transplantation antigens (TATA) are located on the surface of tumour cells
and are capable of protecting pre-immunised animals against subsequent
challenge with the same tumour; most TATA are not specific for malignant
10
cell clones and may be detected on embryonic cells and cells infected with
but not transformed by oncogenic viruses, and so these antigens are better
regarded as "tumour-associated" rather than "tumour-specific"
transplantation antigens'^).
Identification of the precise nature of "tumour surface and
intracellular antigens is not only of academic interest. Malignant tumours
have been regarded as variants of organ allograftsand in some respects
a parallel may exist between allograft rejection and tumour elimination.
However, allografts are rejected universally from unmodified recipients
while malignant tumours frequently progress in spite of' specific
immunological reactions by the host, indicating that the immunogenicity of
the two tissues is different. Altered antigenicity of tumour cells may be
one factor contributing to their immunological escape (Section 1.5.3).
Several biological functions have been ascribed to tumour antigens
(reviewed by Ristow'5)). Tumour antigens may represent important receptor
sites on the cell surface or may have enzymatic activity which influences
the malignant potential of the tumour. Haywood et al'6) found an inverse
relationship between the frequency of normal transplantation antigens (H-2)
and tumour specific antigens on the surface of cells transformed by
methylcholanthrene in syngeneic mice: tumours which were highly immunogenic
had quantitatively less H-2 antigen on their cell surfaces and vice versa,
and early lung metastases were associated with low levels of tumour
specific immunogenicity and high levels of H-2 antigenicity. These
observations suggest that tumour specific antigens play a role in the
tumour-host relationship in that the highly immunogenic tumours remained
localised while tumours of low immunogenicity were able to metastasise.
Thus, surface antigens on tumour cells may be important determinants of the
malignant potential of a tumour and, by implication, the success or
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failure of the host's immune response in arresting tumour spread.
The existence of tumour antigens distinct from surface molecules of
normal cells suggests that it is reasonable to expect specific tumour-
directed immune responses in subjects bearing malignant tumours.
1.4.2 ANTIBODY RESPONSES TO TUMOURS
1.4.2 (a) Circulating antibodies
Anti-tumour antibodies have been detected in the sera of many
patients with different malignant diseases. Antibodies directed against
intracellular antigenic constituents are of uncertain significance; other
antibodies, directed against tumour cell surface components, may be formed
in response to TSA or TATA. Reactions of cancer sera against allogeneic
tumours of similar histogenesis could be due to antibodies formed against
TATA, more than one of which may be expressed by a given tumour cell^43).
The situation is confused by the presence of "anti-tumour"
antibodies {or at least antibodies cross-reacting with tumour cell lines)
in apparently healthy individuals. Edynak et al(4^) detected antibodies
directed against in vitro cultured allogeneic breast cancer cells in 22 of
24 patients with early breast carcinoma but also in 4 of 20 age and parity-
matched healthy individuals. The antibodies detected in healthy controls
could have been allo-antibodies cross-reacting with TATA as no
consideration was given to histocompatibility differences. Also, it is
conceivable that some subjects had overcome and eliminated transformed
malignant cells and that circulating antibodies were the remaining evidence
of a successful immunological challenge.
Some studies have found higher titres of antitumour antibodies in
patients with smaller tumours and have noted a decline in antibody titres
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with advanced malignancy. This may be due to adsorption and sequestration
of antibody by large tumours, or decreased antibody production as a result
of antigenic modulation ( Section 1.5.3), or general impairment of immune
function with advanced malignancy(^8). Alternatively, anti-idiotypic
antibodies could combine with anti-tumour antibodies so that they are no
longer detectable as freely circulating antibody. Anti-idiotypic
antibodies have been identified in some patients with malignancy: anti-Ig-
Fc antibodies have been isolated from tumours and serum of patients with
melanoma and carcinoma of the lung, tongue, colon, rectum, skin and
breast^50), and anti-Fc and anti-Fab antibodies have been detected in
females with breast carcinoma^!) # j^e biological significance of anti-
idiotypic antibodies in cancer patients is uncertain but theoretically they
could result in suppression of responses against tumour antigens or induce
tolerance towards them (Section 1.3.3).
1.4.2 (b) Tumour-associated antibodies
Immunoglobulins can be demonstrated also within solid tumours.
Tumour-associated antibodies are usually of the IgG class in experimental
animals while several classes have been detected in human tumours. Roberts
et al^52) identified IgG and IgA in all extracts from malignant breast
tumours in 55 women but demonstrated IgM in only 19 of the 55 extracts.
Levels of IgG in these malignant tumours correlated with the intensity of
round cell and plasma cell infiltrate^52), suggesting that the antibodies
were synthesised in situ. Indeed, antibody production within tumours
in vitro has been demonstrated by Hurlimann et al(53) in cultures of human
breast cancer.
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1.4.2 (c) The role of anti-tumour antibodies
The obvious role of "antitumour" or tumour-associated antibodies is
destruction of tumour cells, and several mechanisms have been identified by
which tumour cells can be eliminated by antibodies.
Firstly, Ran et al(54) demonstrated complement dependent lysis
(CDL) of tumour cells: their syngeneic polyoma virus-induced sarcoma
(SEYF - a) stimulated a strong antibody response in a murine host and
antibody localised on tumour cells; addition of exogenous complement
resulted in tumour cell lysis. Although CDL is effective in vitro, its
relevance in vivo has been questioned^4®), especially in species (such as
rodents) in which the complement system is developed poorly.
Secondly, specific antibodies can co-operate with macrophages,
polymorphonuclear leukocytes and mononuclear "killer" cells from non-
immunised donors to bring about lysis of a target cell, a phenomenon called
antibody dependent cell-mediated cytotoxicity (ADCC)(5®). All of these
lymphoreticular cells have Fc receptors. ADCC occurs when specific IgG
attaches to appropriate antigenic determinants (epitopes) of the target
cell by the Fab component; the non-sensitised effector cell attaches to the
intact Fc portion of the IgG molecule which effectively bridges the
effector and target cells.
Thirdly, tumour cell destruction can be achieved by macrophages as
a result of opsonisation by specific antibody^5®). Haskill et al^57)
showed that dispersed cells from the murine T1699 spontaneous mammary
adenocarcinoma were destroyed in vitro by host macrophages whereas tumour
cells from mice with low antibody titres were not destroyed; the difference
in killing was attributed to greatly reduced amounts of tumour-associated
antibody in the latter group.
Antibodies adversely affect tumour cells in ways other than cell
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lysis. Binding of antibody may result in inhibition of cell division^46).
The inhibitory effect of antibody on the amoeboid-like movement of tumour
cells could play a significant role in preventing metastases by inhibiting
migration of tumour cells into blood and lymphatic channels^46).
In summary, tumour-bearing hosts are capable of producing specific
anti-tumour antibodies which are often associated closely with the
constituent cells of a tumour. Although mechanisms exist whereby antibody
reactions are able to destroy tumour cells, it is clear that in many cases
antibody responses are weak and tumours continue to grow in the presence of
specific antibody responses.
1.4.3 CELL-MEDIATED RESPONSES TO TUMOURS
Resistance to syngeneic tumour cells in experimental animals is
predominantly a cell-associated reaction of the delayed hypersensitivity
type which can be transferred adoptively by lymphoid cells but not with
serum^40). Therefore, cell-mediated immunity (CMI) may be of greater
importance than humoral responses in the overall response against cancer.
1.4.3 (a) Studies of in vivo and in vitro CMI
Two main approaches have been followed in the study of cellular
immune responses against cancer: firstly, demonstration of host cells
sensitised to tumour cells, tumour extracts or soluble "tumour antigens",
and secondly, demonstration of the ability of host lymphoid cells to
destroy viable tumour cells.
Cutaneous delayed hypersensitivity reactions (CDHR) to autologous
and allogeneic tumours have been interpreted as evidence of anti-tumour CMI
in cancer patients. The subject of CDHR in cancer patients has been
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reviewed recently by Heberman^58). Although techniques for performing CDHR
testing can be standardised, interpretation of the results is often
difficult, especially in malnourished cancer patients^59). The
significance of CDHR in terms of tumour immunity has not been established
satisfactorily.
Cancer patients frequently fail to show CDHR to extracts of their
own tumours and positive CDHR have been observed in patients with
malignancy of tissues quite different from those used to prepare the
challenge tumour extract^60). Also, some healthy individuals produce
positive CDHR when challenged with tumour cell membranes(69). There are
many methodological problems associated with skin testing and these are
compounded by the heterogeneity of the "antigen mixture" used as the
injected stimulus. Tumours bear many different antigens, including some
MHC products, and a positive CDHR to tumour extracts may represent a cross
reaction to TATA rather than TSA. Failure to detect a CDHR to a tumour
extract may simply reflect impairment of the subject's ability to launch an
inflammatory response, or, perhaps of much greater significance, that the
tumour had successfully evaded detection by the immune system.
Alternatively, the tumour may have been recognised by the host but the
effector limb of the response had been inhibited. Thus, the value of CDHR
to the analysis of immune responses against cancer, as well as in the
diagnosis and management of cancer patients, is limited.
Many in vitro studies of CMI have been undertaken to detect
lymphocytes which are sensitised specifically to tumours or capable of
mediating tumour cell destruction^10,58,61^. Peripheral blood lymphocytes
(PBL) from the majority of cancer patients show some evidence of
sensitisation to autologous and allogeneic tumour tissue, as detected by
lymphocyte transformation, macrophage migration inhibition or
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electrophoretic mobility tests. Similar reactions are found in a minority
of apparently healthy subjects, an observation which casts doubt on the
specificity of the reaction and possibly the validity of the control
subjects. Some studies have demonstrated correlations between the degree
of lymphocyte sensitivity and the extent of disease: generally, patients
with advanced malignancy exhibit either weaker responses or a lower rate of
positive lymphocyte responses to tumour extracts than patients with early
disease. In this respect, the findings of Singh et al^8^) are typical: in
a study of several immune parameters in 38 patients with advanced upper
gastrointestinal carcinoma, they found severe depression of absolute and
T lymphocyte counts, depression of CDHR to purified protein derivative of
Mycobacterium tuberculosis (PPD) and phytohaemagglutinin (PHA), and
depressed IgG levels, and found no correlation of these immune parameters
with extent or primary site of disease, the performance status of the
patients, or their response to combination chemotherapy. There was wide
overlap between the results of various subgroups of patients and such poor
specificity that the parameters could not be used as prognostic indicators.
One frustrating aspect of this and other similar studies(90~93) is that it
is impossible to state whether the impairment of immune parameters was a
cause or an effect of the progression of the malignant process. It is well
recognised that immune function may be impaired by malnutrition, surgery,
anaesthesia, chemotherapy and radiotherapy, factors which are associated
frequently with malignant disease. However, a generalised depression of
the host's immune response could be a mechanism by which tumours escape
from detection or destruction by the immune system, a theme discussed later
in Section 1.6.
Some in vitro tests of tumour-directed CMI have been proposed as
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methods of diagnosis of pre-clinical or occult malignancy^62•63). In spite
of initial enthusiasm, such tests have not received general acceptance.
In summary, considerable research effort has been spent
investigating cellular responses to tumours. Although many patients launch
specific tumour-directed responses involving lymphoid cells, clinical
observation indicates that such responses only very rarely rid the host of
a tumour and are depressed in most cancer patients.
1.4.3 (b) Local cell-mediated responses
Russell^64) suggested in 1908 that inflammatory cell infiltrates
seen in tumours were an indication of host resistance. Subsequently, many
authors have studied the nature and activity of host cells within tumours
with the aim of establishing correlations between qualitative or
quantitative aspects of tumour infiltrates and tumour behaviour.
Cellular infiltrates in tumours have been correlated with the
histological type and degree of tumour cell differentiation. Ioachim et
al(65) foun(j that well differentiated squamous cell carcinomas of the lung
contained significantly greater numbers of infiltrating cells than did
poorly differentiated or undifferentiated tumours, the latter being almost
devoid of host cells; lymphocytes were often seen between and even within
tumour cells in heavily infiltrated tumours. Electron microscopy has shown
tumour cells in intimate contact with infiltrating macrophages and
lymphocytes, which exhibit interdigitating surface microvilli
characteristic of cytotoxic T lymphocytes(66) (Section 1.2.2). Plasma
cells have been demonstrated within well differentiated keratin-forming
squamous cell carcinomas of the lung but only infrequently in other types
of lung neoplasms(6^), and similar associations have been found in squamous
cell carcinomas of the skin, oesophagus and cervix.
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Intense lymphocytic infiltration has been observed around
premalignant lesions and in situ carcinomas of the bronchus, cervix, vagina
and skin, and the degree of cellular infiltrate in these early lesions was
nearly always greater than in advanced cancers or their metastases^6).
Thus, the immune response appears stronger (or certainly more evident) in
small tumours than in more advanced tumours, perhaps because smaller
lesions are more immunogenic and the reactive capacity of the host is
greater when the tumour is small^6).
Lauder et al^68) investigated lymphocytic infiltration in 23 cases
of neuroblastoma and demonstrated a good correlation with survival,
although an inverse relationship was observed between plasma cell
infiltrate and a good prognosis. The presence of metastases did not
invalidate the association of lymphocytic infiltration with a favourable
outcome, suggesting that local cellular reactions may reflect the overall
efficiency of the host's response to malignant cells. Other studies have
shown similar results. Cochran^69), for example, concluded from
histological studies of 165 patients with malignant melanomas that the
presence of lymphocytes and absence of plasma cells in tumours were
important determinants of a good prognosis.
Further circumstantial evidence of the role of cell-mediated
immunity in tumour "rejection" comes from histological studies of
regressing tumours. Histologically, tumour regression is always
accompanied by a heavy local lymphoid infiltrate; lymphocytes and
macrophages surround tumour cells which are later destroyed and, as the
tumour reduces in size, healing by fibrosis takes place^9). However, by
time the primary tumour has disappeared, metastases may have occurred and
these are not subject to the same host responses as the primary tumour^*).
1.4.3 (c) The role of infiltrating cells
Many cells of host origin found within tumours are immunologically
active and have been recruited specifically. Klein et al(72) showed that
infiltrating T lymphocytes from a variety of human malignant tumours were
metabolically active and had significantly higher fates of DNA synthesis
than PBL, indicating that they were not simply "resting" cells. Plata et
ai(73,74) studied cellular infiltrates in murine Moloney sarcoma virus
(MSV)-induced tumours (highly antigenic tumours which are rejected usually
unless the host is immunosuppressed); the in vitro cytolytic activity of
intratumour lymphoid cells was maximal at the onset of tumour regression
and removal of macrophages by treatment of tumour-derived leukocytes with
carbonyl iron powder did not reduce the overall leukocyte cytolytic
activity. After removal of T lymphocytes by anti-Thy 1.2 serum and
complement, there was a sharp drop in cytolytic activity although some
remained, presumably due to natural killer cell activity.
In comparative studies of regressing and progressing Moloney
sarcomas in mice, Russell et al^75) and Gillespie et al^78) found that
regressing neoplasms contained relatively more T lymphocytes distributed
throughout the tumour mass, whereas the T cell content of progressing
sarcomas was lower and T cells were confined to the peripheries of tumours.
There is now considerable evidence that macrophages are major
effector cells in both specific and non-specific cell-mediated
cytotoxicity^77). Studies in the rat^78) and with human breast tumours and
melanomas(79) suggest that the activity of phagocytic cells influences the
distribution of metastases. Macrophages participate in tumour cell
destruction by two mechanisms: (a) macrophage activation(80-82) (conversion
of a normal macrophage into a cell exhibiting non-specific cytotoxicity for
tumour cells), and (b) macrophage arming^83-85) (functionally distinct
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cells that are dependent on lymphocytes and kill in an immunologically
specific manner).
Within the last 15 years it has been observed that lymphoid cells
from normal animals and humans not previously exposed to tumour cells or
antigens have significant levels of cytotoxic reactivity against syngeneic
and allogeneic tumour cells. Such natural or "non-immune" cytotoxicity has
been attributed to natural killer (NK) cell activity. Many features of NK
cells have yet to be elucidated but it is generally accepted that NK cells
have significant antitumour potential(86).
Fc receptors have been demonstrated on the surface of NK cells and,
while the role of Fc receptors in these cells is uncertain, NK activity can
be suppressed by immunoglobulins and immune complexes binding by these
receptors and causing steric interference of cell to cell contact^87). NK
cell activity can be reduced greatly by treatment with trypsin, suggesting
that integrity of trypsin sensitive sites on NK cell membranes is important
for expression of cytotoxicity^88). The susceptibility of NK cell
cytotoxicity to protease activity could be of importance to the escape of
tumour cells from cell-mediated destruction (Section 1.5).
In summary, many patients with malignant tumours exhibit specific
antitumour immune responses. In vitro experiments show clearly that
lymphoid cells (lymphocytes, macrophages and NK cells) are able to destroy
tumour cell targets, but only rarely is there in vivo demonstration of
successful immune attacks upon primary tumours. The relevance of such
observations to a patient's ability to resist the spread and progression of
the malignant process is difficult to assess. The dilemma is that although
immunological responses directed specifically against malignant cells may
occur, they are ineffective in destroying clinically detectable neoplasms
and cannot halt the proliferation of tumour cells. Clearly, there exists a
paradox of tumour growth in the presence of antitumour responses. It is as
if established tumours have evaded the immune system, a process which is
fundamental to the success of transformed cells (Section 1.1.1). Possible
mechanisms by which tumours evade the immune system are now reviewed.
1.5 MECHANISMS BY WHICH TUMOURS EVADE IMMUNE DESTRUCTION
Several mechanisms have been proposed to account for the failure of
individuals to eliminate their tumours. Many reports have described
generalised immunological impairment in untreated cancer patients, although
immune defects are not found uniformly in all cancer patients^9"*). There is
some experimental evidence to suggest that the presence of malignant tissue
per se may lead to host immune depression. In mice, for example, the
number of antibody-forming cells was found to decrease gradually with
increasing numbers of Ehrlich ascites tumour cells, the impaired response
being seen as a reduction in antibody production rather than a delay in the
timing of the response^S). other studies failed to detect generalised
depression of immune cells in peripheral blood but found functional
impairment of host cells which had infiltrated carcinomas of the colon^49)
and lung(71). Recently, Holmes^96) attempted to define the functional
capacity of tumour-infiltrating lymphocytes and PBL in patients undergoing
pulmonary resection for primary adenocarcinoma or squamous cell carcinoma,
or lung metastases from carcinomas of the kidney or colon, malignant
melanoma or soft tissue sarcomas; using mixed lymphocyte culture (MLC) and
chromium release cytotoxicity assays, Holmes found that the functional
capacity of tumour-infiltrating lymphocytes and NK cells was suppressed
dramatically in comparison with PBL and NK cells, although the proportions
of T and B lymphocytes, Ts and Th cells and NK cells were similar within
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the tumour and peripheral blood. These studies(96) suggest strongly that
the tumour micro-environment has a profound suppressive influence on host
immune cells and that this immunosuppressive micro-environment serves as a
protective mechanism against host cells.
There are several mechanisms by which local and systemic immune
cells could be suppressed by tumours.
1.5.1 GENETIC CONTROL
Genetic control of immune responses to complex antigens has been
reviewed in Section 1.3.1. Animal studies support the concept that immune
reactions to tumours are under the control of Ir genes. Lilly(97) found
that susceptibility of mice to the Gross leukaemia virus is controlled by
two genes, one of which is linked to the H-2 system: mice without this gene
are about ten times more susceptible than those with the "resistance gene".
Similarly, Kolsch^®^ showed that low responsiveness of DBA/1 mice to an
\
allogeneic (DBA/2) mastocytoma P-815 (H-2^) was inherited in a recessive
pattern and was due to a determinant-specific defect in T cell mediated
cytotoxicity and an inability of the DBA/1 host to produce a secondary
humoral anti-H 2^ response.
The MHC has a role in determining the ability of a host to respond
to some complex antigens (Section 1.4.1). Also, the ability, or otherwise,
to express H-2 gene products at the tumour cell surface has been shown to
be an important determinant of the murine immune response to chemically-
induced tumours^46). The importance of Ir genes in the susceptibility of
humans to cancer or their ability to overcome malignant disease is largely
unknown. However, the high incidence of cancer in certain families(99) and
in some pre-existing medical conditions (e.g. carcinoma of the colon with
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polyposis coli), and the ability of some individuals to induce enzymes to
detoxify chemical carcinogens(100) indicate that genetic factors do have
some influence on the occurrence of malignancy, and may influence the
host's ability to respond to the presence of malignant tissue.
1.5.2 IMMUNOLOGICALLY INACCESSIBLE SITES
Some parts of the body are said to be "immunologically privileged"
in that they are protected from mediators of immune reactions - for
example, the anterior eye chamber and central nervous system. Tumours are
rare in such sites, probably because there are relatively few cells which
have very low mitotic rates - features which are not associated with
tumourogenesis.
Tumours in the eye and brain are not associated usually with
extensive inflammatory infiltrates. However, Cochran(^ has detected
evidence of CMI and humoral responses against ocular melanomas at almost
the same frequency as cutaneous melanomas, although of course ocular
melanomas do not arise within the anterior eye chamber. Overall, it is
very unlikely that immunological privilege within anatomical sites plays a
significant part in evasion by tumours in humans.
1.5.3 CHANGES AT THE TUMOUR CELL MEMBRANE
Cell membranes are dynamic structures and continually undergo
degradation and synthesis of constituent proteins, glycoproteins and
lipids. Thus, replacement of antigenic membrane components without loss of
cell viability but with less antigenic molecular configurations represents
a mechanism by which tumour cells could escape detection or destruction by
the immune system.
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1.5.3 (a) Antigenic Modulation
Antigenic modulation has been demonstrated by Ioachim^102-105)
rat thymomas induced by the Gross murine leukaemia virus (GMuLV) and
maintained continuously in tissue culture, where they strongly express
specific viral surface antigens. Tumour cells which expressed the viral
antigen (i.e. GMuLV +ve cells) were rejected consistently and were unable
to produce tumours in normal adult syngeneic rats but grew progressively in
irradiated immunodeficient rats. After passage into irradiated adults or
immature infant rats, the GMuLV +ve cells lost their GMuLV surface antigen;
these GMuLV -ve tumour cells had greatly increased malignant potential in
that they grew progressively in normal immunocompetent syngeneic adult rats
and metastasised widely. Thus, malignant potential was related to
expression of surface antigens which could be modified by an ineffective
immune response; after in vivo antigenic conversion, the enhanced malignant
potential was passed on and persisted in subsequent generations of tumour
cells.
These experimental studies show that when the immune response did
not destroy tumour cells, substantial alterations in antigenic expression
and immunogenicity were induced. Therefore, an inadequate antibody
response can induce antigenic change which not only allows tumour cells to
escape immune destruction but also endows them with greater malignant
potential; highly immunogenic cells may be destroyed but cells with poor
antigenicity can be induced, thereby ensuring that the most malignant
tumour cells are cloned. This mechanism could explain in part the
association of a local antibody response to tumours with an unfavourable
prognosis (Section 1.4.2).
Antigenic modulation may be important in the development of
metastases. Goldman et al^106) observed that B16 melanoma cells which
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formed pulmonary metastases in C57BL/6 mice had reduced antigenicity
compared with cells from the subcutaneous primary tumour. Also,
antigenicity may be stage-related in some tumours: Black et al^107)
demonstrated by skin window tests and leukocyte migration inhibition tests
that tumour specific antigenicity was maximal in in situ breast carcinomas
and was expressed least in invasive carcinomas with distant metastases,
although it is not clear from this study of human breast cancers whether or
not antigenic modulation had occurred.
1.5.3 (b) Antigen shedding
Oncofoetal (OFA) and tumour associated antigens (TSA) can be
detected in the serum of some individuals with malignant disease. These
antigens are tumour products and are released from the surface of tumour
cells by the process of "shedding"(*98), a mechanism which may help tumour
cells escape immunological destruction in several ways.
Firstly, antigen shedding may prevent or interfere with
tumouricidal immune responses. Local stability of the target cell antigen
and effector cell or immunoglobulin is required for lysis of tumour
cells^18). Antigen shedding removes this stability as well as creating
locally high concentrations of antigen which could mop up specific antibody
and form immune complexes. Secondly, OFA and TSA may induce host
immunosuppression without forming antigen-antibody complexes. For example,
alpha-fetoprotein (AFP) is an OFA and has well recognised immunosuppressive
properties(109'110), and other tumour antigens have also been shown to
suppress immunological reactions(95•126-128)_
Shedding of tumour cell surface products is related to the
malignant potential of a tumour. Black^108^ described two cell lines
26
derived from a murine mammary adenocarcinoma and grown intraperitoneally as
ascites-forming tumours; one cell line, which lost strain specificity so
that it could grow in an allogeneic host, was relatively non-i»munogenic
and had on its surface a large molecular weight glycoprotein which was
continually shed into the ascites fluid, while the other cell line grew
only in syngeneic animals, was more immunogenic and did not have the
surface glycoprotein. Shedding of the glycoprotein was an important
determinant of tumour immunogenicity; the glycoprotein may have represented
surface antigens or may have masked surface TSA or TATA from immune
detection.
1.5.3 (c) Release of proteases
In addition to antigens, a variety of other molecules and membrane
structures are shed from the surface of normal and malignant cells^4®).
These molecules are associated with cell membranes before being released
and so they are said to be "shed" rather than "secreted".
Several protease enzymes are associated with tumour cells. Koono
et al^111) isolated four protease enzymes from rat ascites hepatoma cells;
following intradermal injection of one of the enzymes (a neutral protease),
a factor chemotactic for tumour cells was detected and was able to induce
extravascular migration of circulating tumour cells. Sylven et al^1*2)
demonstrated that interstitial fluid from murine tumours had increased
proteolytic activity and demonstrated the presence of a variety of enzymes
including acid proteases (cathepsin B and D), polypeptidases, dipeptidases,
amino peptidases and carboxypeptidases. They suggested that the ability of
tumour cells to invade could be due to the activity of these enzymes^-*2'.
Wu(H3) demonstrated that glycolytic enzymes as well as pentose
phosphate cycle enzymes were released from intact Ehrlich ascites tumour
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cells but was uncertain whether these were intracellular or membrane-
associated enzymes. Holmberg(144) showed that cytoplasmic enzymes were
released from intact Ehrlich ascites tumour cells and that the degree of
release correlated with the capacity for successful tumour transplantation
into allogeneic mice. Holmberg postulated that "the released cytoplasmic
enzymes might be operative in preparing the soil for tumour take"(114).
Several studies have reported a relationship between cell surface
protease activity and cell growth rate, with cells with the shortest
doubling time having the highest levels of surface protease activity^108).
The presence and release of proteases at the surface of malignant cells
suggests that proteolysis is an important feature of malignancy. It has
been suggested that tumour-associated proteolysis may be important for the
local (112-114) an(j systemic ^ ^ resistance of tumours to immune
destruction. Yefenof et al^11^) found that Epstein-Barr virus (EBV)-
converted B lymphoma cells had a reduced capacity to shed surface-bound
antibodies (compared with EBV negative cells) but had an increased ability
to degrade surface antibodies, which, it was proposed, was due to longer
exposure of the attached antibody to membrane-associated enzymes.
Other functions of surface proteases have been proposed.
Burger^116) showed that cultured mouse fibroblasts escaped contact
inhibition and continued to divide following addition of very small amounts
of trypsin (0.007% of culture medium). This suggests that the proteolytic
enzyme was able to convert the cell surface to the type characteristic of
malignant cells as the fibroblasts responded in a manner which, in some
respects, resembled cell division exhibited by malignant cells in tissue
culture.
Thus, release of proteases may facilitate directly the growth and
28
spread of tumour cells and may help to protect them against attack by
antibody. Somewhat paradoxically, there is good evidence that proteolytic
enzymes stimulate the immune system. Trypsin is a potent stimulator of
B lymphocytes as measured by lymphocyte transformation(H7) and the
mitogenic effect of trypsin can be abolished by addition of soybean trypsin
inhibitor (SBTI). Lymph node and spleen T cells of hampsters can be
stimulated to incorporate 8H-thymidine in vitro under serum-free conditions
by the proteases trypsin and chymotrypsin^^8^.
Gisler et al(119) showed that trypsin in small amounts (1-12 /iig/ml)
in mouse spleen cell cultures potentiated antibody synthesis, and they were
able to substitute trypsin for T cells in antibody responses of mice to T-
dependent antigens. Although the mechanism of action was not known, the
"T substitution" effect of protease was not due simply to transformation of
a T-dependent-immunogen to a T-independent-immunogen^l*9). One possible
mode of action of the neutral protease would be by enzymatic removal of
"natural blocking factors" from the lymphocyte membrane(*20) indeed,
trypsin can induce structural changes in the glycocalyx (cell coat) of
lymphocytes(108) and other proteases can alter the electrophoretic mobility
and migration of lymphocytes(^2*) ( an(j possible that proteases could
act directly on other activities of immune cells. For example, protease
enzymes inhibit macrophage migration, in the same manner as MIF^122).
The data reviewed above indicate that proteases or proteolytic
events have a role in the activation of T and B lymphocytes. Similarly,
protease inhibitors have immunoregulatory activity by their inhibitory
effect on protease activity. Hart et al^*8) showed that the stimulatory
effect of trypsin and chymotrypsin on B lymphocytes was abolished by SBTI.
Other studies have shown that protease inhibitors can suppress lymphocyte
responses in vitro^28^.
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Cells other than lymphocytes and macrophages are influenced by
protease enzymes. Chen et al(^4) have shown that the protease thrombin is
able to stimulate DNA synthesis and cell reproduction in resting chick
embryo fibroblasts in vitro and suggested that this action was due to
cleavage of growth-regulating proteins. Chen et al(125' also suggested
that proteases played a part in host defence at sites of tissue injury and
that thrombin and other proteases could act as non-specific B cell
stimulants during wound healing. An attractive hypothesis concerning the
activities of protease inhibitors can be proposed by developing these
suggestions further. Within the area of a wound, a relatively high
concentration of active thrombin could stimulate B cells non-specifically
as an adjunct to specific stimulation by foreign antigens (e.g. bacteria)
and could also act as a stimulus to wound healing by an effect on
fibroblasts, in addition to acting on specific substrate (fibrinogen).
Other proteases released from damaged tissues would stimulate lymphocytes
with subsequent development of an inflammatory response. One component in
the regulation of such a response would be the naturally occurring plasma
protease inhibitors.
This hypothesis is suggested largely by results of in vitro
experiments but nevertheless it may be relevant to some aspects of the
biological behaviour of tumours. The amount of protease enzymes in a
wound is finite so long as the wounding stimulus (or any stimuli of
continuing tissue death) has been removed; in the case of a tumour, there
would be a constant source of protease enzymes shed from cell surfaces. The
ever-increasing release of proteases must benefit the tumour by aiding
local invasion, encouraging release of cells from the primary tumour mass,
deregulating cellular growth and releasing surface immunoglobulins. On the
other hand, proteases could adversely affect tumour cell growth by
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encouraging an antibody response, inhibiting macrophage migration and
perhaps encouraging a fibroblastic reaction. As the value to the host of
the local antibody response is dubious (Sections 1.4.2 and 1.5.5), the
potentially harmful effects of tumour proteases would probably outweigh the
beneficial effects, in theory at least.
In summary, tumour-related or -associated proteases have wide-
ranging effects on the function of the host's immune system and the
behaviour of tumour cells. It is not surprising therefore that a complex
system of naturally occurring protease inhibitors exists in humans. The
role of protease inhibitors in manipulation of the immune response is
reviewed in Section 1.5.8.
1.5.4 SUPPRESSOR T LYMPHOCYTES (Ts)
Stimulation by foreign antigens induces both antigen specific and
non-specific Ts which have a central role in regulating or restricting
immune responses and inducing antigenic tolerance (Section 1.3.2). Thus,
Ts might be involved in suppressive mechanisms associated with malignant
tumours, and experimental evidence supports this view.
Treves et al^129) demonstrated that spleen cells from C57BL/6 mice
bearing Lewis lung carcinomas enhanced tumour growth when injected together
with tumour cells into syngeneic animals; removal of T lymphocytes by
treatment with anti-Thy serum reduced the enhancing effect and thymectomy
before tumour transplantation led to a significant reduction in the number
of tumour metastases. Direct evidence of T cell-dependent suppression with
specificity for tumour-associated antigens was provided by Fisher et
aj(130) demonstrated a T cell population with suppressive activity and
specificity for syngeneic, but not allogeneic, ultraviolet- and chemically-
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induced tumours. Studies by Greene and colleagues^131-133)^ showed that
"immunosuppressor" T cells were generated in A/Jax mice within 24 hours of
transplantation of a methylcholanthrene-induced sarcoma and disappeared
within five days of tumour excision.
The situation in humans is less clear, partly because of the need
to rely on in vitro assay systems and the large number of variables which
influence human immune functions. However, Ts have been shown to
contribute to the generalised reduction in immune competence observed in
many patients with malignant disease^134). Yu et al^135) reported the
presence of specific suppressor cells which inhibited the cytotoxic
activity of autologous tumour-specific cytotoxic lymphocytes in some of
their patients with osteogenic sarcoma; PBL contained two subpopulations,
one exhibiting tumour-specific cytotoxicity and the second inhibiting this
activity. The existence of Ts is likely to be secondary to the tumour as
the immune deficit in many patients tends to parallel the extent of
disease. The Ts found in patients with lymphoma probably play a more
direct role in the pathogenesis of an associated immune defect which is
frequently evident early in the course of the disease.
1.5.5 "ANTI-TUMOUR" ANTIBODIES
The obvious function of antibodies produced in response to tumour
antigens is tumour cell destruction, and such has been demonstrated in some
human and experimental animal systems (Section 1.4.2). However, anti-
tumour antibodies are not successful universally, and some evidence
suggests that the antibody response may affect the host adversely.
The presence of plasma cells within human malignant melanomas has
been associated with a poor prognosis while lymphocytic infiltration has
been correlated with a good prognosis^69^. Izsak et al^136^ prospectively
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studied 25 patients with malignant disease of the breast, gastrointestinal
or genito-urinary tracts, or soft tissue sarcomas, and found a close
correlation between the presence of tumour cell surface immunoglobulins and
a "malignancy index" which was calculated by scoring parameters such as
sites of spread, histopathological grade, rate of tumour growth, and an
"ability index method" which expressed "somatic objective and subjective
criteria"; nine of 12 highly malignant tumours, but only 5 of 13 tumours
with a low malignancy rating, were associated with surface immunoglobulin.
The study suffers because of the heterogeneous nature of the tumours and
the uncertain validity of some of the methods used to assess prognosis, but
nevertheless a correlation was found between malignancy and surface
antibody. The authors could not explain the presence of antibody on "low
malignancy" tumours, but this could have been due to non-specific
absorption.
Antibodies may impair the immune response against malignant cells
by several mechanisms. Firstly, formation of anti-idiotypic antibodies can
suppress generation of cell-mediated and antibody responses
(Section 1.3.3). Secondly, specific antibodies can bind to tumour cell
surface antigens and prevent them from stimulating further immune
responses. Ting et al^137) demonstrated that pre-coating of tumour cells
with syngeneic tumour-specific antibodies reduced the capacity of cells to
provoke in vivo anti-tumour immunity, and Vanky et al(138) showed an
inverse relationship between the presence of immunoglobulins in tumour
biopsies and the capacity to stimulate autologous lymphocytes as measured
by increased DNA synthesis.
Thirdly, antibodies may facilitate the escape of tumour cells from
immune detection and destruction. Antigenic modulation can be seen as a
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mechanism of tumour evasion (Section 1.5.3(a)) and has been observed
following combination of specific antibody with surface determinants of
tumour cells^^S)) witz^1^®) noted that release of amino acids from tumour
cells incubated with specific antibody was increased significantly, and
interpreted this as evidence of "enhanced membrane catabolism" which
enabled tumours to respond to surface binding of immunoglobulins by
increased shedding of surface proteins.
Some tumour cells are able to rid themselves of surface antibody by
"antibody uncoating"(). Fish et al^14^) showed that most of the IgG
released from murine ascites TA3/SK mammary carcinoma cells was in a
degraded form, indicating that the specific antibody had been "processed"
by the tumour, possibly by surface protease enzymes; not only were these
degraded cytotoxic antibody products inactive, but they were able to block
the cytotoxic capacity of intact antibody because of much higher affinity
for tumour cells. Presumably, immunoglobulin degradation could account for
the apparent absence of anti-tumour antibodies in the circulation of some
patients with malignant tumours (Section 1.4.2).
In summary, antibody responses against tumours are not always
favourable to the host and some tumours can alter specific antibodies by
surface activities which result not only in loss of the anti-tumour humoral
response but also in the appearance of products which are detrimental to
the host response. In this way, the humoral response against tumours may
aid, paradoxically, tumour cell escape from immune destruction.
1.5.6 COMPLEMENT
Although complement dependent lysis (CDL) is a potential means of
eliminating tumour cells (Section 1.4.2), it is not universally successful
in vivo. The presence of complement components in malignant tissue per se
34
does not indicate necessarily that complement has been taken up by
antibody-coated tumour cells: complement may be taken up by host cells with
complement receptors, thereby reducing its availability for CDL, which is
ineffective in certain phases of the cell cycle in some tumour lines(1^3)
Also, neoplastic cells differ greatly in their susceptibility to CDL and
complement inactivating enzymes have been demonstrated on the surface of
some tumour cells^144).
A full review of the role of complement in malignant disease is
beyond the scope of this thesis but it is clear that some tumours are able
to resist the action of tumour-specific antibody and complement.
1.5.7 CIRCULATING NON-SPECIFIC IMMUNOSUPPRESSIVE FACTORS
Several recent studies indicate that circulating non-specific
immunosuppressive factors (CN-SIF) are present in patients with malignant
disease. Surprisingly, very few studies have examined more than a single
factor and so it has been impossible to assess the relative contributions
of such factors to the immunological impairment observed in many cancer
patients.
1.5.7 (a) Immune complexes
Immune complexes (IC) in cancer patients are formed by combination
of cell surface antigens with antibody, either within the circulation after
antigen shedding^145) (Section 1.5.3(b)) or at the tumour cell surface
before shedding occurs (141). ic are detected in about 80% of cancer
sera^l4^).
The presence of IC provides further evidence that antigen shedding
from tumour cells represents a method of immune evasion. Using a
methylcholanthrene-induced fibrosarcoma rat model, Thomson et al^146) found
that specific antibody could only just be detected when tumours were
present but that antibody levels increased significantly within days of
tumour excision; injection of tumour cell suspensions into immunised
animals resulted in a fall of antibody levels, indicating that constant
release of tumour antigens was able to neutralise circulating antibody by
the formation of ic(147>148). The IC in ascitic and pleural fluid
secondary to disseminated carcinoma of the breast and ovary have been shown
to block in vitro lymphocyte-mediated cytotoxicity(149).
IC affect host resistance adversely by other means also. The Fc
portions of antibody molecules in IC can attach to Fc receptors of lymphoid
effector cells such as cytotoxic T cells, macrophages and killer cells; as
the Fab part of the antibody is attached to free tumour antigen, the
effector cell is prevented from attaching to tumour cells, and so this
means of immune attack is lost.
1.5.7 (b) Fc fragments
The protease enzyme papain splits the IgG molecule into three
fragments: two antigen binding fragments (Fab) which are responsible for
antibody specificity, and a fragment which can cystallize (Fc fragment).
The Fc fragment cannot combine with antigen but is responsible for the
capacity of intact immunoglobulin molecules to activate complement and to
bind to cells with Fc receptors, such as most B lymphocytes, monocytes,
killer cells, some T cells (especially when activated) and platelets.
Fc receptors are present on some, but not all, cells of human
malignant tumours (tumours of lung, stomach, colon, breast, bladder, ovary
and thyroid^88)). Even Fc receptor-positive cells express them to varying
degrees. Fc receptors on tumour cells are indistinguishable antigenically
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from those of immune cells. The function of Fc receptors on tumour cells
is not known. Presumably, if immunoglobulin molecules combined with tumour
cells at their Fc part rather than at the antigen specific Fab part, the Fc
region would be unavailable for activation of complement or attachment of
immune effector cells. Also, unrelated antibody could attach to tumour
cells by way of Fc components and cause steric interference with binding of
specific antibody.
Tumour cell-surface protease enzymes cleave specific antibody
molecules so that the Fc portion is released and the Fab portion remains
attached to the antigenic determinant on the cell surface. Thus, antigenic
determinant sites remain covered by Fab fragments and therefore shielded
from immune detection and attack, and antibody-dependent mechanisms of
tumour destruction, such as ADCC and CDL (Section 1.4.2), cease to be
effective because they require intact antibody to endow effector cells with
specificity (ADCC) or to activate complement (CDL).
Fc fragments released from the tumour into the surrounding
environment find their way into the circulation. The effect of circulating
Fc fragments on immune function is uncertain. However, as many immune
cells have Fc surface receptors, free Fc fragments could combine with these
receptors and interfere with immune activities. Studiesof
inactivation of antigen-sensitive B lymphocytes by IC indicate that
inactivation is mediated by a direct Fc-dependent effect on lymphocytes and
that the Fc portion of immunoglobulin molecules and Fc receptors on immune
cells are responsible for some forms of immune regulation. As the Fc
subunit is not antigen specific, inactivation by Fc fragments is non¬
specific; antigen specific forms of antibody feedback could be achieved by
specific attachment of Fab fragments to antigenic determinants(). The
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detection of Fc fragments and their possible effect on immune reactivity in
patients with malignant disease is reported in Chapter 3.
1.5.7 (c) Prostaglandins
Prostaglandins (PG) have been implicated in the regulation of
humoral and cellular immune responses and in the depressed immune function
which is associated frequently with malignant disease. A detailed review
of the role of PG in immunological functions is beyond the scope of this
work but mention should be made of the possibility that PG could aid
tumours in immunological evasion.
PG have a number of inhibitory effects on immune cells including
suppression of mitogen-induced transformation of human PBlJ152), inhibition
of lymphokine production by stimulated lymphocytes(153), suppression of NK
cell activity^154) and activation of B lymphocytes(155). As some
lymphokines (e.g. MIF) stimulate PG synthesis by macrophages, it has been
suggested that PG act by negative feedback in the control of CMI^153).
PG are produced by some tumours in experimental animals(155) and by
some human malignant tumours, such as anaplastic and medullary carcinomas
of the thyroid^15^), carcinoma of the oesophagus(15^) and Kaposi's
sarcoma^15®). Indirect evidence of PG-mediate immune depression has come
from observations that PG synthetase enzyme inhibitors, such as
Indomethacin and Aspirin, can reverse tumour-induced immunosuppression
in vivo and in vitro and retard tumour growth in vivo(159). Other
reports(160) have claimed that PG-producing suppressor cells are
responsible in part for the associated impairment of in vitro reactivity of
PBL in patients with Hodgkin's disease, as suppression can be ameliorated
by Indomethacin.
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1.5.7 (d) Small molecular weight substances
In addition to the blocking activities of antibodies, tumour
antigens and immune complexes (reviewed by Smith and Landy(161)),
substances of small molecular weight (MW) and possessing immunosuppressive
activity have been detected in sera from cancer -patients. The precise
nature of such substances is obscure but several reports suggest that they
are polypeptides.
Holmberg(I62) characterised a peptide obtained by dialysis of cell-
free ascitic fluid from humans with advanced malignancies, and found that
the peptide (MW 1900-2000) decreased mitotic rates of malignant and non-
malignant cell populations. Glasgow et al^1®^) found that the presence of
"immunosuppressive serum" (as determined by inhibition of PHA-induced
in vitro lymphocyte transformation) was associated strongly with absence of
CDHR to PPD, streptokinase-streptodornase and mumps skin test antigen in a
large number of patients with solid malignant tumours; analysis of the sera
by cellulose ion-exchange chromatography revealed a peptide of MW less than
10,000; it was derived from the alpha globulin region and caused marked
inhibition of in vitro lymphocyte transformation and antibody responses of
mice.
Friedman et al(164) showed that inhibition of murine antibody
responses induced by tissue cultured mastocytomas was due to a soluble
factor of MW less than 5000 daltons; ascitic fluid from mastocytoma-bearing
mice contained an additional immunosuppressive fraction of MW 10,000-20,000
daltons. Friedman(164) interpreted these results as indicating that the
mastocytoma tumour cells secreted a small MW immunosuppressive material.
Unfortunately, the suppressive substances were not characterised, although
the paper states that an antibody raised in the rabbit against the low MW
substance could reverse its immunosuppressive activity.
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The origin of CN-SIF of small MW is uncertain. They could
represent whole molecules or fragments of larger molecules shed from the
surface of tumour cells, or they could be products of proteins or
antibodies degraded by tumour-associated protease „enzymes. They could also
be products of the host's immune cells.
There is now a considerable literature concerning soluble factors
released from immune cells as mediators of immune responses. Such factors
have either a helper or suppressor action and normally a balance exists
between the two. Soluble mediators are classified as either non-antigen-
specific (i.e., they do not bear cell surface-related antigenic structures)
or antigen specific (i.e. they bind antigen in order to function). It has
been proposed(165) that non-antigen-specific factors are released from
immune cells only during direct cell-to-cell interaction - widespread
production and diffusion of these mediators during an immune response would
be dangerous to the host, as both helper and suppressor factors may feed
back on distant organs and have effects on precursor cells(*66)
Bankhurst^) recently reviewed the subject of soluble suppressive factors
released by suppressor cells in patients with malignant disease. Several
in vitro studies(168-169) have indicated that non-specific soluble
suppressor factors are released from normal T cells in cancer-bearing hosts
and it is likely that such factors are important in intercellular
communication and regulation of immune responses. The relevance of these
factors to the immunosuppressive activity of plasma in cancer patients is
unknown. Presumably, soluble mediators affect the local immune response to
malignant cells and influence activities of immune cells in and around
tumours such that immune reactivity is regulated.
Immunosuppressive small MW substances are found circulating in
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patients with diseases other than cancer. So called "middle molecules"
with a MW range of 300-5000 daltons accumulate in the plasma of patients
with chronic renal failure and are able to suppress lymphocyte
transforraation(170) an(j BiXed lymphocyte reactions(171), significantly
prolong skin allograft survival and inhibit graft versus host reactions in
rodents ( ^ ^) . Recently, Mabuchi et al(^^) characterised these peptides by
high performance liquid chromatography and concluded that these "middle
molecules" were normal body constituents present in uraemic blood in
abnormally high concentrations because of impaired excretion or metabolic
degradation by diseased kidneys. It is difficult to know if these CN-SIF
bear any relationship to the small MW suppressive molecules described in
patients and experimental animals with tumours. Of course, another
explanation for high circulating levels of such substances is excessive
production: the membrane of the cancer cell is a very active organelle and
if these small MW CN-SIF are tumour products, large quantities would be
produced by metabolically active tumours.
In summary, small MW substances with the ability to suppress immune
functions have been detected in sera from cancer patients and although
their biological significance and origin is uncertain, it is conceivable
that they are tumour products which help the tumour to evade immune
destruction.
1.5.7 (e) Acute phase reactant proteins
Acute phase reactant proteins (APRP) are largely glycoproteins
which alter their concentration in plasma in response to tissue injury,
acute and chronic inflammation, connective tissue disorders and some
malignant diseases. Interest in APRP with respect to cancer has been from
the viewpoints of (i) diagnosis and monitoring, and (ii) the biological
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significance and consequences of changes in APRP. Because of poor
sensitivity and specificity for cancer, APRP currently have little part in
screening and monitoring programmes of patients suspected of or having had
malignant disease.
The subject of APRP has been reviewed extensively^173-175) Tjje
APRP of relevance to human malignant diseases are shown in Table 1.1.
Elevated plasma levels of some or all of these APRP have been reported in
patients with carcinomas of the breast, prostate, stomach, colon, lung,
bladder and liver as well as lymphomas and leukaemia(1^5) In general, a
rough correlation exists between progressive increases in some APRP
concentrations and continued tumour growth; cytoreductive therapy may be
associated with return of APRP levels to the normal range of values, and
recurrence and further tumour growth may be associated with abnormally high
levels. The biological activity of some APRP (e.g. caeruloplasmin,
fibrinogen) is well defined although the reasons for increased serum levels
in some malignant conditions is uncertain.
Some APRP influence the activities of immune cells. C-reactive
protein binds selectively to T lymphocytes and inhibits their ability to
form spontaneous rosettes with sheep red blood cells and their responses to
allogeneic cells in MLC^76). Alpha-l-acid glycoprotein inhibits
proliferative responses of PBL to PHA, Con A and allogeneic cells in
MLC^177). The alpha globulin group of APRP inhibits an extensive range of
T cell-mediated immune responses, such as skin allograft rejection,
elaboration of MIF, and lymphocyte blastogenesis induced by MLC and PHA
stimulation^78^ .
The relevance of these largely in vitro findings to in vivo
biological systems is uncertain. However, demonstration that some APRP are
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Table 1.1 Acute phase reactant proteins relevant to human malignant
disease
PROTEIN MW (xlO-3) NORMAL RANGE (serum) (g/1)




C-reactive protein <10 mg/1
Haptoglobin type 1-1 100 1.0 - 2.2
type 2-1 200 1.6 - 3.0
type 2-2 400 1.2 - 2.6
Fibrinogen 340 2.0 - 4.5
Alpha-2-macroglobulin 725 1.0 - 3.0
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increased in cancer patients (alpha-2-macroglobulin being a notable
exception) and have immunosuppressive properties leads to the conclusion
that APRP could be partly responsible for the immunodepression associated
with malignancy and could facilitate growth and progression of tumours.
1.5.8 ALPHA - 2 - MACROGLOBULIN
The alpha globulins of human plasma may be separated
electrophoretically into alpha-l-globulins (glycoproteins and high density
lipoproteins) and alpha-2-globulins (alpha-2-macroglobulin (A2M),
haptoglobin, caeruloplasmin, prothrombin, very low density lipoproteins and
some glycoproteins). From a functional viewpoint, about 20% of the
globulin fraction of plasma consists of proteolytic enzyme inhibitors of
which the heavy MW alpha-2-globulin, A2M, is a major component. The
literature concerning A2M is extensive, and the biological and chemical
characteristics of the molecule have been reviewed recently(179-185) Tjje
following review will outline briefly the biochemical and physiological
properties of A2M and the relevance of this molecule to human disease.
A2M (MW 725,000 daltons) is composed of two non-covalently bonded
pairs of identical subunits joined by disulphide bonds such that the
molecule has a generally cylindrical shaped 186). Each of the four subunits
contains a specific amino acid sequence (the "bait" region) which is highly
susceptible to proteolytic cleavage, following which the whole A2M molecule
undergoes a conformational change; this results in irreversible binding of
the protease enzyme without blocking the enzyme's active proteolytic
site^1®^). Small MW substances (e.g. aprotinin, MW 6511) are able to gain
access to the active centre of a protease enzyme complexed with A2M, whereas
inhibitors with MW greater than 9000 (e.g. SBTI) cease to have any
influence on the enzyme.
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Electron microscopy^^84» *8^) and gel electrophoresis studies^®^^
reveal that the A2M-enzyme complex is conformationally and
electrophoretically distinct from free or non-complexed native A2M, the
electrophoretically fast nature of complexed A2M being due to the
molecule's more compact configuration.
Human A2M is unique among the numerous naturally occurring plasma
protease inhibitors in its ability to inhibit all four classes of
endopeptidases with nearly any specificity^183) (Table 1.2). After binding
with enzymes, a receptor-recognition site on the A2M molecule is exposed so
that the complex is cleared rapidly and specifically from the circulation
by hepatocytes, fibroblasts and reticuloendothelial cells in the liver,
spleen and bone marrow'18®'^89^. The daily fractional turnover of free
circulating A2M is approximately 10%, (half life = 9-10 days) whereas A2M-
protease (A2M-P) complexes have a half life of between 4 and 8
minutes^188•19°). The rapid elimination of A2M-P suggests that the
biological importance of A2M is in removing proteases from the
circulation^.
The site of synthesis of A2M is uncertain but hepatocytes,
monocytes and lymphocytes in tissue culture can synthesise A2M^83' ).
A2M is distributed widely in body fluids (plasma, extracellular fluid,
synovial fluid, pleural and peritoneal effusions, seminal fluid), and A2M
is a surface component of human and murine B lymphocytes(182) and human
platelets^181). Unlike other plasma protease inhibitors, A2M forms a more
or less continuous lining on the luminal surface of human vascular
endothelium(193).
Several studies have reported A2M concentrations in normal subjects
and patients with various diseases. Generally, A2M levels in serum are
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Table 1.2 Substances which bind with alpha-2-macroglobulin
(from James^180))
Serine proteases Trypsin, chymotrypsin, plasmin, thrombin,
kallikrein, plasminogen activator, urokinase,
polymorphonuclear leukocyte elastase
Thiol protease Cathepsin B1
Carboxyl proteases - Cathepsin D, some acid proteases
Metal proteases Collagenases, thermolysin
Ions Nickel, zinc, lithium
Lymphokines Macrophage activating factor, macrophage slowing
factor
Mitogens - PHA, Con A
Miscellaneous - Methylamine, soluble la antigens, immune
complexes
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higher in females than males, in infants than adults, and may be elevated
in some patients with diseases such as diabetes mellitus, atopic
dermatitis, asthma, agammaglobulinaemia, prostatic carcinoma and dwarfism
secondary to zinc deficiency^194-198) . Concentrations (mean ± ISD) of A2M
measured by radial immunodiffusion in sera from healthy subjects were 2.65
± 0.55 g/1 (males, n=33) and 3.35 ± 0.57 g/1 (females, n=22)(194).
Absolute levels in plasma or serum provide little information about the
functional activity of the molecule. Farrow et al(199) studied metabolic
turnover of 131 j labelled non-complexed A2M in 4 normal subjects and 7
patients with burns to 9-10% of their body surface, and found that although
total intravascular A2M concentration remained relatively normal, A2M
turnover increased to twice normal in the burnt subjects. It is well
recognised that burnt patients are relatively immunosuppressed and that
their serum has immunosuppressive effects in vitro(290). but unfortunately
concurrent immunological tests were not performed(199).
The vital biological importance of A2M is suggested by its presence
in nearly all mammalian species and by the fact that complete deficiency
has not been described in humans, although a family with an inherited
relative deficiency of A2M has been reported recently(201).
The precise physiological role of A2M remains obscure. A2M is
probably the most important of the major plasma protease inhibitors as it
can bind non-specifically and irreversibly to almost any active proteolytic
enzyme which is either freely circulating or already bound to other
protease inhibitors. After formation of A2M-P complexes, activity of
protease enzymes is reduced and the complex is eliminated rapidly by cells
with specific receptors for A2M-P but not free A2M. Therefore, it is
likely that a major role of A2M is removal of protease enzymes, and thereby
limitation of the many physiological and inflammatory events which are
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mediated by the action of proteolytic enzymes (e.g. the blood coagulation
cascade, the fibrinolytic pathway and complement activation mechanisms).
Interaction of A2M with cells of the immune system is poorly
understood but there appears to be a relationship. A2M has been associated
with surface membranes of B lymphocytes in humans and raice(232).
Lymphocytes(203) and monocytes(204) synthesise and release A2M. A2M blocks
antigen-induced production of lymphokine by obscuring antigen recognition,
blockade being greatest when A2M is obtained from pathological sera'2®5^.
(It is of interest to the present study that the authors^205) used an
in vitro cellular electrophoretic method of detecting responsiveness of
sensitised lymphocytes, a subject reviewed in Section 2.3). Remold et
aj.(25,26) found that A2M enhanced the response of guinea pig macrophages to
the action of MIF (Section 1.2.1). McDaniel et al^388) showed that A2M
binds lymphokines and suggested that the molecule has a carrier function
with respect to small MW mediators of cellular immunity. Streilein et
a^(207) showed that A2M depressed lymphocyte blastogenesis to B cell
mitogens in the hamster.
The biochemical data and functional activities have been brought
together by Hubbard^308) to form an hypothesis concerning the physiological
role of A2M. Hubbard proposed that the immunosuppressive quality of A2M is
due to "denaturative alteration" as a result of protease binding^283), an
hypothesis which explains the facts that (i) A2M is apparently
immunosuppressive in some circumstances and yet relatively large amounts of
A2M circulate in healthy immunocompetent individuals, and (ii) that target
cell recognition for the suppressive effect and for clearance appears to be
dependent on conformational change of the molecule. Hubbard also
speculated that as the A2M-P complex is generated by proteolytic activity
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at the A2M "bait" region and that as A2M-P is eliminated and degraded
rapidly by macrophages^209^, peptide fragments should be generated by
cleavage of any of the four A2M subunits following A2M-protease
interaction. At this stage, the experimental work described in this thesis
was undertaken to investigate the hypotheses proposed in Section 1.8.
1.6 MALNUTRITION AND CANCER
Anorexia and weight loss are common symptoms among cancer patients,
many of whom have measurable nutritional abnormalities at diagnosis. The
clinical syndrome of cancer malnutrition or "cancer cachexia" is typified
by the patient who, in addition to symptoms specifically related to his
tumour, has illness-related loss of body fat, muscle wasting, anaemia,
generalised weakness, lethargy and an associated rise in basal metabolic
rate^2*9). The mechanisms responsible for this syndrome are complex but
include reduced intake of food, loss of gastrointestinal mobility,
malabsorption, mechanical restrictions due to the anatomical location of
the tumour, tumour ulceration and bleeding, altered metabolism due to the
presence of the tumour, superadded infection or intercurrent illness, and
fasting because of investigations and treatment.
The tremendous interest in nutrition and nutritional therapy within
the last 10-15 years has been due in part to the realisation that
nutritional impairment of patients with benign or malignant disease has
serious clinical sequelae. As early as 1936 Studley^21*) demonstrated that
the mortality of patients undergoing surgery for benign peptic ulcer was
ten times greater in those who had lost 20% or more of body weight than in
those without weight loss, and in many cases death was attributable to
septic complications.
More recently, Simms et al^212^ studied post-operative
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complications in relation to nutritional status in 97 patients with cancer
and 19 with inflammatory bowel disease and found that complications had a
direct relationship with poor nutritional status; interestingly, the
distribution of complications was related to nutritional status, not the
presence of malignancy.
The increase in morbidity and mortality in malnourished patients
reflects the wide ranging effects of impaired nutrition on virtually all
body tissues. Body composition studies(264,265) have been undertaken
recently using total body neutron activation analysis (TBNAA) techniques
(Section 1.6.2(c)), to identify alterations in body composition and to
determine the relationship between dietary intake and body composition in
cancer patients. Body fat and muscle were often reduced significantly in
patients with gastrointestinal cancers in comparison with age- and sex
matched control subjects: non-muscle lean tissue remained approximately the
same but assumed a greater proportion of body weight(2®4^. in patients
experiencing weight loss over a six month period of observation, protein,
body water and fat were lost, and their mean intake of energy, protein and
fat was reduced markedly^266).
The precise cause for these body composition defects is related to
caloric intake and metabolic effects of the tumour. Cohn et al^65)
studied prospectively groups of patients with gastrointestinal, lung and
head and neck malignancies during periods of chemotherapy and found that
the difference between those who gained weight and those who lost weight
was related more to their protein and calorie intake than to their tumour
burden or the administration of chemotherapy. Similarly, Burke et al^267)
found no significant difference in dietary intake or metabolic rate between
patients with cancer who maintained their weight and those with benign
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disease, but that energy intake was lower in those cancer patients who lost
weight. Patients with inadequate calorie intake have to use their non-
visceral protein and fat stores as energy supplies.
The influence of an actively growing tumour cannot be disregarded
however. In an eloquent study of whole body protein turnover using a
radiolabelled leucine infusion technique in patients with colorectal
cancer, Carmichael et al(268) found that protein synthesis and breakdown
increased with increasing tumour stage but were lower in patients with
marked anorexia; anthropometric studies indicated that most patients had
lost body protein but, as all were in positive nitrogen balance, the
authors concluded that protein stores had been translocated from muscle to
sites of more rapid protein synthesis (i.e. their tumours).
Therefore, a tumour places additional requirements for energy and
nitrogen on the host and if they are not met by dietary intake, host
tissues will be catabolised. Two questions arise with respect to the
present study: what are the immunological consequences of the increased
catabolism which may be associated with the presence of solid tumours, and,
if nutritional therapy is of benefit to cancer patients, does the nature of
the nutritional repletion have any bearing on immune status? These two
questions will be addressed by the experimental work described in
Chapters 3 and 4.
1.6.1 IMMUNOLOGICAL CONSEQUENCES OF MALNUTRITION
The influence of malnutrition on the immune system is difficult to
study in malnourished subjects in the western world where malnutrition is
nearly always secondary to diseases which themselves may affect immunity.
There are several reasons why immunity may be impaired in hospitalised
patients with cancer apart from the effects of malnutrition - advanced
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age(213)( malignancy^214), infection and intercurrent disease^215), and the
effects of anaesthesia and surgery^216), blood transfusion^217),
radiotherapy^218) and chemotherapy^219) and it may be difficult to
implicate one factor more than another. Dominioni et al(22°) attempted to
evaluate the importance of various factors associated with immune
depression in cancer patients by multivariate analysis of impaired CDHR in
111 patients with gastrointestinal and other cancers. Malnutrition and
ageing were identified as the two major factors rather than the presence of
cancer per se, even if the malignant process was advanced; no significant
difference was found in the distribution of anergic, "hypo-ergic" and
"normo-ergic" skin responses between cancer patients and 56 patients with
benign disorders after correction for nutritional status^220). This
important study perhaps plays down the immunological effects of malignant
disease but offers an explanation for the inconsistent findings obtained
from skin testing patients with cancer: although CDHR are impaired
frequently in cancer patients, this finding is by no means
universal(214-22°-222).
Brookes et al^223) have provided evidence to support the contention
that malnutrition is a potent cause of immunological impairment in cancer
patients. In a prospective study of 53 patients with head and neck cancer,
Brookes^223) found a 40% incidence of nutritional deficiency which was due
largely to local obstruction of the upper gastrointestinal tract by tumour;
statistically significant correlations were found between CDHR anergy,
lymphopenia and nutritional deficiency as assessed by static anthropometric
measurements. Similar relationships were found using different parameters
in patients with benign and malignant diseases of the gastrointestinal
tract^224). These studies demonstrate that, in some cancer patients at
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least, reduced immunocompetence is secondary to malnutrition rather than
the presence of malignancy. Further supportive evidence is provided by
studies of nutritional repletion in malnourished cancer patients
(Section 1.7.1).
The influence of malnutrition on the immune system has been
reviewed extensively(215•221>225»226) Although not all studies are in
complete agreement, it is possible to reach a consensus. Malnutrition
leads to adverse effects on specific immunity, with impairment of
T lymphocyte activities being most pronounced (Table 1.3). There is
relative sparing of B cell function. Impaired antibody responses to T-
dependent antigens may reflect reduced Th cell activity rather than
B lymphocyte impairment. Neumann et al{^27) foun(j that IgE levels were
elevated in children suffering from protein-calorie malnutrition when an
associated defect in cellular immunity was detectable, although the
pathogenesis of this elevation is uncertain. The increased incidence of
infective complications in malnourished patients can be explained on the
basis of impaired T lymphocyte and phagocytic cell activity and reduced
serum levels of complement components, in addition to structural and
functional defects in non-specific or innate mechanisms of host resistance.
Apart from studies of peripheral blood concentrations of
antibodies, acute phase proteins and nutrients, there are few data about
the role of immunoregulatory plasma substances in malnourished subjects.
McFarlane^228) reported that subjects with protein-calorie malnutrition had
significantly lower plasma levels of alpha-l-antitrypsin, transferrin, C3
and A2M but increased levels of C-reactive protein. Dionigi was able to
correlate acute phase reactant protein levels with nutritional status^22*).
The significance of these changes is uncertain but, as APRP can influence
immune function (Section 1.5.7(e)), changes in their plasma concentrations
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Table 1.3 A summary of the effects of malnutrition on the human immune
system
(a) Histopathology
Thymus - Total weight
- Cellularity
- Hassall's corpuscles
Lymph node - Paracortical areas
- Germinal centres









(b) Peripheral blood lymphocytes
Total number
Proportion of T cells









(c) In vivo tests of cell mediated immunity
Cutaneous delayed hypersensitivity reactions
Allograft rejection (animal studies)
Graft versus host reaction (animal studies)
Consistent reduction




(d) In vitro tests of lymphocyte function









(d) In vitro tests of lymphocyte function (continued)
Antibody dependent cellular cytotoxicity Increased
T lymphocyte mediated cytotoxicity Increased/decreased
NK cell activity „ Increased
(e) Lymphokine production




(f) Polymorphonuclear leukocytes (PML) and macrophages












(g) Immunoglobulin level in serum









C3, C9 and Factor B
C4, C5 and CI inactivator
Response depressed
Response is variable




could explain partly the immune changes observed in malnourished
individuals. The role of plasma immunoregulatory substances in
malnourished individuals is investigated by the experiments described in
Section 3.3.
1.6.2 NUTRITIONAL ASSESSMENT
The aims of nutritional assessment of an individual are (a) to
identify that the patient is malnourished, (b) to provide an objective and
quantitative assessment of the severity of malnutrition, and (c) to allow
sequential monitoring of the efficacy of nutritional therapy. Ideally, the
method of assessment should be objective, reproducible, straightforward and
quickly performed, as well as having a high degree of sensitivity and
specificity. The following methods of nutritional assessment have been
proposed as suitable for application to hospitalised patients and some have
been used in the present work.
1.6.2 (a) Clinical judgement
A wide range of symptoms and signs may suggest that a patient has
nutritional impairment, and often there is no dispute among practitioners
that a certain patient is malnourished. However, difficulties arise when
only a few signs are manifest or when practitioners differ in the
interpretation of the patient's clinical features. Similarly,
manifestations of the underlying disease may make nutritional assessment
difficult by clinical judgement alone. Also, clinical assessment does not
provide an objective or quantitative measure of the malnourished state.
A comparative study by Baker et al^229) showed that clinical
assessment by two independent practitioners provided a high degree of
concordance (81%) and correlated well with anthropometric and biochemical
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but not immunological methods of assessment. Although the authors^229^
claimed that general clinical assessment was highly reproducible, this is
difficult to substantiate without a highly controlled study and perhaps it
is significant that attempts at correlating _successive assessments
following nutritional therapy were not made.
Although helpful in identifying malnourished subjects, clinical
assessment was not used as a method of quantitative nutritional assessment
in the present study.
1.6.2 (b) Anthropometric measurements
Anthropometric measurements consist of body weight in relation to
height, illness-related weight loss, measurement of skin fold thickness and
measurement of arm muscle circumference derived from triceps skin fold
thickness and mid-arm circumference.
Body weight (BW) provides an overall measure of the total weight of
individual body compartments but provides little information about the
nature or severity of nutritional impairment, except for extreme values.
Changes in body weight reflect changes in any of the labile body
compartments, and an increase in one compartment (e.g. extracellular fluid)
may obscure a decrease in another (e.g. skeletal muscle) without an
accompanying change in BW. As with other anthropometric measurements, BW
for a given height is compared with tables of standard BW or "ideal body
weight for height" tables^230) to provide an estimate of nutritional
status, expressed as a percentage of ideal body weight (IBW). The
limitation of this measurement is illustrated by the example of a
previously obese patient (120% IBW) who suffers significant illness-related
loss of body fat and protein, and at the time of nutritional assessment has
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a BW equal to 98% IBW, which is considered relatively normal and which
obscures significant nutritional impairment.
Weight loss secondary to illness is a better guide to nutritional
impairment and by-passes the need for tables of standard values.
Percentage weight loss is calculated from the formula ^ ~ ^ x 100
UW
(UW = usual pre-illness weight, PW = present weight). However, this
measure is also problematic in that it usually relies upon subject recall
for the value of UW, and accurate and regular measurements of weight are
recorded only occasionally by the patient or by medical practitioners.
Values of weight recalled by memory have been shown to be subject to
error(23^).
Although weight for height correlates well with body cell mass as
determined by body composition radioisotope techniques^232), the value of
BW and weight loss parameters in predicting post-operative complications in
malnourished surgical patients appears limited. Klidjian et al^233) showed
that "BW less than 90% IBW" was correlated significantly (P<0.05) with the
occurrence of post-operative complications but "weight loss of greater than
10% BW" was not.
Skin fold thickness is the simplest and most widely used
measurement of body fat, some 50% of which lies subcutaneously. The skin
fold measured most frequently is the triceps skin fold (TSF) which consists
of a double layer of skin and subcutaneous fat (Figure 1.1). The method
assumes that changes in subcutaneous fat reflect changes in total body fat
and that alterations in fat stores occur proportionately throughout the
body. The TSF can be measured easily with spring callipers
(Section 2.2.4), and repetitive measurements by a single trained observer
are highly reproducible(23^). In contrast, measurements made by different
observers have poor reproducibility(23^).
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AMC = Arm muscle circumference
TSF = Triceps skin fold
Figure 1.1 Measurement of triceps skin fold (TSF) thickness at
point of the arm
the mid-
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The value of TSF measurement for detecting malnutrition has been
questioned recently, as body fat may remain unchanged or may be excessive
in the presence of moderate nutritional impairment. Loss of body fat is
probably not as important from a functional point of view as loss of body
protein^232). Measurements of body fat have been shown to be less reliable
in detecting malnutrition than estimates of skeletal protein and plasma
albumin concentrations(233). However, the amount of subcutaneous fat
indicates the size of energy reserves, and a severe reduction implies
reduced ability to withstand prolonged periods of inadequate caloric
intake. Mullen et al^235^ found that TSF was a predictive parameter of
post-operative morbidity and mortality among patients with severe
nutritional depletion.
Arm muscle circumference (AMC) is a calculated parameter of lean
body mass or skeletal protein mass, and is obtained from the formula
AMC = MAC - (TT x TSF), (MAC = mid-arm circumference, TSF = triceps skin
fold thickness). Although AMC is used widely in nutritional assessment it
has some inherent problems. It assumes that the arm muscles and humerus
are circular, which they are not. Secondly, the arm is fusiform in shape
in its long axis and so measurement of MAC and TSF must be taken precisely
at the same point along the arm each time. Thirdly, the combination of MAC
and TSF measurements increases the possible percentage error of the
estimation, especially with multiple observers^233^.
Opinion is divided as to the value of AMC measurements in
nutritional assessment. Mullen et al^233) found that AMC did not predict
post-operative complications. Conversely, Klidjian et al^233) found that
an AMC of less than 85% of a standard AMC was associated significantly
(P<0.02) with a high risk of post-operative problems, and considered that
AMC should be one of three criteria of protein depletion. Further support
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for the use of AMC is provided by Harries et al(237) who found a strong
positive correlation (r=0.87, P<0.001) between AMC and weight-for-height
measurements (expressed as percentages of standard values) in over 100
patients with inflammatory bowel disease, and observed that the "90% of
ideal values" cut off point for weight-for-height, AMC and serum albumin
was able to distinguish malnourished from well nourished patients.
Anthropometric measurements have two major limitations. First,
there may be considerable observer error, especially when multiple
observers perform the assessment sequentially. The "multiple observer
error" was eliminated in the present study by the author performing all
nutritional assessments. Measurements made by single observers have been
shown to be reproducible^234'238). Second, evaluation of anthropometric
data relies on comparison of measured parameters with those of a standard
or normal population, and problems arise with both the definition of normal
for any particular population and the relevance of the reference population
to particular patients. The most widely used reference values for weight
in relation to height are the Metropolitan Life Insurance Company
tables^230,238), while values used for TSF, MAC and AMC may be determined
by individual researchers(233). The relevance of these factors to the
present study is discussed in Chapter 6.
1.6.2 (c) Biochemical measurements
Many biochemical measurements have been used to define malnutrition
and to identify malnourished individuals. Body composition measurements
can be made from TBNAA and radioisotope dilution studies using a whole body
counter and the radioisotopes 40K, 22Na and tritiated ("heavy") water. Body
potassium is found predominantly in muscle, and total body potassium has
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been used for some time as an index of muscle mass and body cell mass.
Total exchangeable sodium is used as a measure of extracellular mass which
is lean body mass less body cell mass. Total body water provides an index
of the fat-free tissues. The ratio of exchangeable sodium to potassium
(Nae/Ke) will increase in cases of continuing nutritional impairment and
catabolism(264)
Body composition measurements are attractive methods of assessing
nutritional status because they measure directly different body
compartments, they are objective, do not rely on standard or ideal values,
provide a quantitative assessment and can be used for short-term assessment
of nutritional therapy. Although not without sources of error, body
composition measurements are regarded as the "gold standard" of nutritional
assessment^222*2^9). Unfortunately, the techniques are not used widely in
clinical practice because of their high capital costs and the requirement
for personnel with specialised technical expertise; they are time consuming
and cannot be applied at the bed side. Forse et al^222) compared
anthropometric and biochemical methods of assessment with the results of
body composition studies in 206 normal and malnourished general surgical
patients and a small group of morbidly obese patients awaiting weight-
reduction surgery; anthropometric and biochemical parameters correlated
well with appropriate body composition parameters but there was a wide
scatter of results for each parameter. Methods of measurement with low
sensitivity are of limited value for assessment of individual subjects but
are useful in epidemiological studies.
The 24-hour urinary excretion of creatinine has been used as a
biochemical marker for estimation of body muscle mass, and the ratio of
24 hour urinary creatinine excretion of a patient to that of a "normal"
subject of the same sex, height and body build has been proposed as an
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index of somatic protein depletion ("creatinine/height ratio")(240)
Creatinine is a breakdown product of creatine which is an energy storage
protein of muscle and which breaks down spontaneously at a relatively
constant rate. Determination of creatinine/height ratio is fraught with
problems: it relies on accurate collection of all urine samples over a
24 hour period, a procedure which is extremely difficult to do precisely,
even in well controlled metabolic units(240>241); renal function must be
normal; the index changes with increasing age; and interpretation of the
result relies on the use of normal values from a healthy population which
must be relevant to the patient being assessed.
Similarly, measurement of urinary excretion of 3-methyl-histidine,
an amino acid found in myofibrillar but not sarcoplasmic protein, has been
proposed as an index of muscle protein turnover and nutritional
status(242>243). The same criticisms can be made of this biochemical
parameter as of urinary creatinine estimation. In addition, 3-methyl-
histidine reflects the turnover of only 65% of muscle protein and there
appears to be no adequate normal standard available for comparison(.
Body muscle mass represents the somatic mass which is one of the
body protein pools, the other being the visceral protein mass. Serum or
plasma proteins are measured in the hope that they will provide information
about the visceral protein mass, but such measurements can be accepted only
if certain assumptions are made: (i) that the measured proteins (which are
liver-dependent transport proteins) reflect the composition of the visceral
protein mass; (ii) that the serum concentrations reflect substrate
availability (i.e. protein intake prior to assessment) rather than liver
function or changes in liver mass; and (iii) that the disease process
causing the nutritional impairment has no bearing on protein concentration.
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The most frequently measured plasma protein in nutritional assessment is
albumin, a slow turnover protein with a half life of 20 days. Transferrin
is also a slow turnover protein (half life = 8-10 days), while pre-albumin
and retinol binding protein are rapid turnover proteins (half life = 2 days
and 10 hours respectively) and are believed by some to be better indicators
of protein malnutrition than albumin and transferrin^244). Measurement of
these liver-dependent transport proteins is straightforward, rapid and
inexpensive and has been used widely in epidemiological studies and
nutritional studies of malnourished hospital patients.
Although low serum albumin concentrations are well documented in
populations with severe and chronic protein-calorie malnutrition, albumin
is a poor indicator of early or acute protein deficiency because serum
levels fall slowly. Concentrations of albumin and other proteins in serum
are dependent upon several factors including synthesis, catabolism,
excretion and other losses, transvascular movement, administration of blood
and blood products and the patient's state of hydration, and only synthesis
depends on amino acid intake and availability. Albumin concentration is
affected much more by changes in body fluids than by protein
depletion^45*) . It is because of these limitations that plasma albumin
(and transferrin) measurements lack specificity and are of limited value in
assessing the visceral protein compartment^244).
In spite of these inherent problems, serum or plasma proteins
(especially albumin) are used widely in nutritional assessment protocols,
with some justification. Plasma albumin concentration has been shown to
correlate significantly with the fast turnover protein pre-albumin (r=0.72,
P<0.01) in surgical patients with benign or malignant disease and requiring
parenteral nutrition^245). Serum albumin levels correlate with
anthropometric methods of nutritional assessment(227) and are highly
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significant predictors of malnutrition as determined by radioisotope body
composition measurements(232). However, in each of these three
studies^232 '23^ ' 245) ^ co-efficient of correlation was relatively low,
suggesting that albumin does not have high specificity as a nutritional
index. Serum albumin has been shown to be a predictor of post-operative
morbidity and mortality(246-250) For example, Mullen et al^236) found
that patients with low serum albumin had a rate of significant
complications two and a half times that of patients with normal albumin
levels, although 45% of hypo-albuminaemic patients did not have
complications. Klidjian et al^233) found a significant association
(P<0.001) between low albumin concentrations and post-operative
complications in 225 patients undergoing major abdominal surgery for benign
(n=157) or malignant disease (n=68). As a result of this study, Klidjian
recommended that a low plasma albumin be included with reduced AMC and grip
strength in the definition of "appreciable protein depletion"(233).
Protein turnover studies provide a great deal more information
about rates of synthesis and catabolism than single serum determinations.
They provide better definition of the type and degree of malnutrition, but
at present they are best regarded as research tools and cannot be used for
rapid bedside diagnosis (23;I- >.
1.6.2 (d) Functional assessment
An alternative to static indices of nutritional status is
assessment of physiological functions, on the basis that physical activity,
work performance, cognitive ability and the response to disease are
clinical expressions of functional competence which is likely to be
affected adversely by malnutrition. The loss or impairment of such
functions should be more important biologically to the host than levels of
a particular nutrient or protein in the circulation. A large number of
functional indices of nutritional status have been described; they include
tests or analyses of tissues of structural importance, host immunological
responses (Section 1.6.2), nutrient transport, haemostasis and nerve
function^252) Assessment of work capacity involves testing muscle
function. The ability to perform specific tasks of relatively high energy
expenditure (such as bicycle ergometry) has been used to evaluate
nutritional status in epidemiological studies, some of which have shown
close agreement between anthropometric and functional indices and that
reduction of work performance is related closely to reductions in body size
and tissue mass(2^2,254)_
Tests such as climbing, treadmill walking or bicycle ergometry are
not applicable to bedside nutritional assessment of malnourished hospital
patients suffering from diseases or the after-effects of anaesthesia and
surgery. Klidjian et ai(233,255) pr0posed the functional test of handgrip
dynamometry as a useful non-invasive screening method of detecting
malnutrition. They found that grip strength was more sensitive than
anthropometric (weight for height, weight loss, AMC and forearm muscle
circumference) or plasma albumin measurements in predicting post-operative
complications in 102 patients undergoing major abdominal surgery. However,
handgrip dynamometry lacked specificity in that it had a false positive
rate of 50%, a rate similar to that of anthropometric tests(233) jjje
major problem with grip dynamometry and other functional tests of work
capacity is that standard or normal values are required for comparison and
this entails ready access to healthy age- and sex-matched control
subjects. Klidjian's study used a control population of hospitalised
patients (who were supposedly "healthy") and were younger than the test
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population, which had a higher proportion of males(233).
The aims of functional assessment are relevant to populations of
malnourished hospital patients in as much as they seek to test the capacity
of the individual to respond in a physiologically normal manner to added
stress. There are many inherent problems with functional tests of muscular
capacity and the results of such tests are clearly influenced by
motivation, physical fitness and understanding of the task required, as
well as body composition. Also, exercise capacity has very wide variation
in both well-nourished and malnourished subjects and so problems arise in
establishing control populations and appropriate cut-off points to ensure
high sensitivity and specificity. Tests such as handgrip dynamometry
represent a method of functional assessment which is potentially useful to
the clinician as a predictive measure of the consequences of malnutrition
secondary to disease, although further confirmation of their value is
awaited(2^6,257) _
1.6.2 (e) Immunological assessment
Protein-calorie malnutrition and deficiencies of specific nutrients
are associated frequently with impaired immune function (Section 1.6.1).
Thus, tests of immune function have been used to quantify nutritional
status. Mullen et al^236) prospectively studied the impact of nutritional
status on post-operative morbidity and mortality in 64 consecutive general
surgical patients: nutritional status was assessed by anthropometric
(weight loss, triceps skin fold, mid-arm muscle circumference), biochemical
(serum albumin and transferrin levels, protein electrophoresis, creatinine-
height index) and immunological parameters (total and T lymphocyte count,
serum complement level, neutrophil migration and CDHR), and patients were
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monitored for post-operative complications. Serum albumin and transferrin
levels and CDHR were found to be the most accurate indicators of a poor
prognosis; anergic patients had a 33% complication rate, which was 2 1/2
times greater than that of patients who reacted to at least one of three
skin test antigens. In another study of 162 consecutive non-emergency
surgical patients, Mullen^235) used discriminant analysis and a
computerised regression procedure to identify the individual power of the
most important predictive variables. Again, serum albumin and transferrin
levels and delayed hypersensitivity skin reactions, as well as triceps skin
fold measurement, were the most useful predictive indices of complications
associated with malnutrition, with serum albumin concentration being the
most powerful measurement. These and other studies^253^ indicate, firstly,
that some parameters of immune function can be correlated with more
traditional means of nutritional assessment in malnourished individuals
and, secondly, that immunological assessment of malnourished patients is of
some predictive value, although the specificity and sensitivity of immune
function tests are not high. This second point is a feature of many of the
methods of nutritional assessment.
The two immunological parameters used most widely for nutritional
assessment have been CDHR ("skin testing") and the PB lymphocyte count.
The value of CDHR tests in nutritional assessment of cancer patients
remains unclear. Although some studies (reviewed by Hessov^259)) have been
able to correlate "anergy" (or more correctly absence of an inflammatory
response to intradermal injection of antigen) with significant increases in
post-operative septic complications, other well conducted studies(260»261)
have failed to confirm the predictive value of skin testing. Advocates of
CDHR have claimed that serial skin tests are a guide to the adequacy of
nutritional therapy and surgical treatment in septic patients and in
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patients following major trauma^216), but the logistic difficulties of
performing serial CDHR in acutely ill patients precludes use of the method
in all but the most enthusiastic and well-staffed units. Although the
conflicting results obtained from skin testing can be explained partly by
variations in the study populations, different combinations of disease and
treatment, and different criteria for grading the results, it is clear that
the role of CDHR as an index of malnutrition is limited.
There are theoretical objections to the use of CDHR in the
assessment of malnutrition in hospital patients. The diagnosis of impaired
nutritional status by CDHR relies on the absence or reduction in size of
the response to intradermal antigens. Apart from technical problems with
the performance of the test and the general lack of standardisation of
positive and negative responses, a negative response cannot be equated
necessarily with depression of cellular immunity^^^: a CDHR has at least
three distinct components - (a) an afferent component which requires
sensitisation of T lymphocytes to a macrophage-processed antigen, (b) an
efferent component which requires interaction of sensitised T cells with
antigen and subsequent release of lymphokines, and (c) an inflammatory
component which is read as a positive skin test but which is not
immunologically specific as it may be induced by non-specific irritants. A
defect in any component may account for an impaired skin test response.
Factors suppressing the cutaneous inflammatory response (e.g. raised plasma
steroid levels or acute phase reactant proteins, the plasma concentrations
of which may be raised with tissue injury and in untreated cancer patients)
can affect the results of CDHR. Most clinicians agree that a number of
parameters should be measured when assessing the immunological status of
patients, including quantitative and qualitative in vitro lymphocyte
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studies, because dissociations between skin tests and in vitro lymphocyte
responses are well recognised^2®2).
Peripheral blood total lymphocyte (PBL) counts have been used in
nutritional assessment and to predict the likelihood of post-operative
septic complications. A PBL count below 1.2 x 10® per ml is said to
represent relative anergy as a result of moderate visceral protein
depletion. The value of the PBL count as an index of nutritional
impairment is not generally accepted because of its poor sensitivity.
However, studies have shown that the PBL count is of prognostic
significance: a retrospective survey of 105 patients found that those with
lymphocyte counts of less than 1.0 x 10® per ml had significantly more
post-operative sepsis than those with lymphocyte counts above this
value^2®3). Johnston et al^23®) reported a 509s mortality among patients
with subnormal lymphocyte counts, although few details of other variables
were given. Others(236,260) have found this measurement to be of no
prognostic significance.
A criticism of static anthropometric methods of assessment is that
they reflect simply the size of a body compartment and may have little
bearing on the function of that compartment or, more importantly, the
ability of the host to withstand periods of inadequate nutritional intake
while maintaining complete functional integrity. The same criticism can be
applied to the use of the total lymphocyte count as a measure of
nutritional status. The function of the immune cells would seem to be of
greater importance to the host than just their number.
1.6.2 (f) Summary
It is clear from this review that no method of nutritional
assessment is entirely satisfactory and that general agreement has not been
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reached concerning the best protocol for assessing the nutritional status
of hospitalised patients. Methods which are the most accurate and
objective (e.g. TBNAA) are not suitable for use at the bedside; the most
readily available and practical methods have lower specificity and
sensitivity, are subject to observer error and their interpretation may be
problematic (e.g. anthropometry, dynamometry); poor specificity is a
feature of biochemical and immunological methods also. However, attempts
have to be made to assess nutrition, and most practitioners use several
techniques rather than one method alone. Until an accurate comprehensive
method or index is identified, clinicians will rely on a dietary history,
physical examination, anthropometry, and laboratory (biochemical)
measurements. The use of functional methods is appealing but at present
their value remains to be confirmed and standards for comparison are not
available generally. The role of immunological methods has yet to be
defined.
1.7 NUTRITIONAL THERAPY IN CANCER PATIENTS
The evidence reviewed in the previous section indicates that
malnutrition is a common feature of malignancy and has wide ranging adverse
effects on the immune system, and that serious complications following
surgical treatment of cancer patients occur far more frequently in those
who are malnourished. Current practice dictates that, in the case of many
solid tumours, surgery should be performed to remove the bulk of the
malignant tissue and that chemotherapy and radiotherapy be employed to
eliminate residual cancer cells. Immune mechanisms may participate in the
destruction of malignant cells, and so restoration of normal immune
function in cancer patients could be an important factor in host resistance
against malignancy after tumour debulking. Full evaluation of the benefits
of nutritional therapy in malnourished patients with cancer is still
awaited.
1.7.1 EFFECTS OF NUTRITIONAL REPLETION
Although long-term studies of cancer patients who have received
nutritional therapy during anti-neoplastic therapy are lacking, attempts
have been made to assess the effects of nutritional repletion on body
composition, immune function and short-term clinical progress in cancer
patients.
1.7.1 (a) Body composition
The effect of nutritional support in cancer patients has been
studied by Cohn et al^269) who reported that patients receiving total
parenteral nutrition (TPN) for six weeks during chemotherapy showed
increases in body weight as a result of increased body fat and water
whereas the gain of protein was small; TBNAA showed that feeding had a true
anabolic effect. A similar pattern was observed in patients who received
enteral nutritional supplements and who gained significant (>1 kg) body
weight: however, protein was lost while body fat increased in those who
simply maintained their weight. In patients who lost weight during
supplementation, weight loss was due largely to a reduction in total body
water and a small loss of body protein: TBNAA showed that these patients
had continued catabolism. Cohn et al^2") also compared standard
anthropometric and biochemical indices of body composition with results
obtained from TBNAA and isotope dilution techniques during periods of
parenteral and enteral feeding; the anthropometric indices (AMC and TSF)
correlated well with the body composition results but biochemical indices
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(serum albumin and transferrin levels) and PB total lymphocyte count did
not.
In summary, some evidence shows that nutritional repletion leads to
increased body weight, but the functional value of this is dubious because
the increases result largely from retained body water with little
improvement in body protein. However, lean body tissue, subcutaneous fat
and whole body protein synthesis can be increased in some patients.
1.7.1 (b) Immunological parameters
Nutritional repletion with enteral or parenteral feeding has been
shown to restore some of the immmune deficits associated with malnutrition.
Haffejee et al(27°) use(j enteral feeds to correct protein-calorie
malnutrition in 15 patients with inoperable carcinoma of the oesophagus;
increases in total and T lymphocyte numbers and in vitro lymphocyte
reactivity occurred after achieving a positive nitrogen balance.
Interestingly, improvement in immunological parameters occurred without any
attempt at therapeutic reduction in tumour bulk, a finding which adds
weight to the conclusions of Dominioni et al^220) that malnutrition, rather
than the presence of malignancy, is the major factor in the impaired
immunological parameters found in many malnourished cancer patients.
Enteral feeding of malnourished animals has been shown to restore depressed
cellular and humoral immunity(271) and to reverse their increased
susceptibility to bacterial and viral infections^272).
Dionigi et al^273) demonstrated in dogs with subacute malnutrition
that TPN with fat-free solutions resulted in a return to normal of
neutrophil chemotaxis and serum concentrations of IgG, IgM and C3, and that
the primary immune response of the dogs to thymus-dependent antigens was
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stronger and more rapid following TPN. In contrast to earlier
findings^274^, treatment of the dogs with TPN did not restore in vitro
proliferative responses of lymphocytes to mitogenic stimulation. This
result, which is at variance with those of others(258•275»276), was thought
to be due to either the relatively short period of treatment (21 days) or
the persistent stress of having permanent indwelling central venous
catheters and being constrained constantly in metabolic cages.
Law et al^275) showed in 7 malnourished patients with benign
diseases that intravenous feeding with fat-free solutions for 18 days
resulted in significant improvement of in vitro lymphocyte proliferative
responses to T cell mitogens, although humoral immunity was not affected.
Copeland et al(276) reported that prolonged parenteral nutrition with fat-
free solutions in malnourished cancer patients resulted in improvement of
CDHR - 19 of 33 patients with initial negative skin responses converted to
positivity during parenteral feeding. Significantly, of patients
undergoing surgery, all with negative skin responses either died or had
prolonged post-operative complications, whereas two-thirds with positive
skin responses had uncomplicated post-operative courses. Of patients
receiving chemotherapy, tumour regression was seen only in patients whose
skin tests converted from negative to positive during intravenous feeding
or who had positive skin tests before intravenous feeding commenced.
It is evident, therefore, that nutritional repletion can reverse
some immunological abnormalities observed in malnourished cancer patients.
These findings give indirect support to the use of immunological parameters
in nutritional assessment of cancer patients, although the limitations of
such assays must be borne in mind (Section 1.6.2).
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1.7.1 (c) Clinical results
Weight loss in patients with cancer has been identified as a factor
associated with decreased survival(277) an(j severai studies have been
undertaken to evaluate nutritional therapy as an adjunct to antineoplastic
therapy. Generally, such studies have attempted "to answer two questions:
does nutritional therapy influence the outcome of antineoplastic
chemotherapy or radiotherapy, and does nutritional therapy influence the
morbidity and mortality of surgery in cancer patients?
A summary of seven randomised clinical trials of TPN in addition to
chemotherapy is given in Table 1.4. No significant improvement in survival
or response to treatment was associated with the use of TPN in addition to
chemotherapy in any of these studies of patients with advanced cancer, but
it should be noted that the number of patients in each study is small, with
the exception of the study by Clamon et al^280). When considered together,
the results are consistent with the view that provision of calories and
amino acids does not alter the clinical course of patients receiving anti¬
cancer chemotherapy. Parameters such as patient wellbeing were not
considered by many of these studies, which may have included too few
patients or provided nutritional support for too short a time for major
benefits to be obvious. Similarly, TPN appears to have no place in the
routine management of cancer patients undergoing radiotherapy^288^.
However, that is not to say that malnourished patients will not require
some form of nutritional support during their radiotherapy if they are
unable to eat or drink nutritious substances.
The second major area of interest has been the value of short-term
nutritional support in preventing complications following surgical
treatment of malignancies. A summary of seven randomised trials of surgery
with or without TPN is given in Table 1.5. Again, these studies(286-292)
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Table 1.4 Summary of seven randomised trials of TPN in addition to
chemotherapy in patients with advanced cancer
Tumour Number of Duration Result Ref.








Increased weight and 278
significantly decreased
survival with TPN
NSD in chemotherapy 279
tolerance
NSD in survival or 280
response rate




in CDHR with TPN
NSD in response rate or 282
haematological
complications






NSD in response rate or 284
long-term survival
TPN = Total parenteral nutrition
NSD = No significant difference
NS = Not significant
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Table 1.5 Summary of seven randonised trials of TPN in addition to




















Pre-op, 12 NSD in survival or 287
complications




Upper GI 74 Pre and 7-15
post-op
NS reduction in 289
mortality and morbidity
and significant reduction
in wound infection with TPN


















and NS reduction in
mortality and anastomotic
leak rate with TPN
N = Nitrogen
NS = Not significant
NSD => No significant difference
TPN = Total parenteral nutrition
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involved small numbers of patients and the periods of nutritional support
were short. Most studies showed some benefit of TPN in patients with
operable cancer of the gastrointestinal tract although differences between
test and control groups did not always reach statistical significance.
1.7.1 (d) Potentially adverse effects of intravenous nutrition
Intravenous nutrition requires central venous catheterisation which
exposes patients to many potential complications related to infection,
venous thrombosis and mechanical problems with the catheters, connector
pieces, intravenous lines and delivery systems(2") . jn addition to
mechanical and metabolic problems, reservations have been raised about the
use of nutritional support for cancer patients because of the possibility
that the tumour might sequester nutrients for its own growth and thereby
benefit disproportionately in comparison with host tissues. Carmichael et
a|(268) showed in humans that protein was translocated from protein stores
(such as muscle) to tumours where protein synthesis was rapid and greater
than that of host tissues. Stein et al(294) found that tumour-bearing rats
retrieved more nitrogen than control rats on the same dietary intake and
that the tumours demonstrated a rapid rate of protein synthesis on all but
the most restrictive diets; even on deficient diets the rate of protein
synthesis in tumours was greater than that of any other tissue. White(295)
noted that protein-energy malnutrition inhibits tumour growth in rodents
and increases the tumour latency period after implantation.
Other workers have reported stimulation of tumour growth by
nutritional repletion of protein-depleted animals. Popp et al^2")
demonstrated in Fisher rats with sarcoma transplants that tumour weight
increased more than the host lean carcase weight as the rate of calorie
infusion increased. No evidence has appeared as yet to indicate that
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nutritional support stimulates tumour growth in humans(297)
1.7.2 INTRAVENOUS NUTRIENT SOLUTIONS AND IMMUNE FUNCTION
A further source of insult to the cancer patient receiving TPN is
the intravenous fluids themselves, apart from any effect which they may
have on nutritional status. When evaluating the effects of intravenous
nutrition, account must be taken of the effects of the intravenous nutrient
solutions themselves, in addition to effects brought about by improved
nutritional status. This is of particular importance when intravenous
nutritional therapy is given only for a short time, when improvements in
nutritional status may not occur. For example, if an intravenous solution
was found to have a detrimental effect on immune function, it would not be
advisable to use it in patients with proven reduced immunity because the
immune system would be impaired further before any beneficial effect of
improved nutrition was evident.
The studies of parenteral feeding of malnourished cancer patients
(Section 1.7.1) showed improvement of immunological parameters and some
improvements in post-operative morbidity and mortality(273>27^>276>286-
292). Interestingly, all of these studies used combinations of amino acid
and carbohydrate solutions as protein and energy sources respectively, and
none used fat emulsions.
The apparent absence of fat emulsions in many studies of
hyperalimentation is probably due to their relatively late appearance in
the USA, where most studies have been performed, and to the widely held
belief that fat is inferior to glucose as an energy source. With the
recognition that fat emulsions have some definite advantages over
carbohydrate as sources of energy(29**»299), it is probable that they will
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be used more widely and included in studies of parenteral nutrition.
Fat emulsions suitable for clinical use were produced first in
Japan in the 1920's and have become accepted components of TPN regimes.
They contain essential fatty acids and provide relatively large amounts of
calories in small isotonic volumes. Most fat emulsions contain only a small
proportion of free fatty acids but have a high content of esterified
polyunsaturated fatty acids (PUFA). For example, oleic, linoleic and
linolenic acids account for 86% of the esterified unsaturated fatty acids
in "Intralipid" (Kabivitrum Ltd, Stockholm), the most widely used
commercially available fat emulsion. Fatty acids exist normally as either
triglycerides or phospholipids, and similarly, free fatty acids comprise
less than 1% of commercially available fat emulsions.
There are several reports concerning the immunosuppressive effects
of PUFA. Mertin et al^°°), in a comparative study of five fatty acids
(palmitic (C16:0), stearic (C18:0), oleic (C18-.1), linoleic (C18:2) and
arachidonic acid (C20-.4)) found that in vitro transformation of normal
human lymphocytes was inhibited by all of these fatty acids at
concentrations equivalent to and greater than physiological concentrations.
The inhibitory effects were dose-related, with oleic acid being the most
potent inhibitor; among the unsaturated fatty acids, there was a stepwise
increase in inhibitory activity (arachidonic < linoleic < oleic). PUFA
showed a significant difference between inhibition of transformation of
stimulated (with PPD and PHA) and non-stimulated lymphocytes(300),
suggesting that PUFA have a specific inhibitory action restricted to
activated lymphocytes, whereas the inhibitory effects of saturated fatty
acids were seen with stimulated and non-stimulated lymphocytes, suggesting
non-specific inhibition. Mertin et al^Ol) found that linoleic and
arachidonic acids significantly inhibited in vitro reactivity of human
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lymphocytes to PPD, and that inhibition occurred only when PUFA were added
to lymphocytes before but not after antigen was added, suggesting PUFA
interfered with recognition of antigen by lymphocytes. Similarly, Offner
et al^303) found that oleic, linoleic and arachidonic acids and
prostaglandin El and E2 at physiological concentrations significantly
inhibited lymphocyte activity, with the same stepwise increase in
inhibitory activity observed by Mertin et al(300>301).
The inhibitory effects of PUFA on cellular immune responses have
been demonstrated in vivo also. Ring et al^303) demonstrated that survival
of skin allografts in rats was prolonged significantly by oral or
intraperitoneal administration of linoleic acid. Kort et al^304)
demonstrated significant prolongation of kidney allograft survival by
feeding rats with a diet rich in sunflower seed oil which contained about
four times the amount of linoleic acid given to control animals. Similar
results have been obtained in mice with skin allografts^305). The
immunosuppressive properties of linoleic acid have been explored in human
cadaveric renal transplantation by the use of sunflower seed oil in
addition to conventional immunosuppressive therapy in recipients of renal
allografts^306).
The demonstration that saturated and unsaturated fatty acids have
immunosuppressive properties is of concern to clinicians who might
prescribe fat emulsions for nutritional therapy in clinical practice.
Patients who are candidates for parenteral nutritional support frequently
have impaired cellular immunity and so the possibility arises that the use
of fat emulsions, with their high content of fatty acids, could result in
further suppression of cellular immunity, thereby exposing patients to
increased risks of septic complications. Although evidence shows that
restoration of nutritional status by prolonged intravenous feeding with
fat-free fluids can result in improvement of immune function, the short-
term effects of the intravenous nutrients themselves, especially those
containing fats, are unknown. Thus, the effects of intravenous nutrient
solutions on lymphocyte activity were studied and .the results reported in
Chapter 4.
1.8 HYPOTHESES
It is apparent from the reviewed literature that the immune system
is a highly complex integrated system which has far reaching influences in
the intact human and which itself is influenced by regulatory systems and
mechanisms. The cell of central importance is the lymphocyte. The
reactivity of individual components of the immune system can be impaired by
many factors and disease states, including malignant disease and
malnutrition.
The paradox of progressive tumour growth in the presence of
specific anti-tumour humoral and cell-mediated immune responses has led to
the concept of "immunological escape" of tumours from the control and
influence of their host. One of the many abnormal findings in cancer
patients is the presence of immunosuppressive factors in plasma. These
factors are poorly defined, and their importance and contribution to the
impairment of immune competence and to the growth of tumours is unknown.
It has been pointed out that tumours release many molecules from their
constituent cell surfaces, including protease enzymes (P), and that alpha-
2-macroglobulin (A2M), a plasma protease inhibitor, has the ability to
eliminate proteases, with the result that a relatively immunosuppressive
A2M-P complex is formed.
The first hypothesis of this study is that the presence of
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malignant disease is associated with factors which are non-specifically
immunosuppressive and which, having been produced or induced by a tumour,
cause the plasma of patients with cancer to have increased suppressive
activity compared with that of normal subjects; in view of the wide ranging
activities of A2M, it is proposed that A2M has an important role in the
immunoregulation of cancer patients and that this naturally occurring
molecule has a different or additional biological function in such
patients. If this hypothesis is correct, then modification of a naturally
occurring "homeostatic" molecule by the presence of a tumour or tumour-
derived factors could represent another mechanism of immunological escape.
It is evident from the reviewed literature that malnutrition
impairs host immunity. Interest in the adverse effects of malnutrition has
centred largely on cellular defects and very little is known about changes
in humoral components apart from the immunoglobulins. In view of the wide
ranging and relatively non-specific nature of the immune deficit found in
malnourished subjects, the second hypothesis proposes that non-specific
immunosuppressive factors are present in the plasma of such subjects and
may be responsible in part for their immune deficit.
The problems of nutritional assessment have been reviewed and it is
clear that no single method exists to satisfactorily classify or quantify
the malnourished state. The value of functional as opposed to static
nutritional parameters has been considered. Malnourished patients have a
high incidence of infections and so researchers have attempted to correlate
tests of immune function with the more traditional methods of nutritional
assessment. This experimental work will determine whether a correlation
exists between a new parameter, the lymphocyte suppressive activity in a
subject's plasma, with standard well-accepted anthropometric methods of
nutritional assessment.
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Routine intravenous nutritional support of cancer patients
undergoing surgery or chemotherapy has been shown to be of dubious value in
terms of survival, increasing tolerance to chemotherapy or reducing the
morbidity of anti-neoplastic therapy. Several studies have shown that
intravenous feeding with fat-free fluids improves tests of immune function.
Modern TPN regimes usually include emulsions of fatty acids, which have
immunosuppressive properties in vitro. Thus, the third hypothesis is that
such fat emulsions will adversely affect host immune function, and this has
been investigated by experimental studies.
The hypotheses have been examined by experiments with the following
aims:
1. To measure in vitro lymphocyte reactivity and the non-specific
lymphocyte suppressive activity of plasma in patients with
malignant or benign disease and in healthy subjects.
2. To determine if in vitro lymphocyte reactivity and the lymphocyte
suppressive activity are abnormal in malnourished individuals, and
if so, to identify any correlation between these parameters and
conventional methods of nutritional assessment.
3. To identify the factor or factors in plasma associated with
measurable lymphocyte suppressive activity.
4. To define the role of A2M with respect to lymphocyte reactivity and
the suppressive activity of plasma in the above mentioned subjects.
5. To assess the relationship between the suppressive activity of
plasma and the growth of tumours, using an animal model.
6. To measure the effect of some intravenous nutrient solutions in
common use on in vitro reactivity of lymphocytes and to
measure lymphocyte responsiveness in patients receiving these
fluids.
CHAPTER 2
, MATERIALS AND METHODS
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2.1 EXPERIMENTAL SUBJECTS
There were three groups of experimental subjects in this study:
(i) healthy volunteers, (ii) patients with benign conditions, and
(iii) patients with malignant disease. Healthy volunteers were members of
staff of either the Department of Surgery, University of Newcastle upon
Tyne, or the Royal Victoria Infirmary, Newcastle upon Tyne, England. The
patients were in-patients receiving treatment on the Professorial Surgical
Unit, Royal Victoria Infirmary. All subjects agreed to withdrawal of 20 ml
of venous blood specifically for this research; some patients kindly
donated blood on more than one occasion.
A diagnosis was established for each patient by traditional
methods. No clinical investigation was performed purely for the sake of the
project. Details of history, physical examination, investigations and
nutritional assessment were recorded by the author on a specially designed
proforma. Patients were excluded from the study if a firm diagnosis could
not be made. All patients underwent surgery, some being operated upon by
the author. Confirmation of the diagnosis was made at operation and
histopathological examination was made of any excised tissue.
The details of subjects used in different parts of the study are
given within relevant sections.
2.1.1 PATIENTS WITH MALIGNANT DISEASE
Sixty-nine patients with malignant disease were studied. The
primary sites of malignant disease are shown in Table 2.1. Tumours were
staged according to the TNM classification^307^ and assigned to one of four
clinical stages which are used widely in clinical practice (Appendix 1).
Attempts were made to determine accurately the extent of disease in each
patient by: (i) pre-operative investigations such as ultrasonography and
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Table 2.1 Sites of primary tumours in patients with malignant disease
PRIMARY SITE MALE FEMALE TOTAL
Colon or rectum 20 16 36
Breast 0 14 14
Stomach 8 4 12
Pancreas 2 57
Total 30 39 69
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isotope scintigraphy, (ii) operative assessment by the surgeon by visual
inspection and palpation of regional lymph nodes and relevant viscera, and
(iii) histopathological examination of resected tissue by pathologists in
the Department of Pathology, Royal Victoria Infirmary, Newcastle upon Tyne,
England.
2.1.2 PATIENTS WITH BENIGN DISEASE
Fifty-two patients with symptomatic benign diseases were studied
(Table 2.2). Diseases were of such severity that surgery was required. No
attempt was made to match patients in the benign and malignant groups in
terms of matching one disease process with another, although attempts were
made to match symptoms and the tissues or viscera which were the sites of
disease. This has relevance to clinical situations: the clinician may be
faced with a patient who has a symptom complex compatible with either a
benign or malignant disease, or the site of disease may have been localised
by examination or investigation but the nature of the disease remains
unknown. The age and sex distributions of the two groups were similar.
2.2 NUTRITIONAL. ASSESSMENT
The methods of nutritional assessment used in the present study
were body weight-for-height, weight loss expressed as a percentage of usual
or pre-illness weight, standard anthropometric measurements of skin fold
thickness and arm muscle circumference, and serum albumin. These methods
were chosen because of the availability of reference standards, and the
ease with which they could be used repeatedly in sick immobilised patients.
Nutritional assessment of patients was performed on admission to
hospital before any form of treatment was undertaken. Anthropometric
87
Table 2.2 Diagnoses o£~patients-with benign disorders
DIAGNOSIS MALE FEMALE TOTAL
Cholelithiasis 2 13 15
Diverticular disease 6 6 12
Inflammatory bowel
disease 4 26
Peptic ulceration 3 14
Chronic pancreatitis 4 04
Benign breast disease 0 44
Oesophageal stricture 2 13
Haemorrhoids 2 02
Gastro-intestinal fistula 2 02
Total 25 27 52
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assessments were performed by the author.
2.2.1 WEIGHT-FOR-HEIGHT
Patients were weighed on a standard hospital beam balance scale
while wearing only pyjamas. Most patients were weighed by the nursing
staff after instruction by the author who undertook the weighing of some
patients. Patients' weights ("present weight" - PW) were recorded in
kilograms. The height of each patient was measured using a metric vertical
wall ruler with the patient standing upright without shoes. Patients who
were immobilised in bed on admission were measured before discharge from
hospital.
The ideal body weight (IBW) for height and sex was obtained from
the Metropolitan Life Insurance Company tables adapted by Jelliffe(230)
Each patient's PW was compared with his or her IBW by the ratio PW/IBW
which was expressed as a percentage.
2.2.2 WEIGHT LOSS
Assessment of weight loss was made by comparing each patient's PW
with his or her pre-illness or usual weight (UW), using the formula UW - PW
UW
and expressing the result as a percentage. The value of UW was obtained
from medical records or the patient's own documentation, or by patient
recall. The potential inaccuracies of patient recall of weight loss have
been acknowledged (Section 1.6.2) but had to be accepted for the purpose of
the study.
2.2.3 ARM MUSCLE CIRCUMFERENCE
Arm muscle circumference (AMC) was used to assess lean body mass.
The arm was assumed to be spherical (Figure 1.1) and AMC was calculated by
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correcting the whole arm circumference measured at the mid point of the arm
(mid arm circumference ; MAC) for the subcutaneous fat layer as measured by
the triceps skin fold (TSF) thickness, using the formula :
AMC = MAC - (Ox TSF)
Measurements were performed by firstly identifying the mid-point of
the non-dominant arm as the point mid-way between the tip of the acromion
process of the scapula and the tip of the olecranon process of the ulna
with the elbow joint flexed at 90 degrees. The non-dominant arm was used
for all measurements as it was considered that its size would be less
likely to be affected by variations in physical activity and exercise. The
circumference of the arm at the mid-point was measured three times in
centimetres and the mean value recorded. AMC values for each patient were
compared with standards for healthy males or females(230) and expressed as
percentages of these standards (AMC %).
2.2.4 TRICEPS SKIN FOLD THICKNESS
Fat stores were assessed by measurement of the triceps skin fold
(TSF) thickness of the non-dominant arm. With the patient's elbow joint
extended, the skin fold immediately above the mid point of the arm was
picked up gently between thumb and index finger, lifting the skin and
subcutaneous fat away from the underlying triceps muscle. Spring calipers
(Holtain Ltd., Dyffed, UK) were applied to the skin fold at the mid point
of the arm (Figure 1.1). The tension of the spring was such that it did not
compress the skin or fat unduly and the procedure was not uncomfortable.
The TSF was measured three times and the mean value recorded.
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2.2.5 SERUM ALBUMIN
The concentration of albumin in serum was used as a measure of
visceral protein(108). Estimations were performed in either the Department
of Clinical Chemistry at the Royal Victoria Infirmary, Newcastle upon Tyne,
using a colorimetric auto-analyzer, or by the author using single rocket
Immunoelectrophoresis (Section 2.6).
2.3 THE TANNED ERYTHROCYTE ELECTROPHORETIC MOBILITY (TEEM) TEST
The TEEM test was used throughout this study to measure in vitro
lymphocyte reactivity. The TEEM test measures the effect of soluble
lymphokine on the electrophoretic mobility of indicator particles.
Interaction of lymphocytes with an antigen or mitogen releases soluble
lymphokine which alters the normal surface electric charge of tannic acid-
treated sheep erythrocytes, which simply act as indicator cells; the
change in surface charge alters the mobility of the tanned sheep
erythrocytes within the electric field of the cytopherometer, which is the
instrument in which movement of the sheep erythrocytes can be observed and
measured.
2.3.1 BACKGROUND
Detection of in vivo cell-mediated immunity (CMI) has relied
traditionally on CDHR. A positive result requires that the subject is pre-
sensitised to the antigen and that the afferent and efferent limbs of the
immune response and components of the inflammatory response are intact, a
situation which may not exist in patients with cancer or nutritional
deficiency^59). There are many inherent problems with CDHR tests, not the
least of which is their actual performance. The advantages of in vitro
tests of CMI include the potential to examine and quantify just one
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component of the series of events which make up CDHR, ability to control
test conditions (and thereby eliminate many of the problems and sources of
error of in vivo tests), and the relative ease with which In vitro tests
can be performed.
The first in vitro assay system which correlated with delayed
hypersensitivity reactions was described in 1922 by Holst^308) who observed
that the migration of human white blood cells was sometimes inhibited after
exposure to tuberculin. Rich et al^309) in 1932 showed in vitro that
tuberculin significantly inhibited the migration of spleen cells and PB
white cells of guinea pigs immunised with non-virulent human tubercle
bacilli. Since then, several in vitro assay systems have been developed to
examine cell-mediated immunity.
The Macrophage Migration Inhibition (MMI) test was described by
David et al^310^ in 1964 and became an accepted in vitro method of
assessing delayed hypersensitivity reactions. David observed that the
migration from capillary tubes of cells obtained from peritoneal exudates
of guinea pigs sensitised to PPD was inhibited consistently and markedly by
small amounts of PPD. Later, it became clear that lymphocytes in the
peritoneal exudate were the immunologically active cells and that the
sensitised lymphocytes after in vitro contact with the sensitising antigen
(PPD) elaborated a soluble material capable of inhibiting migration of the
macrophages(311), which were simply indicator cells. Diengdoh and
Turk^312) found that the electrophoretic mobility of peritoneal exudate
macrophages from tuberculin-sensitised animals was altered by the
supernatant of the lymphocyte-antigen interaction; they concluded that a
soluble factor (or factors) liberated from stimulated lymphocytes altered




2.3.1 (a) Cell electrophoresis
Electrophoresis means the movement of particles with a net electric
charge in a solution under the influence of an electric field. Reuss(313)
in the early nineteenth century observed the movement of kaolin particles
towards the cathode when an electric current was passed across a tube
containing water, sand and kaolin. The theoretical basis of
electrophoresis was defined by Helmholtz^*^) in 1879 and Smoluchowski (3*3)
in 1903: they reasoned that the migration velocity of a particle within an
electric field depended on the electric charge of the particle, the size of
the electric field and the properties of the medium containing the
particle. The Helmholtz-Smoluchowski equation describes the
electrophoretic mobility of a particle :
u = E x D
4 n n
u = electrophoretic mobility (microns/second/volt)
E = potential difference between the surface of shear and the
suspending medium
D = dielectric constant of the suspending medium
f[ = constant (3.14159)
n = viscosity of the suspending medium
Cell electrophoresis was used almost solely as a research technique
to investigate electric potentials at cell surfaces until the 19601s.
Electrophoretic techniques have been applied to immunological research
since 1967 when Sundaram et al^316) showed that the electrophoretic
mobility of sensitised lymphocytes was reduced significantly following re-
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exposure to the sensitising antigen. Thereafter, tests utilising the
electrophoretic mobility of cells were applied widely to immunological
studies, such as the investigation of human blood groups(317), specificity
of antibody production by lymph node cells(316) and monitoring of
absorption of viruses and antibodies to cell surfaces^3*3'3*3).
2.3.1 (b) The Macrophage Electrophoretic Mobility test
Field et al(32°) applied an electrophoretic method to the MMI test,
and demonstrated that incubation of sensitised PBL with the sensitising
antigen in the presence of irradiated guinea pig peritoneal exudate
macrophages resulted in reduction of the electrophoretic mobility of the
macrophages, which acted as indicator "particles" in the electrophoretic
chamber. This single step test, the Macrophage Electrophoretic Mobility
(MEM) test, provided a rapid in vitro quantitative assessment of lymphocyte
reactivity(323).
The MEM test has been compared with established in vitro tests of
cell-mediated immunity by Mertin et al^32*) who demonstrated a very close
correlation between results obtained with the MEM test and those from
classical lymphocyte transformation. Hughes et al^322) compared the MMI
test with the MEM test in studies of guinea pigs sensitised to
encephalitogenic factor, a brain extract; they found a highly significant
correlation between the two tests and noted that the MEM test was readily
repeatable and of greater value than MMI in estimating the degree of
sensitivity to the stimulating antigen. Others^323) have made similar
observations.
Criticisms of the MEM test have been aimed mainly at the method.
The possibility of a mixed lymphocyte reaction occurring between human test
lymphocytes and lymphocytes present in the guinea pig peritoneal exudate
94
was ail obvious source of error, which was partly overcome by irradiating
the peritoneal exudate with 100 Rads^323). To remove the possibility of a
mixed lymphocyte reaction interfering with the lymphocyte-antigen reaction,
Pritchard et al^324) introduced a two stage MEM test or "modified MEM"
(MOD-MEM) test, so that there was no contact between test lymphocytes and
any cells in the guinea pig peritoneal exudate. Excellent correlations
between the MEM and MOD-MEM tests have been demonstrated(324,325)
Most of the difficulties relating to operation of the MEM and MOD-
MEM tests were due to the production and intrinsic characteristics of
guinea pig macrophages which could not be stored, and had low and somewhat
variable electrophoretic mobility. These problems were overcome by
Porzsolt et al^326) who showed in 1975 that sheep red blood cells (RBC),
stabilised with tannic acid, could be used as indicator particles in place
of guinea pig macrophages for detecting lymphokine slowing factor. This
improved test, using tanned sheep erythrocytes, is the Tanned Erythrocyte
Electrophoretic Mobility (TEEM) test^323'327) . Substitution of tanned
sheep RBC for peritoneal macrophages as indicator cells has several
advantages. Firstly, RBC are extremely homogeneous with respect to their
electrophoretic mobility and so any alteration of their mobility within the
test system is obvious. Secondly, RBC have good stability in the
cytopherometer and are not subject to the same rapid sedimentation as
macrophages. Thirdly, sheep RBC are readily available and inexpensive, and
the method of preparation is simple (Section 2.3.3(c)).
Shenton et al^327) showed clearly that the kinetics of the TEEM
test closely resemble those of the MEM and MOD-MEM tests with respect to
(a) antigen response curves for the interaction of human lymphocytes with
PPD antigen; (b) lymphocyte number response curves with PPD as the test
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antigen; (c) the effect of diluting slowing factors on electrophoretic
mobilities of indicator cells; (d) the temperature-time response curve for
the first stage of the MOD-MEM and TEEM tests; and (e) the temperature-time
response curve for the second stage of the MOD-MEM and TEEM tests. The
active components in the supernatant of lymphocyte-antigen interactions
(i.e. macrophage- and tanned sheep erythrocyte-slowing factors) have been
characterised, and have molecular weights between 13,000 and 15,000 daltons
and have similar gel filtration patterns. The results obtained with the
MEM and TEEM tests for mixed lymphocyte reactions and lymphocyte reactivity
to PPD correlate well^33^). More recently, the TEEM test has shown
excellent correlation with the classical lymphocyte transformation assay in
measuring lymphocyte sensitivity to Cortisol^333). The principle of the
TEEM test is shown in Figure 2.1.
With the description of the MEM test in 1970 came immense interest
in the possible application of cell electrophoresis to clinical medicine.
Perhaps greatest enthusiasm was centred around the use of electrophoretic
mobility tests in the diagnosis of malignant disease. In Field's original
description of the MEM test^333) he reported that lymphocytes sensitised to
a basic protein extracted from brain tissue, encephalitogenic factor,
occurred not only in patients with carcinomatous neuropathy but also in
subjects with malignant tumours without neurological damage. Further
studies by Field et al^330,331) confirmed the early findings and extended
them to demonstrate that the test could identify many individuals with
malignant tumours, irrespective of site or extent, as well as those who had
undergone surgical excision of a malignant growth and were apparently
disease-free. Although the value of the MEM test in detecting the presence
of malignancy by measuring lymphocyte sensitisation was confirmed by




Alteration of surface electric charge
of tanned sheep erythrocytes
Reduction of electrophoretic mobility
Reduced mobility of tanned sheep erythrocytes
as measured in a cytopherometer




Cell electrophoresis has also been used in the investigation of
subjects with suspected neurological diseases(320) an(j measurement
of mixed lymphocyte reactions as a prognostic factor in human kidney
transplantation^341). The TEEM test has been used extensively in clinical
organ transplantation^342) and cancer research^343•344).
In spite of an extensive literature relating to the use of cell
electrophoresis (and the TEEM test in particular) in clinical medicine, the
technique has not been accepted widely. The technique was seen in a poor
light after early and often extravagant claims for its value in cancer
diagnosis were not substantiated. However, such claims were made by a
small group of enthusiasts and reflected on the application of the
technique, not the technique itself. The two major limitations of the TEEM
test are the requirement of expensive equipment in which to perform the
test and the laborious nature of the performance of the test. Fortunately,
the equipment necessary for the TEEM test was available in the laboratory
in which the present work was performed, and the tests were performed by a
recognised expert in the field, Dr. Brian Shenton.
2.3.2 THE CYTOPHEROMETER
The cytopherometer (Carl Zeiss, GDR) is the machine in which the
TEEM test is performed (Figure 2.2). It consists of an electrophoretic
chamber, in which cells migrate under the influence of an electric field,
and an optical system for observation of cell movements (Figure 2.3). The
chamber has a volume of 3.0 ml which determines the volume of each sample
to be tested. Samples are introduced into the right hand side of the
chamber and eluted from the left. The chamber is surrounded by a water
bath and maintained at a constant temperature of 23°C by a thermostat. The
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Figure 2.2 The cytopherometer
DIAGRAMOFCYTOPHE OMETER
Figure2.3Diag amofcytoph rometer C=Chamber,Electrodes,M=Phasecontrastmicroscope,G=raticule,Waterjacket,F=lt rfunnel, IT=Tapcontrollingtheinflowithecytopherometer OT=Tapcontrollingu flowfr mcytopherometer
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electrodes, which are platinum wire covered electrolytically with a layer
of silver chloride, are isolated from the chamber by glass sinters.
Cells in the chamber are visualised by a phase contrast microscope.
In the right-sided eyepiece of the cytopherometer is a graticule composed
of one hundred 16 micron squares. The visual field seen on looking into
the cytopherometer is illustrated in Figure 2.4.
Samples to be tested were introduced into the chamber through the
filter funnel and the tanned sheep red blood cells (TSRBC) were allowed to
recover from the turbulence of introduction for a short time before
measuring their electrophoretic mobility.
The viewing microscope was focused on the stationary layer of the
electrophoresis chamber and only cells in sharp focus were measured. There
was a slow constant upward drift of cells when observed through the
microscope eyepiece, due to an inverted image of gravitational
sedimentation. A constant electric current of 7.5 milli amps was applied
between the electrodes at 180 volts and cells in the chamber moved towards
the cathode. Cells were timed in one direction between the two vertical
lines of one of the 16 micron squares in the eyepiece grid, and then each
cell was made to move in the opposite direction by reversing the current.
The time taken to move in both directions was measured by a digital
electronic timer. Any cell showing more than a 10% difference in velocity
for the two directions was excluded. Ten cells were counted for each
sample.
The following is an example of the times obtained for 10 TSRBC to
move in both directions, that is over the 32 micron distance: 6.01, 5.96,
5.91, 5.98, 6.03, 6.13, 5.89, 6.00, 5.93, 5.97. Mean time ± 1SD =5.981 ±
0.065 seconds. After measuring and recording the times for 10 cells, the
sample was eluted from the left side of the chamber which was washed with
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Figure 2.4 The visual field which is seen when looking through the right
sided eye piece of the cytopherometer
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Hank's BSS before the next sample was introduced.
The cytopherometry was performed by Dr. Brian Shenton, Principal
Scientific Officer in the Transplantation Laboratory. Dr. Shenton has an
international reputation in the field of cytopherometry and has made
substantial contributions to the application of cell electrophoresis to
clinical medicine. An independent worker in this part of the study enabled
the samples to be studied without knowledge of their source and, therefore,
complete objectivity was achieved. His willing assistance is gratefully
acknowledged.
2.3.3 PERFORMANCE OF THE TEEM TEST
The general method of measuring lymphocyte reactivity using the
TEEM test is shown in Figure 2.5. The method has been described
previously().
2.3.3 (a) Preparation of lymphocytes
Lymphocytes were prepared from PB by the one step sodium
metrizoate/Ficoll procedure described by Boyura^^®) in 1968. Each blood
sample was diluted with an equal volume of Hank's BSS. 10 ml of sodium
metrizoate/Ficoll mixture ("Lymphoprep", Nyegaard and Co. Oslo, Norway) was
placed in a sterile 20 ml Universal container (Sterilin Ltd., Teddington,
Middlesex, England), and 10 ml of diluted blood was layered carefully onto
the lymphoprep using a Pasteur pipette. The sterilin container was placed
carefully into a centrifuge so that mixing at the blood-lymphoprep
interface was avoided. The sample was centrifuged at room temperature for
30 minutes at 1300 revolutions per minute (RPM), resulting in 400 x G at
the interface.
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0.5 x 106 lymphocytes + Stimulus*
in 3 ml Hank's BSS
Incubate for 1 1/2 hours at 23°C
Centrifuge at 400 G for 10 minutes
Supernatant
4 x 107 tanned sheep red blood cells
Incubate for 1 hour at 23°C
Measure electrophoretic mobility of tanned sheep erythrocytes
* Stimulus (1) PPD 100 MS
(2) PHA 10 MS
(3) Con A 100 MS
(4) PWM 100 MS
Figure 2.5 The tanned erythrocyte electrophoretic mobility (TEEM) test
method
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During centrifugation erythrocytes aggregated into rouleaux under
the influence of Ficoll and passed to the bottom of the container;
lymphocytes formed a layer immediately above the lymphoprep, while
leucocytes and platelets remained in suspension in the diluted plasma
layer. The lymphocyte layer was removed carefully with a Pasteur pipette
and placed in another sterilin container. Lymphocytes were washed twice by
adding Hank's BSS and centrifuging at 2000 RPM for 5 minutes at room
temperature, and the cell pellet was resuspended in Hank's BSS.
Lymphocytes were counted in a Neubauer haemocytometer and the volume
adjusted with Hank's BSS so that the final concentration was 1 x 10®
lymphocytes per ml.
Using this method of lymphocyte separation, contamination by RBC is
minimal and amounts to only a very small percentage of the final cell
count^®^®). Some immature granulocytes may follow the lymphocytes during
separation when there is a granulocyte shift to the left, but patients from
whom blood was obtained did not have conditions associated with a
granulocyte shift. The main source of contamination of lymphocytes occurs
during their removal from the diluted plasma. Lymphocytes appear as a
thick white layer immediately above the clear cell-free lymphoprep layer
and beneath the pale pink layer of plasma diluted with Hank's BSS.
Significant contamination of lymphocytes with diluted plasma was detected
by pink discolouration of the lymphocyte suspension and such samples were
discarded. The washing procedure removed traces of plasma and platelets
from the lymphocyte suspensions.
2.3.3 (b) Lymphocyte-antigen/mitogen interaction
Reactivity of lymphocytes to several stimuli was measured. PPD was
used as a stimulating antigen. The assumption was made that the local
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population either had been exposed to tuberculosis or had received BCG
vaccination. It was accepted locally by clinical microbiologists that in
excess of 95$ of the regional population had been exposed at some time to
tuberculin. PPD was used in the animal studies, * but as these in-bred
laboratory animals had not been sensitised knowingly to tuberculin, it is
likely that PPD acted as a non-specific lymphocyte stimulant (cf mitogen)
rather than a recall antigen.
Several mitogens were used. Phytohaemagglutinin (PHA) (Wellcome
Reagents Ltd., Beckenham, England) is a lectin derived from the red kidney
bean Phaseolus vulgaris and stimulates predominantly T lymphocytes.
Concanavalin A (Con A) (Sigma Chemical Company, St. Louis, USA) is a lectin
derived from the jack bean and preferentially stimulates suppressor
T cells, while PHA preferentially activates helper T cells^^). Pokeweed
mitogen (PWM) (Sigma) is derived from the pokeweed Phytolacca americana
and was discovered following observation of cells resembling plasma cells
in PB of children who had eaten pokeweed berries. PWM stimulates B
lymphocytes and a T cell subset in humans.
2.3.3 (c) Preparation of tanned sheep red blood cells
Tanned sheep red blood cells (TSRBC) are used as indicator
particles in the TEEM test and were prepared by a method based on that of
Stavitsky(^8) anci modified by Shenton^^®^. Sheep whole blood in Alsevers
medium (Appendix 2) (Mercia Diagnostics Ltd., UK) was washed three times in
normal saline by adding 1.0 ml packed cells to 20 ml normal saline and
centrifuging at 800 G for 10 minutes. Then, 1.0 ml packed washed sheep RBC
was diluted with 39 ml of pH 7.2 Stavitsky's phosphate buffered saline
(PBS) (Appendix 3) and 1.0 ml of 1 mg/ml tannic acid (Merck, UK) in PBS.
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The cell suspension was incubated at 37°C for 10 minutes with constant
agitation. Cells were washed three times in PBS and finally resuspended in
Hank's balanced salt solution (BSS) (Appendix 4). The TSRBC were kept at
4°C for not more than 24 hours before use.
2.3.3 (d) Expression of results
The supernatant obtained from the interaction of lymphocytes with
antigen or mitogen has been shown to decrease the electrophoretic mobility
of TSRBC, and the decrease in mobility, or degree of TSRBC slowing, is
proportional to the size of the lymphocyte response(327) In calculating
the results of lymphocyte reactivity, the mean time of ten TSRBC migrations
over the 32 micron distance for each test sample was compared with the mean
migration times of ten TSRBC from two control samples : (1) TSRBC alone,
and (2) TSRBC in the presence of antigen or mitogen. The second control
was necessary because of the possibility that soluble antigen or mitogens,
present in the supernatant which was added to TSRBC, could have bound to
the TSRBC and altered their electrophoretic mobility.
The results of antigen and mitogen binding experiments are given in
Section 3.1. It was found that antigen and mitogens had no significant
effect on TSRBC electrophoretic mobility at concentrations used in this
study. Therefore, the results of all samples were calculated using the
mean migration times of indicator cells in the absence of antigen or
mitogen, (i.e. TSRBC alone, or "control TSRBC") using the formula:
Tt - Tc x 100
Tc
Tt = mean migration time in seconds of 10 indicator cells after
incubation with supernatant ("test TSRBC")
Tc = mean migration time in seconds of 10 control TSRBC
107
For example:
Mean control TSRBC (Tc) = 5.981 seconds
Mean test TSRBC (Tt) = 7.057 seconds
TSRBC slowing due to the effect of antigen/mitogen on lymphocytes:
= Tt - Tc X 100
Tc
= 7.057 - 5.981 x 100
5.981
= 1.076 x 100
5.981
= 17.9%
2.3.4 MEASUREMENT OF SUPPRESSIVE ACTIVITY
Suppressive activity (SA) of a plasma sample or fraction of plasma
was quantified by measuring the amount of sample required to suppress a
standarised lymphocyte response to PPD. The TEEM test was used for
measuring SA but it had to be modified as follows (Figure 2.6):
1. Test solutions were incubated with lymphocytes for 30 minutes at 23°C
before addition of PPD.
2. Lymphocytes were either autologous or allogeneic with respect to the
test plasma or plasma fraction, and so the SA of a sample using
autologous lymphocytes was referred to as "autologous SA", and as
"allogeneic SA" if the sample was tested against allogeneic lymphocytes.
3. Only PPD was used as the lymphocyte stimulant.
Three control incubations were required for each test sample:
(i) TSRBC alone, and (ii) TSRBC with PPD, as explained in Section 2.3.3(d);
and (iii) TSRBC with plasma or a fraction of plasma. It was observed that
neither PPD at the concentration of 100 yg in 3 ml nor plasma or plasma
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0.5 x 106 autologous or allogeneic lymphocytes
in 3 ml Hank1s BSS
+
Plasma (50 fi1, 25 fil, 12.5 /tl or 6.25 /x1 etc)
1




Incubate for 1 1/2 hours at 23°C
I




4 x 107 TSRBC
I
Incubate for 1 hour at 23°C
I
Measure electrophoretic mobility of TSRBC
Figure 2.6 The TEEM test method of measuring suppressive activity of
plasma
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fraction had any significant effect on the electrophoretic mobility of the
TSRBC (results presented in Section 3.1). Therefore, lymphocyte responses
were expressed in the same manner as stated earlier, that is, as a
percentage slowing of TSRBC.
It was found that plasma and plasma fractions consistently
inhibited lymphocyte responses to PPD by varying degrees as revealed by
varying degrees of TSRBC slowing. The degree of inhibition caused by
plasma or . a plasma fraction sample was expressed as "% inhibition" using
the formula:
Pa_ - Ppa. x 100 = % inhibition.
Pa
Pa % TSRBC slowing as a result of lymphocyte-antigen interaction
Ppa = % TSRBC slowing as a result of lymphocyte-plasma antigen
interaction.
A method had to be found for quantifying the strength of the
suppressive activity contained within a plasma sample. The highest plasma
dilution which failed to cause any inhibition of lymphocyte responses could
have been used but this method presumed that substances in plasma exerted
their inhibitory activity according zero order kinetics, a presumption
which may not have been justified. Also, it would have involved
considerable work in the laboratory: numerous dilutions of plasma samples
would have been required to identify precisely the highest dilution which
did not inhibit lymphocyte responses. Alternatively, the lowest dilution
causing 100% inhibition could have been used, but the same arguments would
have applied.
The method chosen for quantification of SA was as follows: eight
dilutions of each test sample were prepared ( 1/60, 1/120, 1/240, 1/480,
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1/960, 1/1920, 1/3840, 1/7680) by adding defined volumes of plasma to
3.0 ml BSS (50 /il, 25 /il, 12.5 /(I, 6.25 fi1, 3.12 /il, 1.56 /cl, 0.78 jul and
0.39 /xl respectively). The volumes of plasma fractions added to BSS are
given in the respective experimental sections. The % inhibition of
lymphocyte reactivity for each plasma dilution was plotted on a graph, with
the percentage lymphocyte inhibition on the ordinate and the plasma volume
used to make up the dilution on the abscissa (Figure 2.7). The volume of
plasma at which 50% inhibition would occur was determined by extrapolation
and simply read from the graph; this volume was taken as the SA of samples
and was recorded in microlitres of plasma. A small microlitre volume of
plasma indicated that the test sample had high SA, as only a small volume
was required to suppress the standard lymphocyte reaction to PPD by 50%.
Conversely, a large plasma volume indicated that a sample had low SA.
2.3.5 PREPARATION OF PLASMA
Plasma samples were obtained from venous blood which was collected
in sterile heparinised tubes and centrifuged at 2000 RPM for 20 minutes.
The plasma was removed with a Pasteur pipette and placed in plain sterile
tubes. All samples were used fresh and untreated.
2.4 PLASMA,LYMPHOCYIQX0XICLTY TESTS
All plasma samples were examined for lymphocytotoxic antibodies by
the method described by Dewar et al^350^. Lymphocytotoxicity tests were
performed in duplicate against allogeneic lymphocytes from three healthy
adult donors.
All tests were performed at 23°C using Falcon microtest plates. A
1.0 fj.1 sample of test plasma was placed in the test plate well and 2000
fresh allogeneic lymphocytes in 1.0 ml of Hank's BSS were added. After
Ill
Figure 2.7 The calculation of plasma suppressive activity (PSA)
The percentage inhibition of lymphocyte reactivity of each dilution was
plotted graphically; the plasma volume causing 50% inhibition was then read
from the graph.
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30 minutes 5.0 /xl of rabbit complement was added to each well and after
incubation for 60 minutes 1.0 ill of 5% Eosin was added. Control wells were
set up using the same procedure except that complement was not added. The
plates were read immediately under em inverted phase contrast microscope.
A background kill of 5-1036 was observed frequently in control
plates. A cell kill of 20% or more was regarded as positive. Two plasma
samples from chronic renal failure patients who were known to have broadly
reacting cytotoxic antibodies to the panel of allogeneic lymphocytes were
included as positive controls.
2.5 GEL FILTRATION
Gel filtration column chromatography was used to fractionate plasma
samples on the basis of molecular weight. Ultrogel AcA 22 (LKB Produckter
AB, Bromma, Sweden) was used as the filtration gel. AcA 22 consists of a
polyacrylamide gel (2%) and an agarose gel (2%) matrix with a bead diameter
of 60 - 140 microns. The effective fractionation range for globular
proteins and peptides is 50,000 - 1,200,000 daltons and so AcA 22 is
suitable for fractionating whole plasma.
The chromatography column is shown in Figure 2.8. The column was
housed in a cold cabinet at a temperature of 6°C which is within the
recommended temperature range for AcA 22 gel.
The main components required for column chromatography are
illustrated in Figure 2.9. The buffer reservoir stored Tris-buffer
(Appendix 5) which was used for all fractionation studies. Plasma samples
were put onto the column by way of a "T" connector in the tubing between
the buffer reservoir and the gel column.
A peristaltic pump was situated at the lower end of the column and
drew the buffer and plasma sample onto the column at a pre-determined flow
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Figure 2.8 The gel filtration chromatography column
114
Figure 2.9 A diagram of the gel filtration column
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rate. Eluate from the column passed through an ultraviolet analyser (2138
Uvicord S, LKB) which measured the protein concentration spectro-
photometrically. The optical density of the eluate at 280 nm was recorded
on a chart recorder. The eluate passed to a fraction collector and
100 fractions, each 5.0 ml in volume, were obtained from each plasma sample
applied to the column.
2.5.1 PREPARATION OF THE CHROMATOGRAPHY COLUMN
The precision glass tube used for the gel titration studies was
95 cm in length with an internal diameter of 2.5 cm. Ultrogel AcA 22,
which was supplied pre-swollen in citrate buffer with sodium azide, was
washed thoroughly in Tris-buffer and dissolved gases were removed by
applying a vacuum. The gel was poured along a glass rod into the glass
tube so as not to introduce air bubbles into the column of gel. An
extension cylinder was attached to the upper end of the glass tube which
was then over-filled. During the next two days the gel sedimented so that
the gel bed settled into the column beneath the extension cylinder which
then contained only buffer. The column was "packed" by running Tris-buffer
through it by means of a peristaltic pump. The packing flow rate was
17.0 cm3/hour and packing was continued for 24 hours. During this
equilibration the Uvicord and recorder were started and baseline recordings
obtained.
2.5.2 PLASMA FRACTIONATION
The flow rate through the column during fractionation of a plasma
sample was 15 cm3/hour so that three 5.0 ml fractions were obtained each
hour. The final length of the gel bed within the glass tube was 82.0 cm.
The volume of each plasma sample applied to the gel was 2.0 ml. The void
116
volume of the column was 110 ml.
Complete elution of a test sample was confirmed by the trace of
optical density returning to the base line. Between experiments the pump
was switched off and the gel remained in equilibrium with the buffer. If
the gel column packed down between experiments, producing a dead space of
clear buffer above the gel, a new column was prepared. A summary of
details of the gel filtration chromatography column is given in Appendix 6.
Immuno-electrophoresis (IE) was used to identify the distribution
of proteins within plasma fractions obtained by column fractionation
("fused rocket" technique) and to quantify proteins in plasma and plasma
fractions ("single rocket" technique). The method was based on that of
Laurell^3®*).
2.6.1 PREPARATION OF IMMUNO-ELECTROPHORESIS PLATES
2.6.1 (a) Fused rocket immuno-electrophoresis
Glass sheets measuring 205 mm x 110 mm x 2 mm were used as
supporting plates for the IE gel. The glass was cleaned meticulously and
positioned on a flat adjustable bench top table on which spirit levels were
placed. The gel was 1% agarose. One gram of MX Agarose (Mercia Brocades,
West Byfleet, Surrey, England) was dissolved in 100 ml Tris-barbitone
buffer (TBB) (Appendix 7) by mechanically stirring the suspension while
heating to 100°C and then cooling to 60°C.
The required thickness of gel on the glass plate was 2 mm.
Therefore, the gel volume was 205 x 110 x 2 = 45.1 mm3. For practical
purposes 50 ml of heated agarose solution was prepared for each plate, as a
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small amount of gel was lost from adherence to the container in which it
was heated.
Antibody to all human plasma proteins ("anti-all") was incorporated
into the major part of each IE plate. Some plates had antibodies to IgM,
IgG, caeruloplasmin, alpha-l-antitrypsin, transferrin, fibrinogen and
alpha-2-macroglobulin (A2M) incorporated into additional bands 2 cm in
width, placed between the plain gel band and the main "anti-all" antibody
band. Antibodies were used in the following concentrations: anti-all
plasma proteins = 4.0 /zl/cm2 plate area, anti-IgM = 1.0 /zl/cm2 plate area,
anti-IgG = 1.0 /xl/cm2 plate area, anti-A2M = 1.0 ^il/cm2 plate area,
anti-alpha-l-antitrypsin = 1.5 /zl/cm2 plate area, anti-albumin
0.75 jil/cm2 plate area, anti-caeruloplasmin = 1.5 /il/cm2 plate area,
anti-transferrin = 1.0 /xl/cm2 plate area and anti-fibrinogen = 2.0 jtl/cm2
plate area.
The lowermost band on the IE plate was the band in which antigen
wells were cut and did not contain antibody. A clean straight-edged
aluminium bar was placed on the glass plate 25 mm from the lower edge. An
appropriate volume (205 x 25 x 2 = 10.25 mm3) of heated agarose gel was
poured onto this part of the plate. The bar was removed after allowing the
agarose to cool for 30 minutes, and a 5 mm width of gel was cut away with a
scalpel to remove the concave meniscus of gel which formed adjacent to the
aluminium bar.
If an agarose band containing mono-specific antibody was to be
formed in addition to the main "anti-all" antibody band, the additional
band was made next. The aluminium bar was placed on the plate parallel to
and 25 mm away from the band of plain agarose. The appropriate volume of
heated agarose solution was allowed to cool to 55°C, antibody was added and
mixed evenly into the liquid agarose by mechanical stirring. The agarose
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was poured onto the glass plate between the aluminium bar and plain agarose
band, and, after the gel had solidified, the bar was removed and the
meniscus was trimmed as before.
The "anti-all" band was formed on the remaining plate area. The
required volume of gel was prepared, an appropriate amount of antibody was
added when the gel reached 55°C, and the liquid agarose was poured as
before.
The glass plate was transferred to a hole-cutting frame after the
agarose had cooled so that antigen wells could be cut in the plain agarose
band. Wells were cut with a sharp-edged steel tube (diameter 2.5 mm)
attached to a suction pump. The first row was cut so that the centre of
each well was 5 mm from the antibody band. A second staggered row of holes
was cut so that the well-centres were midway between the holes of the first
row but 5 mm further back from the antibody band. Each well had a volume
of 5.0 jul.
2.6.1 (b) Single rocket immuno-electrophoresis
Although minor variations in gel thickness, and hence antibody
concentration, are not critical in the determination of protein
distribution (fused rocket technique), it is essential that the gel is of
uniform thickness for quantification of protein concentrations. Therefore,
the agarose plates used for single rocket electrophoresis were prepared in
a modified fashion.
A "U"-shaped plastic frame was cut from a single plastic sheet 2 mm
thick. It was held firmly with clips between two glass plates
(205 mm x 110 mm x 2 mm) so that the frame, once in position, sealed the
two short sides and one long side of the space between the two glass sheets
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(Figure 2.10). The space between the glass sheets was
185 mm x 100 mm x 2 mm. The volume of gel required was 37 mm3 and the
appropriate amount of antibody was added to the liquid agarose at 55°C.
The liquid agarose was introduced into a 50 ml syringe and injected slowly
into the space between the two glass plates via an umbilical catheter.
When the gel had set, the glass plates were placed horizontally and the
clips removed. The upper glass plate was removed carefully, and the lower
plate and gel were transferred to the hole-cutting frame. Holes were cut
5 mm apart and 5 mm from a long edge of the plate to form a single row of
36 antigen wells.
2.6.2 PERFORMANCE OF IMMUN0-ELECTR0PH0RSIS
Each antigen well was filled with a 5.0 /il sample. The agarose IE
plate was placed on the cooling plate of the electrophoresis tank
(Figure 2.11). The cooling plate consisted of a long hollow coil within a
glass slab and cold tap water flowed continuously through the coil.
Adjacent to the long sides of the cooling plate was a reservoir containing
500 ml of TBB. Bridges were created between the buffer reservoirs and the
long edges of the agarose gel by Whatmann No. 1 filter paper soaked in TBB.
Electrodes were inserted into the TBB reservoirs and a current of 20 m amps
was applied at a potential difference of 100 volts. The lid was placed
securely on the tank to prevent drying of the gel by evaporation, and
electrophoresis was performed for 16 hours.
After completion of electrophoresis, the precipitation lines of
antigen-antibody complexes within the gel had to be visualised. The
surface of each gel was washed with de-ionised water. Four pieces of
Whatmann No. 1 filter paper were cut to the same size as the plate and
placed on the gel. A flat 2.5 kg weight was applied for 5 minutes. Filter
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Figure 2.10 The "U" shaped frame used to make the antibody containing gel
for single rocket immuno-electrophoresis
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Figure 2.11 The electrophoresis tank in which the immuno-electrophoresis
experiments were performed
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papers were removed and the gel was washed in 0.1 M NaCl for 15 minutes to
remove non-precipitated protein. After pressing again, the gel was washed
in de-ionised water for 15 minutes. The plate was pressed for a third time
and dried at 30°C until the thin gel layer was firm. It was stained with
Coomasie Brilliant Blue solution (Appendix 8) for 15 minutes and then
washed immediately in de-staining solution (Appendix 9). The protein
precipitates stained dark blue and the background was pale blue
(Figure 2.12).
2.6.3 QUANTIFICATION OF SINGLE ROCKETS
Each test sample was prepared in two dilutions and each dilution
assayed in duplicate. Serial dilutions of a standard reference protein were
applied to antigen wells on the left of each plate. Thus, the height of
precipitation rockets of test samples could be compared with those of the
reference protein of known concentration. The height of each rocket was
taken as the distance from the centre of each antigen well to the tip of
the rocket. Dilutions of standard reference proteins and test sera and
concentrations of standards are given in Appendix 10.
2.7 IMMUNO-SPECIFIC AFFINITY CHROMATOGRAPHY
Immuno-specific affinity chromatography (IAC) was used to remove
A2M, IgG and Fc subunits of IgG from plasma samples and pooled fractions of
plasma. Sepharose 4B Gel (Pharmacia Chemicals, Uppsala, Sweden) was used as
the IAC column gel. Sepharose 4B consists of spherical 4% agarose gel
beads of 40 - 190 jtm diameter which have an open pore structure so that the
interior of the matrix is available for ligand attachment. The gel
exhibits very low non-specific adsorption, an important feature in a




Figure 2.12 Examples of stained immuno-electrophoresis plates produced by
single (upper plate) and fused (lower plate) rocket techniques.
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2.7.1 PREPARATION OF IMMUNO-SPECIFIC AFFINITY CHROMATOGRAPHY COLUMNS
The 4B gel was washed three times before being coupled with
antibody. Three grams of Sepharose beads were placed in a sintered glass
funnel attached to a vacuum flask and washed with 100 ml 1 M hydrochloric
acid; after 15 minutes a vacuum was applied until the beads were nearly
dry. The washing procedure was repeated twice and the beads were washed
finally with 100 ml Stavitsky's PBS (Appendix 3).
Antibodies against A2M, IgG and Fc fragments were coupled to the
sepharose. Two ml of each antibody were precipitated with 2.5 ml saturated
ammonium sulphate at room temperature and the supernatant discarded after
centrifugation at 3000 RPM for 10 minutes. The precipitate was dissolved
in 10 ml Stavitsky's PBS; ammonium sulphate was removed by three one hour
dialyses, against 500 ml Stavitsky's PBS, and the antibody preparation was
added to Sepharose beads in sterilin tubes. After gentle mixing on a
Matburn rotary mixer at room temperature for two hours, the beads were
washed on a sintered glass funnel with 50 ml Stavitsky's PBS to remove
excess antibody. The beads were resuspended in 12 ml 1 Molar ethanolamine
(pH 8.0) at room temperature for two hours to block any reactive groups
remaining after coupling. The beads were washed sequentially in a sintered
glass funnel with 50 ml 0.2 M Walpoles acetate buffer (Appendix 11),
50 ml 0.1 M Clark-Lubbs Borate buffer, (Appendix 12), and 50 ml
Stavitsky's PBS, to inactivate any active radicals remaining in the beads
and to remove non-covalently bound protein. The gel was resuspended in
10 ml of Stavitsky's PBS in a sterile container.
Affinity chromatography columns were made by placing a small pad of
glass wool within the barrel of a 10 ml plastic syringe from which the
plunger had been removed. A three-way tap was attached to the tip of the
barrel, and 5 ml of coupled Sepharose gel was placed into each syringe.
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The glass wool supported the gel and prevented it from leaving the syringe
whereas buffer could flow through the gel and glass wool pad. When not in
use the columns were filled with Stavitsky's PBS with 1% sodium azide, a
bacteriostatic agent, and a cap placed over the open end of each column.
Columns were stored at 6°C.
A control column was made using normal rabbit serum, instead of
antibody, coupled to the Sepharose beads.
2.7.2 PERFORMANCE OF IMMUN0-SPECIF1C AFFINITY CHROMATOGRAPHY
Each column was washed with 20 ml Stavitsky's PBS before use. Test
samples were applied to the top of the column, the amount of each sample
being either 0.5 ml plasma or the volume of a plasma fraction which
contained the equivalent of 0.5 ml plasma. Each test sample was incubated
in a column at room temperature for 30 minutes and then eluted with 20 ml
Stavitsky's PBS and collected.
Adsorbed protein was removed from the Sepharose column by washing
with 20 ml of 3 Molar sodium thiocyanate. Sodium thiocyanate was removed
from the eluate by dialysing against 500 ml Hank's BSS for four hours. The
column was washed with 20 ml Stavitsky's PBS after use, and the adsorbed
protein was collected.
2.8 DETECX10N-QF IMMUNE COMPLEXES
Immune complexes (IC) were detected in pooled fractions of plasma
by precipitation with polyethylene glycol (PEG), an uncharged, synthetic,
linear polysaccharide. When added to serum, PEG precipitates proteins in
proportion to its concentration and the molecular size of the proteins.
For example, 20% PEG precipitates most native immunoglobulins and many
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other proteins; 5% PEG precipitates a significantly smaller proportion of
immunoglobulins but the same proportion of IC^352). The PEG method of IC
precipitation is well accepted, straight-forward, reproducible and
correlates well with other methods of IC detection^333,331*).
A criticism of the PEG method is that free and non-specifically
aggregated immunoglobulins may be precipitated and wrongly interpreted as
true IC. Therefore, steps were taken to eliminate this source of error by
not testing whole plasma or serum but rather plasma fractions after removal
of IgM and IgG by gel filtration. Also, procedures which encourage non¬
specific antigen-antibody aggregation, such heating or freeze-thawing of
samples, were avoided.
The method of PEG precipitation of IC was that of Creighton^352).
Solutions of 5%, 10% and 20% PEG of MW 6000 (BDH Chemicals Ltd, Poole,
England) were made with 0.1 Molar borate buffer (Appendix 12). Each test
sample consisted of only the heaviest fractions of plasma obtained from gel
filtration, these fractions having been pooled to form a single region or
peak ("region 1") for each plasma sample. (The method of pooling gel
filtration fractions is explained in Section 3.6.2). The volume of each
test sample was 5% of the total volume of each region 1, and was added to
an equal volume of each PEG solution. Test samples were prepared in
duplicate, resulting in 6 samples (5% x 2, 10% x 2, 20% x 2) for the region
1 of each subject's plasma specimen.
Test samples were incubated with PEG for 18 hours at 4°C, and then
centrifuged at 5000 G for 20 minutes. Each precipitate appeared as a white
pellet at the bottom of the conical centrifuge tube. The supernatant was
aspirated and collected, and the PEG removed from the supernatant by
ultrafiltration, using an ultrafiltration membrane with an exclusion limit
of 300,000 daltons. The supernatant was tested for SA after removing PEG.
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The precipitate was dissolved in 3.0 ml Hank's BSS by vigorous shaking and
then tested for SA.
2.9 RADIAL IMMUNODIFFUSION
Single radial immunodiffusion (RI) was used to measure IgM, IgG and
albumin concentrations in samples of plasma and fractions of plasma.
RI plates containing antibody to IgM, IgG - Fc or albumin and appropriate
standard antigens were purchased (Behringwerke AG, Marburg, W. Germany).
Test samples were prepared in two dilutions, each of 5.0 /j.1 volume.
RI plates were placed on a flat adjustable table within a humid, sealed
plastic box. Spirit levels were used to check that the table was level.
Antigens (test samples or standards of known concentration) were added to
antigen wells and the plates were left undisturbed for 3 days. The
diameters of the resulting precipitation rings were measured. Standard
curves were constructed by plotting the squares of diameters of the
precipitation rings for each standard against their concentrations^355^,
and the values of the test samples were read off from the graphs.
2.10 STATIST!CAL METHODS
Statistical analysis of results was performed with parametric and
non-parametric tests. The Students t test, a parametric statistical test
formulated largely by Gosset in 1908, was used whenever the data were
distributed normally, were independent of each other and had similar
degrees of variance. The non-parametric statistical tests were the Mann-
Whitney U test(356) and the Wilcoxon two sample rank sum test for unpaired
data^357). They were used when the above criteria for use of a parametric
test could not be fulfilled.
128
Correlations between variables were investigated by constructing
scatter diagrams and calculating the correlation coefficient r. Scatter
diagrams were drawn by plotting the dependent variable against the
vertical (y) axis and the independent variable against the horizontal (x)
axis for each pair of data to be correlated._ The coefficient of
correlation (r) was calculated from the formula:
E Ujl - x) (y1 - y)
r =
V E (*i - X)2 E (VI - y)2
where
Xj = values of the independent variable
x = the mean of the x observations
y^ = values of the dependent variable
y = the mean of the y observations
The significance of correlation was determined by calculating the





r = correlation coefficient
n = number of observations
The test of significance was considered to be valid if the data
points of the scatter diagrams had an approximate elliptical shape,




3.1 STUDIES OF THE EFFECTS OF ANTIGEN AND MITOGEN ON TANNED
SHEEP ERYTHROCYTE ELECTROPHORETIC MOBILITY
The results of a series of experiments aimed at defining the
effects of PPD antigen and PHA, Con A and PWM mitogens on the
electrophoretic mobility of TSRBC are reported in this section. These
experiments had to be performed so that any influence of the lymphocyte
stimulating antigen or mitogen could be taken into account when measuring
lymphocyte reactivity (Section 2.3.3.(d)).
3.1.1 METHOD
The electrophoretic mobility of TSRBC in Hank's BSS was measured,
as described in Section 2.3.3. Seven concentrations of PPD, PHA, Con A and
PWM were made up in 3.0 ml of Hank's BSS containing 4 x 107 TSRBC. The
concentrations were: 10 /zg/ml, 100 /ig/ml, 200 /xg/ml, 400 /zg/ml, 600 /ng/rnl,
800 fig/ml, 1000 fj.g/ml. TSRBC were incubated with antigen or mitogen for
one hour at 23°C and then the electrophoretic mobility of ten TSRBC from
each test incubation was measured. Results were expressed as % slowing of
TSRBC. The mean electrophoretic mobility (in seconds) of ten TSRBC from
each test incubation was compared with that of ten TSRBC alone. This
latter value was taken as the "zero" point: therefore, a positive result
indicated inhibition of TSRBC by antigen or mitogen while a negative value
indicated an increase in electrophoretic mobility compared with untreated
TSRBC. The Student's t test was used for statistical analysis.
3.1.2 RESULTS
The results are given in Tables 3.1 - 3.4 and illustrated in
Figure 3.1. PPD and PWM caused only minimal slowing of TSRBC; inhibition
tended to increase with increasing antigen/mitogen concentration. However,
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Table 3.1 The effect of PPD on the electrophoretic mobility of tanned
sheep red blood cells (TSRBC)
Dose of PPD * slowing of TSRBC p value - PPD x Control
(jil/ml) (mean ± 1SD, n = 10)
10 0.3* ± 1.1% NS
100 0.6% ± 1.2* NS
200 1.1% ± 1.4* NS
400 0.9% ± 1.3* NS
600 1.4* ± 2.7* NS
800 3.8* ± 1.4* <0.001
1000 2.0* ± 1.5* <0.01
Table 3.2 The effect of PHA mitogen on the electrophoretic mobility of
tanned sheep red blood cells (TSRBC)
Dose of PHA * slowing of TSRBC p value - PHA x Control
(/il/ml) (mean ± 1SD, n = 10)
10 0.4* ± 1.3* NS
100 1.1* ± 0.8* <0.01
200 3.2* ± 0.9* <0.001
400 18.9* ± 1.4* <0.001
600 19.5* 1.1* <0.001
800 28.8* + 7.9* <0.001
1000 36.8* ± 1.9* <0.001
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Table 3.3 The effect of Con A mitogen on the electrophoretic mobility of
tanned sheep red blood cells (TSRBC)
Dose of Con A * slowing of TSRBC p value - Con A x Control
(fil/ml) (mean ± 1SD, n = 10)
10 1.0* ± 0.5* NS
100 1.4* ± 0.8* NS
200 0.9* ± 0.6* NS
400 1.3* ± 1.6* NS
600 4.2* ± 2.5* <0.01
800 7.9* ± ro <0.001
1000 9.4* ± 1.0* <0.001
Table 3.4 The effect of PWM mitogen on the electrophoretic mobility of
tanned sheep red blood cells (TSRBC)
Dose of PWM * slowing of TSRBC p value - PWM x Control
(/xl/ml) (mean ± 1SD, n = 10)
10 0.5* + 2.3* NS
100 0.8* 1.2* NS
200 2.1* ± 2.9* NS
400 00ri ± 1.3* NS
600 1.2* ± 0.8* NS
800 1.1* + 0.9* NS
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Figure 3.1 The effect of antigen (PPD) or mitogen (PHA, Con A or PWM) on
the electrophoretic mobility of tanned sheep red blood cells
(TSRBC)
only at concentrations of 800 jig/ml (PPD) and 1000 jig/ml (PPD and PWM) did
TSRBC mobilities differ significantly from control values. PHA and Con A
caused significant interference with TSRBC electrophoretic mobility at much
lower concentrations: the only concentration of PHA which did not cause
significant slowing was 10 jig PHA/ml, and concentrations of Con A greater
than 400 jig/ml inhibited TSRBC mobility significantly.
3.1.3 DISCUSSION
The experiments demonstrate that PPD, PHA, PWM and Con A can alter
the electrophoretic mobility of TSRBC although, with the exception of PHA,
alteration of surface electric charge occurred only at relatively high
concentrations. The antigen and mitogens did not cause TSRBC clumping or
aggregation even at high concentrations. Obviously, it was necessary to
use these lymphocyte stimulants at relatively low concentrations in
subsequent experiments so that they did not influence TSRBC electrophoretic
mobility. The concentrations used throughout this study were:
PPD : 100 jig per 3 ml test sample 33 jig/ml
PHA ; 10 jig per 3 ml test sample 3.3 jig/ml
PWM : 100 jig per 3 ml test sample 33 jig/ml
Con A :: 100 jig per 3 ml test sample 33 jig/ml
These concentrations of each stimulant were within the ranges that
had no significant effect on TSRBC electrophoretic mobility, so that any
alteration in TSRBC mobility detected in subsequent experiments could not
be ascribed to a direct effect of antigen or mitogen interfering with the
indicator cells.
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3.2 STUDIES OF LYMPHOCYTE REACTIVITY
3.2.1 INFLUENCE OF DISEASE
As a prerequisite to the study of plasma factors which may
influence lymphocyte reactivity, it was necessary to measure lymphocyte
reactivity in an environment free of plasma so that a baseline value of
lymphocyte reactivity could be established. Thus, in vivo tests of
lymphocyte function could not be used. However, it is accepted generally
that in vitro reactivity of lymphocytes to antigenic stimulation is a
correlate of cell-mediated immunity(347) and so an in vitro test (the TEEM
test) was used to measure lymphocyte reactivity in the absence of plasma.
3.2.1 (a) Method
Lymphocytes were obtained from 136 subjects by the method described
in Section 2.3.3(a). The experimental subjects have been described in
Section 2.1 and further details are given in Table 3.5. Lymphocytes were
stimulated with PPD, PHA, Con A and PWM. The TEEM test method has been
described in Section 2.3. The Student's t test was used for statistical
analysis of results.
3.2.1 (b) Results
Lymphocyte responses to PPD, PHA, Con A and PWM are shown in
Figures 3.2 - 3.5 respectively.
Responses to PPD were uniform in normal subjects, with a mean of
19.2% TSRBC slowing. Responses of patients with benign diseases had a
wider distribution which was skewed towards lower values. Their responses
were significantly lower than those of the normal group (p<0.001). The
responses of the malignant group were distributed widely also and were
significantly lower than those of the benign group (p<0.001). Similar
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Table 3.5 Subject groups investigated in the studies of lymphocyte






















































































































Figure 3.5 Results of in vitro lymphocyte responses to PWM
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results were obtained from lymphocyte responses to the three mitogens.
Although there was overlap between responses of each group, those of the
normal group were significantly greater than those of the benign group,
which were greater than responses of the malignant group.
3.2.1 (c) Discussion
The results show that the presence of malignant disease is
associated with reduced lymphocyte reactivity as measured by the TEEM
test. There was minimal overlap of results from the malignant and normal
groups. The benign group had a wide scatter of results, the majority of
which fell within the same range as the results of the normal group. This
suggested that the benign group contained several subpopulations. Overall,
the results suggest that factors in addition to malignancy can influence
lymphocyte reactivity.
The normal subjects were not well matched with the other two groups
with respect to age or sex distribution. Difficulty was experienced in
obtaining blood samples from elderly healthy adults; those admitted to
hospital could not be included in the normal healthy group. However, as
further analysis did not show any trend or significant correlation between
lymphocyte responsiveness and age or sex for any subject group, use of this
control group appeared to be valid. Further analyses were undertaken to
identify factors other than disease which could explain differences between
the groups.
3.2.2 INFLUENCE OF NUTRITIONAL STATUS
As malnutrition has a profound effect on the immune system
(Section 1.6.1), the results of lymphocyte reactivity reported in
Section 3.2.1 were analysed on the basis of nutritional status.
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3.2.2 (a) Method
Each experimental subject underwent nutritional assessment (weight-
for-height, weight loss (only in patients), arm muscle circumference (AMC),
triceps skin fold thickness (TSF) and serum albumin). Lymphocyte responses
to each stimulant were plotted graphically against each nutritional
parameter by constructing scatter diagrams. A correlation co-efficient (r)
was calculated for each set of data and the t test was used to assess the
significance of correlation (Section 2.10).
3.2.2 (b) Results
The co-efficients of correlation (r) and probability values (p) for
correlations between lymphocyte responses and nutritional parameters are
given in Tables 3.6 and 3.7 for the benign and malignant groups
respectively. Scatter diagrams showing lymphocyte responses to PHA plotted
against each nutritional parameter are reproduced in Figures 3.6 - 3.10 and
3.11 - 3.15 for the benign and malignant groups respectively. Scatter
diagrams for each of the three mitogens have not been included because of
limitations of space.
No correlation was found between lymphocyte responses and
nutritional parameters in normal subjects.
Lymphocyte responses to each stimulus showed significant
correlations with each nutritional parameter in the benign group
(Table 3.6). The best correlation was obtained between lymphocyte
responses to PHA and the TSF thickness (r = 0.79, p<0.001). Although the
correlation was reasonably strong, the scatter of results was wide,
indicating poor sensitivity of lymphocyte responsiveness as an index of
body fat stores. In the same way, lymphocyte responses to PPD and the
mitogens could be correlated with nutritional parameters but the
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Table 3.6 Correlations of lymphocyte responses with nutritional
parameters in patients with benign diseases
COEFFICIENT OF CORRELATION (r)













Arm muscle 52 0.68
circumference
Serum albumin 52 0.54
0.66 0.59 0.60
0.61 0.76 0.72
All correlations were significant at p < 0.001
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Table 3.7 Correlations of lymphocyte responses with nutritional
parameters in patients with malignant diseases














































Lymphocyte response toPHA (%slowing ofTSRBC)
























Figure 3.7 Correlation of lymphocyte responses to PHA with percentage
weight loss in patients with benign disease
Percentage weight loss
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Figure 3.9 Correlation of lymphocyte responses to PHA with arm muscle
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Figure 3.10 Correlation of lymphocyte responses to PHA with serum albumin
concentrations in patients with benign disease
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Figure 3.12 Correlation of lymphocyte responses to PHA with percentage
weight loss in patients with malignant disease
Lymphocyte response toPHA (%slowing ofTSRBC)
r=0.532 p<0.001
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Figure 3.15 Correlation of lymphocyte responses to PHA with serum albumin
concentrations in patients with malignant disease
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correlations, although significant, were weak.
Correlations of lymphocyte responses to PPD and PHA with
nutritional parameters in patients with malignancy (Table 3.7) were
statistically significant but of poor sensitivity, but were frequently not
significant for Con A and PWM. The strongest correlation was between the
response to PPD and weight loss (r = 0.55, p<0.001).
3.2.2 (c) Discussion
Correlation between in vitro lymphocyte reactivity and nutritional
parameters could not be identified for normal subjects because of the
relatively narrow range of results of lymphocyte reactivity and the absence
of nutritional impairment. Generally, all subjects had high lymphocyte
reactivity and all had normal nutritional assessments. It was observed
that some individual nutritional parameters differed from standard values
in a few subjects because of idiosyncratic variation in the size of the
measured body compartments (TSF, AMC, serum albumin) or in overall body
weight (PW/IBW).
Nutritional deficiency was associated frequently with poor
lymphocyte reactivity in patients with benign diseases, whereas in the
absence of objective evidence of malnutrition, lymphocyte reactivity was
similar to that observed in healthy subjects.
The nutritional parameters of weight for height (PW/IBW) had the
weakest correlations with lymphocyte reactivity in benign patients. This
finding may be due partly to the use of standards of weight for height
which may not have reflected accurately the average values of the local
population. Also, weight for height measurements give no indication of
changes in nutritional status and do not take account of the previously
obese patient who has lost a significant amount of body weight.
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The results show that in malignant disease lymphocyte responses to
PPD antigen and particularly mitogens correlated poorly with nutritional
status. Severe nutritional impairment adversely affected lymphocyte
reactivity in patients with malignant disease, a situation also seen with
benign disease. The nearer the nutritional parameters were to standard
values, the wider was the scatter of responses, suggesting that factors
other than nutrition influenced lymphocyte reactivity in some patients with
cancer.
Percentage weight loss (UW-PW %) showed the best correlation with
UW
lymphocyte reactivity in the malignant group and was the only parameter to
exhibit significant correlations with all four lymphocyte stimulants. The
weight loss index measures illness-related weight loss and does not
differentiate between particular body compartments which may be depleted to
different degrees. Not surprisingly, the sensitivity of this index was
poor but the results indicate that recent or acute malnutrition was
associated with poor lymphocyte reactivity in these cancer patients. In
benign patients the same index of percentage weight loss correlated well
with lymphocyte reactivity but the association of impaired lymphocyte
responsiveness with poor nutritional status was stronger in the benign
group anyway.
It is of interest to note that illness-related weight loss was
detected in 25 of 52 benign patients (48%) and 55 of 69 cancer patients
(79%). Although neither group was a consecutive series, patients were not
selected on the basis of nutrition status, and the finding of a high
incidence of weight loss among patients with benign as well as malignant
disease draws attention to the frequency of nutritional problems in
patients in a general surgical ward. It also draws attention to the need
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to define and control for the nutritional status of patients involved in
immunological research.
3.3 DEFINITION OF MALNUTRITION
It was necessary to define "malnutrition" for the purpose of this
study. The problems of defining malnutrition have been reviewed in
Section 1.6.2 and, realising the inherent faults in the methods of
nutritional assessment, it was decided to use the five nutritional
parameters described in Section 2.2, (weight-for- height, weight loss, arm
muscle circumference, triceps skin fold thickness and serum albumin). The
"85% cut-off level" was used - that is, an anthropometric measurement was
regarded as indicating significant nutritional impairment if it was less
than 85% of the standard value; weight loss of greater than 15% of usual or
pre-illness weight was taken to indicate significant nutritional
impairment. A serum albumin concentration below the lower limit of the
laboratory reference range (30 - 50 g/1) was regarded as an index of
significant nutritional deficit.
The distribution of abnormally low nutritional parameters is shown
in Table 3.8. 62% of patients had less than two abnormal parameters, 5%
had two and 33% had more than two. It was decided to classify patients as
malnourished if the majority (three or more) of their parameters were
abnormally low. Using this criterion none of the healthy group, 18 (35%)
of the benign group and 22 (32%) of the malignant group were classified as
malnourished.
3.3.1 LYMPHOCYTE RESPONSES IN WELL NOURISHED AND MALNOURISHED
SUBJECTS
Lymphocyte responses to PPD, PHA, Con A, and PWM were analysed for
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Table 3.8 Distribution of abnormal anthropometric and biochemical
































Total 52 69 100%
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the five groups of subjects: (1) normal, (2) benign well nourished,
(3) benign malnourished, (4) malignant well nourished, and (5) malignant
malnourished.
Scatter diagrams were constructed for lymphocyte responses. An
example is given in Figure 3.16. There was a wide xange of responses in
each subject group. All groups overlapped except the normal group did not
overlap with the malignant malnourished group. There was no significant
difference between responses to PHA of lymphocytes from normal subjects and
well nourished patients with benign disease. Comparison of benign well
nourished and benign malnourished groups showed a highly significant
difference between responses (p<0.001). The malignant malnourished group
had significantly lower lymphocyte responses to PHA than the malignant
well nourished group (p<0.001). Responses of the two benign groups were
significantly higher than the responses of their malignant counterparts
(p<0.001 in each case). Lymphocyte responses to PPD, Con A and PWM
produced similar patterns of distribution as responses to PHA. For each
stimulant, comparison of the two benign and malignant groups revealed
statistically significant differences between the lymphocyte responses of
well nourished and malnourished patients (p<0.001). Similarly, there was
no significant difference between normal subjects and benign well nourished
patients.
These experiments show that malnutrition secondary to a disease
process suppresses lymphocyte reactivity. Even in conditions known to
adversely affect immune function, such as cancer, the influence of
malnutrition on lymphocyte reactivity was demonstrated clearly. Lymphocyte
reactivity could be correlated with nutritional impairment as identified by
these anthropometric and biochemical methods of assessment in patients with
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p = NS p <0.001 p <0.001
Figure 3.16 The results of in vitro lymphocyte responses to PHA of each of
the five groups of subjects classified by nutritional status
N = Normal
BW = Benign well nourished
BM = Benign malnourished
MW = Malignant well nourished
MM = Malignant malnourished
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lymphocyte activity and malnutrition was stronger in the benign group of
patients, suggesting that additional factors influenced lymphocyte
responses in patients with malignancy. Definition of nutritional
impairment by five simple criteria allowed two sub-groups of benign and
malignant patients to be identified.
Lymphocyte responses of the benign well nourished group did not
differ significantly from those of the healthy group although the responses
of some benign patients were below the range of results of the normals
(Figure 3.16). These low results could have been due to the influence of
the disease process or the failure of the nutritional assessment to detect
significant nutritional deficit which adversely affected lymphocyte
reactivity.
Problems relating to the definition of the malnourished state have
been discussed in Section 1.6.2. The present definition used (a) both
anthropometric and biochemical methods of assessment, (b) an 85% cut off
level to define a result as being abnormally low, and (c) a 'majority rule'
to classify patients as malnourished. Clearly, this definition is still
open to criticism about the methods of assessment, but it proved to be a
clinically useful definition, and its validity was supported by the results
reported in this section.
The study highlights the influence of nutrition on jji vitro
reactivity of lymphocytes in patients encountered in hospital practice.
Such patients (especially those with malignancy) are frequently included in
immunological research, and the present results indicate that close
attention must be paid to the nutritional status of patients when
interpreting tests of immune function.
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3.4 PLASMA LYMPHOCYTOTOXICITY
All human plasma samples were examined for the presence of
lymphocytotoxic antibodies. Lymphocytotoxicity tests were performed as
described in Section 2.4. No plasma sample had cytotoxic activity against
the panel of lymphocytes, thereby excluding the presence of pre-formed
lymphocytotoxins as a cause of impaired lymphocyte reactivity.
3.5 STUDIES OF PLASMA SUPPRESSIVE ACTIVITY
Plasma suppressive activity (PSA) refers to the ability of a plasma
sample to suppress or inhibit the reactivity of lymphocytes following
antigenic or mitogenic stimulation.
A study was undertaken to examine the SA of plasma from cancer
patients in an attempt to explain the immunological impairment so
frequently observed in cancer patients (Section 1.4). PSA was assessed
using autologous and allogeneic lymphocytes.
3.5.1 AUTOLOGOUS PSA
3.5.1 (a) Method
PSA was measured against each patient's own lymphocytes using the
TEEM test method (Section 2.3.4). Lymphocytes and plasma samples were
prepared as described in Section 2.3. Patients were classified into five
groups as described before (normal, benign well nourished, benign
malnourished, malignant well nourished, or malignant malnourished)
according to the previously adopted criteria (Sections 2.1 and 3.3). The
Mann Whitney U test was used for statistical analysis.
3.5.1 (b) Results
Results of PSA against autologous lymphocytes are shown in
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Figure 3.17 and Table 3.9. PSA of the normal group had a relatively small
range, (27.6 - 36.7 fil plasma), and the median was 32.0 n1 plasma.
There was a wide range of results in the benign well nourished
group, with a skew towards the lower values. The group did not differ
significantly from the normal group. There was some overlap between the
two benign groups but generally the PSA of malnourished patients with
benign disease was high, as indicated by the relatively small microlitre
volumes of plasma. PSA's of the two benign groups were significantly
different (p<0.001).
Plasma suppressive activity was high in well nourished and
malnourished patients with cancer and there was no statistically
significant difference between the two groups. The PSA of each malignant
group was significantly greater than the benign and normal groups, the
median PSA's being 2.01 jul plasma (well nourished) and 1.96 /xl plasma
(malnourished).
3.5.1 (c) Discussion
The results demonstrate that all plasma samples, even those from
healthy subjects, contained some SA, suggesting that plasma factors have a
role in health and disease in the regulation of lymphocyte activity. It
appears to be a natural phenomenon as it was observed using untreated
autologous lymphoctyes in all subjects. This important observation points
to a possible mechanism of immune regulation and will be examined in
greater detail later.
Malnourished patients with benign disease had a significant
increase in PSA which could have been due to their impaired nutritional































































Figure 3.17 Plasma suppressive activities (PSA) against autologous
lymphocytes
N = Normal
BW = Benign well nourished
BM = Benign malnourished
MW = Malignant well nourished
MM = Malignant malnourished
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Table 3.9 Plasma suppressive activities against autologous lymphocytes
according to nutritional status






















PSA = Plasma suppressive activity (/xl plasma)
NS = Not significant
* = Mann Whitney U test
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patients could not be matched in terms of their disease because their
nutritional status was secondary to their disease, and so it cannot be
concluded that their increased PSA was due solely to impaired nutrition.
The importance of the disease process cannot be ignored. It can be
seen in Figure 3.17 that the lowest seven PSA values of the benign well
nourished group were all below the lowest PSA value of the normal group;
closer examination of these seven patients showed that six had a degree of
illness related weight loss, although in only three did it amount to 10% or
more of body weight. Five of the seven had inflammatory bowel disease and
this may well be relevant to the finding of increased plasma suppressive
activity. The other two patients had fibroadenosis of the breast and a
villous adenoma of the rectum. The possible importance of an increased
PSA in these patients is discussed in Chapter 6.
The differences in PSA's of the two benign groups is striking, and
it is unlikely that they can be explained on the basis of disease alone.
Two patients in the benign malnourished group had long-standing
oesophageal strictures with little inflammatory reaction and so presumably
the complicating factor of their underlying disease would be minimal; both
patients had high PSA values.
The SA of any plasma sample depends on its inherent suppressive
ability as well as the strength of the lymphocyte response which the plasma
has to suppress. The use of autologous lymphocytes was considered to be a
more accurate reflection of the in vivo situation than the use of
allogeneic lymphocytes.
3.5.2 ALLOGENEIC PSA
Because measurement of PSA relies on the ability of plasma to
suppress a lymphocyte response, it is important to standardise the
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lymphocyte response for studies concerned with identifying and measuring
suppressive plasma factors. If lymphocyte responses were not standardised
then a sample of plasma would have different PSA values according to the
strength of the responses that it had to suppress.
3.5.2 (a) Methods
Lymphocytes were obtained from a panel of three healthy adult male
donors who had kindly donated blood samples to the laboratory on numerous
occasions during the three year period. The reactivity to PPD of
lymphocytes from these donors was remarkably similar and consistent during
this time (Appendix 13). Lymphocytes were prepared as described earlier
but cells from different donors were never mixed. PSA was estimated as
described previously.
3.5.2 (b) Results
The pattern of PSA against allogeneic lymphocytes was broadly
similar to that of PSA against autologous lymphocytes (Figure 3.18 and
Table 3.10). The normal group was not significantly different from the
benign well nourished group, which had significantly lower PSA's than the
benign malnourished group (p<0.001). PSA was increased in six well
nourished benign patients who also had raised PSA against autologous
lymphocytes. Two malnourished patients had values of PSA against
allogeneic lymphocytes which fell within the range of PSA's of the normal
group. These two patients had high PSA's when tested against autologous
lymphocytes, suggesting that the apparently high 'autologous PSA' was due
to poor lymphocyte reactivity rather than a true effect of their plasma.












































Figure 3.18 Plasma suppressive activities (PSA) against allogeneic
lymphocytes
N = Normal
BW = Benign well nourished
BM = Benign malnourished
MW = Malignant well nourished
MM = Malignant malnourished
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Table 3.10 Plasaa suppressive activities against allogeneic lyaohocytes
according to nutritional status






















PSA = Plasma suppressive activity (;ul plasma)
NS = Not significant
* = Student's t test
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significant difference between the PSA's of well nourished and malnourished
patients with malignant disease.
3.5.2 (c) Discussion
The use of allogeneic lymphocytes indicates that SA in plasma is
mainly non-specific as it is able to inhibit both autologous and allogeneic
cells. Also, it is clear that the high PSA of patients who are
malnourished or who have malignant disease is actually due to factors
within plasma and not simply due to reduced lymphocyte reactivity alone.
It is of interest to compare the PSA results with the two different
lymphocyte populations for the five subject groups (Tables 3.9 and 3.10).
Allogeneic PSA was significantly lower (higher /il volume) than autologous
PSA in normal subjects and in benign well nourished subjects, the latter
group behaving very similarly to normal subjects with respect to lymphocyte
reactivity (Section 3.3.1) and PSA. There was also a reduction in mean PSA
in the benign malnourished with the use of allogeneic cells; the difference
did not reach statistical significance. PSA values of this group were
scattered widely. Allogeneic PSA was greater (smaller (jlI volume of plasma)
than autologous PSA in both groups of malignant patients. This last
observation is intriguing, as it implies that there are plasma factors in
cancer patients which are suppressive for allogeneic but not autologous
lymphocytes. The differences are even greater than the PSA values lead one
to believe, as the allogeneic lymphocyte responses are significantly
stronger than the responses of lymphocytes from cancer patients
(Section 3.3).
3.5.3 INFLUENCE OF NUTRITIONAL STATUS IN PATIENTS WITH BENIGN DISEASE
The PSA studies indicate that PSA against autologous and allogeneic
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cells is related to nutritional status in patients with benign disease but
not in cancer patients.
The relationship between PSA and nutrition was quantified by
calculating a correlation coefficient (r) and value of p for each set of
data from the benign group of patients (Table 3.11). Correlations of
nutritional parameters with autologous and allogeneic PSA were generally
strong and all were significant (p<0.001). Correlations were stronger with
PSA against allogeneic rather than autologous cells for four of the five
nutritional parameters.. Correlations of percentage weight loss with
autologous and allogeneic PSA values are shown in Figures 3.19 and 3.20
respectively as examples. It is of interest to note that correlations of
PSA with serum albumin were not only statistically significant (p<0.001)
but were the strongest (r = 0.83 (autologous) and r = 0.78 (allogeneic)).
The fact that all nutritional parameters correlated with PSA
suggests strongly that is was nutritional impairment rather than "disease
factors" that increased SA in these patients with benign disease. However,
these observations do not prove this contention; to do so, it would have
been necessary to measure PSA in a series of patients with the same
disorder of exactly the same extent, duration and severity but with varying
degrees of nutritional impairment. Such a situation is rarely found in
clinical practice and would have required a considerable time in order to
collect a sufficiently large number of similar patients.
3.5.4 INFLUENCE OF THE STAGE OF MALIGNANT DISEASE
Malignant disease is associated with an increase in the SA of
plasma (Sections 3.5.1 and 3.5.2). The PSA results of the 69 patients with
malignancy were analysed on the basis of the stage of disease to determine
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Table 3.11 Correlations of plasma suppressive activity with nutritional
assessment of patients with benign disease
NUTRITIONAL
PARAMETER
n COEFFICIENT OF CORRELATION (r)*
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Figure 3.19 Correlation of plasma suppressive activity (PSA) against










Figure 3.20 Correlation of plasma suppressive activity (PSA) against
allogeneic lymphocytes with percentage weight loss in patients
with benign disease
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whether PSA was related to the amount of malignant tissue. Malignant
diseases were staged according to clinical staging criteria (Appendix 1).
There were four patients with Stage A disease, 21 Stage B,
19 Stage C and 25 Stage D. The PSA results have been shown in Figure 3.21
as logs of microlitre volumes of plasma required to cause 50% inhibition of
the responses of autologous lymphocytes. There was no statistically
significant difference between the four groups. Comparison of PSA values
of Stage A and B patients just failed to reach statistical significance
(p=0.06, Mann Whitney U test). The number of patients with Stage A disease
was small and so the data could be subject to a type II, or beta,
statistical error in which the small number of subjects has obscured a true
difference. While there is, perhaps, a trend towards a lower PSA in early
disease, there was no correlation between PSA values and Stages B, C and D.
To establish the presence of an association between early disease and low
PSA it would be necessary to study, firstly, a larger number of patients
and, secondly, to study patients with early stages of a variety of
different malignancies to exclude the influence of disease specificity.
All of the Stage A patients in this study had carcinoma of the breast.
The failure to demonstrate a correlation between PSA and stage of
disease could be due to the nature of the suppressive substances, or their
effect on lymphocytes within the TEEM test system, or the relative crudity
of the staging system. If SA is due to substances released from the
surface of tumour cells, then it would be expected that PSA would be
proportional to tumour bulk. If, however, SA was the result of interaction
of host factors with tumour-related factors, then SA would depend on the
amount of or functional capacity of the host factors in the presence of an
abundance of tumour-related factors. Thus, the present result is
consistent with the initial hypothesis (Section 1.8).
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Figure 3.21 Plasma suppressive activities and the stage of disease in 69
patients with malignant disease
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The inability to estimate adequately the volume of malignant
disease is a long-standing problem in oncology. Most staging systems use
criteria which can be related to prognosis, which may not necessarily
depend on the absolute volume of malignant tissue but rather the strategic
location of malignant deposits. Clearly, the extent of a malignant disease
may be very varied within each of the four clinical stages, and inadequacy
of currently available staging systems could contribute to the apparent
failure to correlate PSA with the extent of disease. Alternatively, the
existence of PSA in malignant disease could be an "all or none" phenomenon,
in which case all malignancies irrespective of stage would be associated
with a high PSA. Further studies are required to investigate the factors
responsible for SA before this explanation can be accepted.
3.5.5 INFLUENCE OF THE SITE OF MALIGNANT DISEASE
An attempt was made to identify an association between PSA and the
primary site of malignant disease. Scatter diagrams were drawn by plotting
PSA values for each patient with a particular malignancy. No consistent
pattern was found for either autologous or allogeneic PSA, except that the
group of patients with carcinomas of the breast had a slightly lower mean
PSA than the other groups. However, the breast group contained four
patients with Stage A disease whereas no other malignant group had any
patients with Stage A tumours. After excluding patients with carcinoma of
the breast, the PSA's of patients with other primary sites of cancer were
not significantly different.
3.5.6 SUMMARY
The plasma of all subjects had the ability to suppress to some
degree in vitro responses of autologous and allogeneic lymphocytes to
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antigenic stimulation. This finding is consistent with the view that there
is a factor, or factors, in plasma which regulates the activity of
lymphocytes in relation to their responses to stimuli. Suppressive
activity was increased in patients with benign diseases, such as
inflammatory bowel disease, and in patients who were malnourished as a
result of a benign disease. PSA was increased significantly in patients
with malignant disease, where the influence of malnutrition on PSA was not
apparent. There was a suggestion that PSA might not be quite so high in
patients with early malignancies as in patients with advanced disease,
although the number of patients with early cancer in this study was too
small for a definite conclusion to be made.
3.6 IDENTIFICATION OF PLASMA SUPPRESSIVE FACTORS
Studies were performed to identify the suppressive factor or
factors in plasma. Experiments were designed to identify the suppressive
factor(s) in normal subjects and to determine whether or not the same
factor(s) was supppressive in patients in whom PSA was raised, and whether
or not this factor(s) was quantitatively or qualitatively different in such
patients. A search was also made for additional suppressive factors in
patients with raised PSA.
3.6.1 COLUMN FRACTIONATION OF PLASMA
3.6.1 (a) Method
Plasma samples were obtained from five groups of subjects:
1. healthy adult volunteers (n=5); 2. well nourished patients with benign
disease (n=5); 3. malnourished patients with benign disease (n=5); 4. well
nourished patients with malignant disease (n=6); and 5. malnourished
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patients with malignant disease (n=6) . Details of the 22 patients are
given in Table 3.12. An attempt was made to study patients with disorders
of the same viscera; e.g. four patients with breast disorders, two with
fibroadenosis and two with carcinoma. The patient groups were well matched
for age and sex distribution, but were all significantly older than the
group of healthy volunteers. Plasma samples (2.0 ml) were fractionated by
gel filtration (Section 2.5). Each fraction of plasma was analysed for
(1) total protein content by spectrophotometry,- (2) SA against autologous
and allogeneic lymphocytes, using the TEEM test (Section 2.3), and
(3) constituent proteins as determined by fused rocket
immunoelectrophoresis (Section 2.6).
Thus, four sets of results were obtained from each plasma sample as
a result of gel filtration - protein content, SA (autologous),
SA (allogeneic) and a pattern of protein distribution. These results were
expressed graphically for each plasma sample and one representative example
from each of the five subject groups is shown in Figures 3.22 - 3.26. The
void volume of the gel filtration column was collected in the first 20 - 22
fractions, and these were discarded and not represented in Figures 3.22 -
3.26. The first fractions to be eluted from the column are represented on
the left of the Figures and the later fractions are towards the right.
At the uppermost part of each Figure is the plot of optical density
at 280 nm. This continuous line represents the tracing produced by the
chart recorder of the spectrophotometer. The two histograms represent
fractions of plasma in which SA against either autologous or allogeneic
lymphocytes was detected. SA was quantified by adding 0.5 ml of each
plasma fraction to 2.5 ml Hank's BSS (Appendix 4) which was then incubated
with 0.5 x 10® autologous or allogeneic lymphocytes for 30 minutes, after
which the TEEM test method was followed (Section 2.3.3). Each vertical bar
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Table 3.12 Details of. the 22 patients studied in Section 3.6
GROUP NUMBER AGE SEX
(mean ± 1SD) (M:F)
DIAGNOSIS



























Figure 3.22 An example of the optical density, percentage inhibition of
autologous and allogeneic lymphocytes and distribution of alpha












Figure 3.23 An example of the optical density, percentage inhibition of
autologous and allogeneic lymphocytes and distribution of alpha
2 macroglobulin, IgG and albumin in the plasma fractions of a


















Figure 3.24 An example of the optical density, percentage inhibition of
autologous and allogeneic lymphocytes and distribution of alpha
2 macroglobulin, IgG and albumin in the plasma fractions a
malnourished patient with a benign oesophageal stricture
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MALIGNANT
Figure 3.25 An example of the optical density, percentage inhibition of
autologous and allogeneic lymphocytes and distribution of IgM,alpha 2 macroglobulin, IgG and albumin in the plasma fractions
of a patient with gastric cancer
The brackets indicate the fractions which were pooled together



























Figure 3.26 An example of the optical density, percentage inhibition of
autologous and allogeneic lymphocytes and distribution of IgM,
alpha 2 macroglobulin, IgG and albumin in the plasma fractions
of a malnourished patient with a gastric carcinoma
The brackets indicate the fractions which were pooled together
to form the six regions or peaks (Section 3.6.2).
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of the histograms represents the percentage inhibition of one plasma
fraction and SA was detected in only those fractions represented by a
vertical line. The lowermost part of each Figure shows the relative
positions of some plasma proteins in relation to the distribution of SA.
Only a limited number of proteins have been shown for ease of presentation.
3.6.1 (b) Results
Plasma from normal subjects had SA against autologous and normal
allogeneic lymphocytes concentrated in only a few fractions which formed a
single region or peak corresponding to the distribution of the plasma
protease inhibitor A2M (Figure 3.22). Similar results were obtained by
fractionation of plasma from well nourished patients with benign disease
(Figure 3.23).
A different pattern of results was found in the benign malnourished
group (Figure 3.24). The optical density tracing was broadly similar to
that of the benign well nourished except that the albumin peak was
noticeably smaller. SA (autologous) was present in approximately twice as
many fractions and was grouped into two distinct and quite obvious regions.
One region corresponded almost exactly with the distribution of A2M, and
the second region was placed after the albumin peak towards the low MW
fractions. SA (allogeneic) was detected in more elution fractions which
could be grouped into three obvious regions: one corresponding with A2M,
another corresponding exactly with the low MW fractions which had SA
against autologous lymphocytes, and another region which corresponded well
with the distribution of IgG but no other protein.
Plasma fractions from well nourished cancer patients gave a
different pattern of results (Figure 3.25). Optical density was similar to
that of other well nourished subjects. Many fractions had SA against
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autologous lymphocytes and formed three distinct regions: one with a MW
greater than IgM, another corresponding to A2M and another at the low MW
end of the elution range. This third region did not have the "bell" shape
of the other regions, suggesting that it consisted of at least two
subregions SA. SA against allogeneic cells was detected in a greater
number of fractions and a fourth region of SA corresponding with the
distribution of IgG was evident. The smaller MW region of SA (allogeneic)
appeared to consist of at least two peaks in all patients.
The results of the malnourished cancer patients were broadly
similar to the well nourished cancer group, except that the albumin peak
was reduced in height. There were three peaks of SA against autologous
lymphocytes, corresponding with the distribution of substances with MW
above that of IgM, A2M and small MW substances. This third region (which
was present in all samples from patients with cancer and those with benign
disease and malnutrition) was broad, did not correspond with any protein
detected by the anti-all human protein antibody and appeared to consist of
several lymphocyte suppressive factors of differing MW. A fourth region of
SA was identified by the use of allogeneic lymphocytes, this region
corresponding with the distribution of IgG.
Representative examples of the percentage inhibition of autologous
and allogeneic lymphocytes in plasma fractions from each subject group are
given in Tables 3.13 - 3.17.
3.6.1 (c) Discussion
All of the plasma samples examined had a constant region of SA
against both autologous and allogeneic lymphocytes that correspond to the
location of A2M. Although the results do not prove that A2M is a
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Table 3.13 Percentage inhibition of autologous and allogeneic lymphocytes.
Plasma fractions from a normal subject
FRACTION NUMBER PERCENTAGE LYMPHOCYTE INHIBITION
Autologous Allogeneic
1-20

















50 - 100 0 0
Table 3.14 Percentage inhibition of autologous and allogeneic lymphocytes.
Plasma fractions from a patient with a benign gastric ulcer
FRACTION NUMBER PERCENTAGE LYMPHOCYTE INHIBITION
Autologous Allogeneic
1-20
(void volume) 0 0















46 - 100 0 0
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Table 3.15 Percentage inhibition of autologous and allogeneic lymphocytes.
Plasma fractions from a malnourished patient with a
benign oesophageal stricture
FRACTION NUMBER PERCENTAGE LYMPHOCYTE INHIBITION
Autologous Allogeneic
1-20
void volume) 0 0




































96 -100 0 0
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Table 3.16 Percentage inhibition of autologous and allogeneic lymphocytes.
Plasma fractions from a patient with carcinoma of the stomach
FRACTION NUMBER PERCENTAGE LYMPHOCYTE INHIBITION
Autologous Allogeneic
1-22









































FRACTION NUMBER PERCENTAGE LYMPHOCYTE INHIBITION
Autologous Allogeneic











Table 3.17 Percentage inhibition of autologous and allogeneic lymphocytes.
Plasaa fractions from a malnourished patient with gastric
cancer
FRACTION NUMBER PERCENTAGE LYMPHOCYTE INHIBITION
Autologous Allogeneic
1-20




























































suppressive factor, they suggest strongly that this is the case. The
results also suggest that A2M is a universal suppressive factor, if the
results can be extrapolated from a small number of subjects to the
population in general. Thirdly, it is evident that the suppressive nature
of the region corresponding with A2M is non-specific as it inhibited the
reactivity of both autologous and allogeneic lymphocytes.
The distribution of SA against autologous and allogeneic
lymphocytes was the same in normal subjects and well nourished patients
with benign disease - that is, a single region of SA corresponding with
A2M. This finding might have been predicted from the observation that the
SA of these two groups did not differ significantly (Sections 3.5.1 and
3.5.2) .
Malnutrition was associated with an increase in the number of
plasma fractions with SA. A small MW region with SA against autologous and
allogeneic lymphocytes was present; the origin and nature of this region
was uncertain and so further experiments were performed to elucidate its
nature (Section 3.10). A peak of SA against allogeneic lymphocytes
corresponded to the distribution of IgG (Section 3.7). The presence of
additional fractions with SA was associated with co-existent nutritional
impairment: although the two benign groups did not include patients with
the same surgical conditions, only three of the 10 patients had a marked
inflammatory component to their disease (diverticular disease (1) (well
nourished), and ulcerative colitis (2) (malnourished)). However, the
distribution and number of suppressive fractions was consistent within each
patient group and was related to nutritional status rather than disease
process. The presence of additional suppressive fractions is consistent
with the finding of increased PSA in benign malnourished patients (Sections
3.5.1 and 3.5.2). However, the question of qualitative and quantitative
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changes in naturally occurring suppressive factors as a result of disease
states remains unanswered at this stage.
Cancer plasma had several regions of SA: the first consisted of
substances of high MW (higher than that of IgM, 10® daltons), such as
immune complexes or lipoproteins. Other suppressive regions coincided with
A2M (autologous and allogeneic) and IgG (allogeneic only), and there was a
broad band of suppressive fractions of small MW. These results are
consistent with the earlier finding of a greatly increased PSA in cancer
patients and indicate clearly, that the SA was due to several factors in
addition to A2M. The experiments suggest that SA was associated with
specific plasma proteins.
3.6.2 POOLING OF PLASMA FRACTIONS
The SA identified by the above experiments was found in plasma
fractions which were grouped naturally together (Figures 3.22 - 3.26). In
order to verify the association of certain plasma constituents with SA,
experiments were performed to quantify the SA of each suppressive region
before and after removal of the plasma components. This necessitated
pooling of plasma fractions to form specific regions of SA. Fractions were
pooled on the basis of SA, and six regions were created from each plasma
sample (Figures 3.25 and 3.26). The brackets around groups of fractions
indicate which fractions were pooled together. The MW ranges and principal
proteins within each of the six regions are shown in Table 3.18.
Generally, there was good agreement between the distributions of SA
and plasma proteins, although proteins were not contained exclusively in
just one region. For example, it is apparent in Figure 3.25 that most of
the IgG was contained in region 4 but small amounts were present in the
194




2 106 - 8 x 105
3 8 X 105 - 2 x 105
4 2 X 105 - 9 X 104
5 9 x 104 - 5 x 104


















adjacent regions 3 and 5.
The volumes of each region of each experimental subject were
measured and found to be almost identical, indicating a relatively
constant pattern of SA for subjects within any one group.
3.6.3 QUANTIFICATION OF SUPPRESSIVE ACTIVITY IN THE SIX REGIONS
The SA of each of the six regions was measured against autologous
and allogeneic lymphocytes so that the relative contributions of each
region to the total PSA could be defined.
3.6.3 (a) Method
Throughout this work the first dilution of whole plasma to be
assayed for SA was always 1 in 60. The measuring chamber of the
cytopherometer had a volume of 3.0 ml and a 1 in 60 dilution of whole
plasma was made by diluting 50 n1 of plasma in 3.0 ml of Hank's BSS.
However, 50 /zl of each region would contain different amounts of plasma as
the volumes of the six regions were different. To compare the SA of each
region, it was necessary to standardise the dilution of each region by
relating the dilution of each principal plasma protein to the volume of the
region which contained the protein and not to the final dilution of the
whole plasma sample. For example, IgM was contained in region 2 and so the
dilution factor for IgM was the volume of region 2 divided by the volume of
the original plasma sample (2.0 ml). The volume of each region which was
made up to 3.0 ml with Hank's BSS was calculated by the formula:
VRR = VT x DT x DF
where VRR = Volume of the region required for SA determination
VT = Volume of the test sample (3.0 ml)
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DT = Dilution of the test sample (1/60)
DF = Dilution factor (volume of region divided by volume of
plasma, 2.0 ml)
For example, the mean volume of all second regions was 25.3 ml; therefore,
the volume of region 2 required for SA assay was:
VRR = 3.0 x 1/60 x 25.3/2
= 0.6325 ml
= 632.5 nl
Therefore, 632.5 /il of region 2 was made up to 3.0 ml with Hank's BSS to
produce a 1/60 dilution of "plasma equivalent". Similar calculations were
performed for the other regions. The maximum volume of a region which
could provide a 3.0 ml volume diluted 1 in 60 was 120 ml and, as some
regions (especially region 6) exceeded 120 ml, it was necessary to
concentrate them by ultrafiltration using Amicon Diaflo ultrafiltration
membranes (Amicon, Massachusetts, U.S.A.). Filtration membranes were
selected appropriately for each region on the basis of pore size so that
all proteins within the region were retained by the membrane. The final
volumes of the concentrated regions are given in Appendix 14. Dilutions of
the volumes were made using the above formula to produce a 3.0 ml volume of
1 in 60 dilution suitable for assay by the TEEM test. Suppressive activity
was expressed as the |il volume of the original plasma sample required to
suppress the standard lymphocyte response by 50%, as described in
Section 2.3.3.
3.6.3 (b) Results
The SA of each region from each of the 27 experimental subjects is
shown in Table 3.19 and results are summarised in Table 3.20. Region 1
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Table 3.19 Suppressive activities against autologous and allogeneic
lymphocytes of each sample of each pooled region
Values are given as the equivalent volume of plasma (/xl) required
suppress the lymphocyte response to PPD by 50%.
SUBJECT N BWN BMN MWN MMN
Region 1 - Autologous
1 - - - 24.0 32.4
2 - - - 19.8 20.4
3 - - - 17.7 34.6
4 - - - 42.4 45.5
5 - - - 39.8 39.6
6 36.1 39.2
Region 1 - Allogeneic
1 - - - 24.0 37.7
2 - - - 38.2 80.0
3 - - - 18.4 18.7
4 - - - 36.3 45.0
5 - - - 36.2 35.8
6 32.5 37.0
Region 2 - No suppressive activity was detected
Region 3 - Autologous
1 35.7 34.0 18.8 3.05 5.32
2 35.0 39.4 35.1 2.8 5.4
3 35.4 46.5 7.9 2.31 2.11
4 34.3 42.3 9.5 1.41 2.7
5 30.5 39.8 12.6 1.18 8.6
6 2.26 3.05
Region 3 - Allogeneic
1 38.1 35.7 15.8 1.12 4.8
2 38.0 40.9 35.8 2.06 1.22
3 37.2 44.2 4.2 2.09 2.0
4 38.0 39.6 4.37 1.08 1.64
5 35.5 40.6 4.5 1.12 2.35
6 2.22 2.18
Region 4 - Autologous. No suppressive activity was detected.
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Table 3.19 (continued)
Region 4 - Allogeneic
1 - 76.0
- 4.5 19.0
2 - 0 34.8 30.6
3 - 33.2 18.0 35.0
4 - - 29.0 35.1 35.0
5 - 36.0 18.3 57.1
6 20.0 37.1
Region 5 - No suppressive activity detected.
Region 6 - Autologous
1 - - 63.2 10.7 16.7
2 - - 75.6 15.2 34.4
3 - - 31.0 19.6 24.3
4 - 35.3 19.8 37.5
5 - 30.2 37.1 29.3
6 40.0 42.8
Region 6 - Allogeneic
1 - - 74.2 9.9 16.6
2 - - 73.8 20.2 37.4
3 - - 35.4 18.6 8.5
4 - - 30.1 9.1 17.0
5 - - 36.2 34.4 33.0
6 19.6 49.0
N = Normal
BWN = Benign well nourished
BMN = Benign malnourished
MWN = Malignant well nourished
MMN = Malignant malnourished
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Table 3.20 Suppressive activities. (mean ± 1SD) against autologous
lymphocytes in whole plasma and in each of the six regions of
plasma




1 2 3 4 5 6
N 5 32.00 0 34.2 0 0 0
±3.7 ±1.89
BWN 5 36.80 0 40.5 0 0 0
±4.2 ±3.98
BMN 5 8.03 0 0 16.7 0 0 47.1
±4.75 ± 9.8 ±18.7
MWN 6 1.59 29.9 0 2.16 0 0 23.7
±1.28 ±9.81 ±0.67 ±10.9
MMN 6 2.25 35.2 0 4.53 0 0 30.8
±1.09 ±7.83 ±2.21 ±8.6
N = Normal group
BWN = Benign well nourished group
BMN = Benign malnourished group
MWN = Malignant well nourished group
MMN = Malignant malnourished group
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Table 3.20 (continued)
Suppressive activities (mean ± 1SD) against allogeneic
lymphocytes in whole plasma and in each of the six regions of
plasma
























































N = Normal group
BWN = Benign well nourished group
BMN = Benign malnourished group
MWN = Malignant well nourished group
MMN = Malignant malnourished group
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contained SA (autologous and allogeneic) only in patients with malignant
disease and there was no significant difference between the values of SA of
the two groups with cancer. Region 2 was not suppressive in any subject.
Region 3 was the only region found to be suppressive in all subjects,
irrespective of the source of test lymphocytes. Region 4 was suppressive
only in subjects with a significantly raised PSA (reduced /xl volume of
plasma) and only against allogeneic lymphocytes. No SA was detected in
region 5. Region 6 had SA against autologous and allogeneic lymphocytes
only in patients with elevated PSA. The value of SA (/xl plasma) for any
particular region was relatively constant for the subjects within each of
the 5 experimental groups.
3.6.3 (c) Discussion
Region 3 contained the greatest amount of SA of any region,
irrespective of whether subjects were healthy or had a benign or malignant
disease. Comparison of the SA (/xl plasma) of whole plasma and region 3
indicates that this region followed closely the pattern of SA in whole
plasma and accounted for most of the SA in plasma. Therefore, as one might
expect, the SA of region 3 was low (high /xl volume of plasma) in normal
subjects and well nourished benign patients, and significantly greater in
benign malnourished patients and all patients with cancer. Thus, the
region corresponding with the distribution of A2M was the principal non¬
specific lymphocyte suppressive factor in all subjects examined.
Regions 2 and 5 did not contain SA against autologous or allogeneic
lymphocytes as determined by the TEEM test. Region 2 corresponded closely
with the distribution of IgM, and region 5 contained several proteins
including albumin, pre-albumin and transferrin. As this study was
undertaken to examine immunosuppressive substances, the regions not having
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SA (regions 2 and 5) were not examined any further.
Region 1, the region of greatest MW, was suppressive in all cancer
patients. As SA was directed against autologous and allogeneic cells, the
substances responsible for SA acted non-specifically. SA in region 1 was
related in some way to the presence of a malignant tumour and was not a
function of tumour type or stage.
Region 6 contained small MW substances and was suppressive against
autologous and allogeneic lymphocytes in benign malnourished patients and
cancer patients with and without nutritional impairment. It has already
been suggested that this region may contain several lymphocyte suppressive
factors, on the basis of the distribution of SA among fractions with
different molecular weights. SA was non-specific. This suppressive region
was present only in patients with tumours or in highly catabolic
malnourished subjects, suggesting that the suppressive nature of the region
was a result of tissue turnover or was due to products shed from actively
dividing or catabolic cells.
Region 4 was suppressive in all subjects with a raised PSA (except
one subject; Table 3.19) but was suppressive against allogeneic lymphocytes
only. Thus, the suppressive factor(s) in region 4 could be a product of
tissue breakdown or turnover (cf region 6) and was specific in its
suppressive action in that suppression was not directed against host
lymphocytes.
It has been shown in this section that some plasma regions with
differing molecular weights contained lymphocyte SA, and that healthy
subjects and those with benign or malignant disease differed in the amount
of SA contained in these regions. Region 3 was the major non-specific
suppressive region, accurately reflecting the total SA in whole plasma.
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The SA of some regions coincided with the distribution of specific plasma
proteins. Thus, further studies were performed to determine whether SA
could be attributed to such substances and whether these factors differed
quantitatively or qualitatively between the various subject groups.
3.7 STUDIES OF REGION 1
Region 1 consisted of the first 8-10 fractions eluted from the
gel filtration column after the void volume, and contained substances with
a minimum molecular weight of 106 daltons (Table 3.18). Region 1
contained proteins, as it had measurable optical density at 280 nm, and had
SA against autologous and allogeneic lymphocytes in all cancer patients but
no other experimental subject.
From the review of circulating non-specific immunosuppressive
factors associated with malignancy (Section 1.5.7) it was thought that
immune complexes (IC) could be responsible for some or all of the SA in
region 1. IC have heavy MW and so would be located in region 1, and as
they have non-specific SA (Section 1.5.7(a)) they would inhibit both
autologous and allogeneic lymphocytes. Beta - lipoproteins would be
present in region 1 also but there was no reason for lipoproteins to be
suppressive in cancer patients but not other subjects. Therefore, it was
decided to investigate region 1 by firstly separating IC from the region,
and secondly measuring SA after depletion of IC.
3.7.1 METHOD
The polyethylene glycol (PEG) method^352) was used to precipitate
IC (Section 2.8). Three PEG dilutions were used - 5%, 10% and 20% - as
recommended by Creighton^352), to increase the sensitivity of the
technique. SA was measured using allogeneic lymphocytes because autologous
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cells were not available in some cases when samples were tested. A 1 in 30
dilution was the first dilution used for measuring SA and subsequent
dilutions were 1 in 60, 1 in 120 and so on.
3.7.2 RESULTS
Precipitates of IC were obtained from all region 1 samples of
patients with malignant disease but not in any sample from normal subjects
or patients with benign disease. IC precipitates were seen as small white
pellets or thin white rims at the bottom of the conical glass centrifuge
tubes in which PEG precipitation was performed. There was no visible
quantitative difference in the precipitates obtained with the three PEG
dilutions.
The SA of untreated region 1, the precipitates obtained with 5% PEG
and the supernatants were measured using allogeneic lymphocytes
(Table 3.21). The value for each SA measurement was the mean of the values
obtained from duplicate samples. The percentage recovery of SA in the
precipitates was calculated by dividing the SA of region 1 by the SA of the
precipitate. As no SA had been detected previously in the region 1 of
normal subjects and benign patients, SA measurements of these regions were
not repeated.
SA activity was detected in all precipitates (with 5% PEG), and in
nearly all patients the SA of the precipitate corresponded closely with SA
in the untreated region 1. No supernatant contained SA at a 1 in 30
dilution, indicating that IC accounted for all of the SA in region 1.
3.7.3 CONTAMINATION BY FREE IMMUNOGLOBULIN
The precautions taken to avoid contamination of region 1 by free
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Table 3.21 Suppressive activities (allogeneic) of region 1,
precipitates and supernatants
SUBJECT SUPPRESSIVE ACTIVITY (m1 plasma)
Malignant Region 1 Precipitate Supernatant % recovery
well with 5% PEG of SA in
nourished precipitate
1 24.0 76.0 ND 323S
2 38.2 38.1 ND 1003S
3 18.4 20.2 ND 91%
4 36.3 40.1 ND 913s
5 36.2 38.9 ND 93%
6 32.5 43.9 ND 93%
Malignant
malnourished
1 t-C9 38.0 ND 99%
2 80.0 66.2 ND 120%
3 M 00 19.8 ND 94%
4 45.0 40.2 ND 111%
5 35.8 39.0 ND 92%






immunoglobulins were stated in Section 2.8. While region 1 may have been
contaminated slightly by IgM (contained predominantly in region 2) it is
highly unlikely that any free IgG would be found in region 1. IgG
(MW = 150,000 daltons) was collected in region 4, the beginning of which
was separated from the last fraction of region 1 by at least 20 elution
fractions. Also, region 1 was concentrated by ultrafiltration using a
filter which retained only substances of MW greater than 300,000 daltons.
Thus, any IgG found within region 1 could not have been due to
contamination by free IgG, and so comparison of IgG levels within the
untreated region 1 and within the precipitate would provide a means of
assessing the efficiency of the PEG method.
3.7.3 (a) Method
Each region 1 and corresponding precipitate (with 20% PEG) of the
12 cancer patients was titrated with dilute HCl until a pH of 4.0 was
reached. Samples were acidified to dissociate the antigen-antibody
complexes^359) . Precipitates obtained with 20% PEG were used because 20%
PEG was more likely to have precipitated free immunoglobulin than the other
two dilutions^353) jgg concentrations were measured by single radial
immunodiffusion (Section 2.9). A 10 ^1 volume of each sample was used in
the wells of the immunodiffusion plates.
3.7.3 (b) Results
There was a strong and highly significant correlation between IgG
concentrations in untreated region 1 and in precipitates of region 1
(Figure 3.27), indicating that the PEG precipitation technique was highly
efficient in precipitating IC which contained IgG. The percentage of IgG
in the untreated region recovered in the precipitate was between 58%
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Figure 3.27 The correlation between the concentrations of IgG in original
region 1 samples and in precipitates of region 1
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121%, with a median of 93.5%. The percentage recovery was greater than
100% in four cases, presumably due to experimental error.
3.7.4 DISCUSSION
SA was found in region 1 samples of canceT patients only, and
precipitation of IC with 5% PEG removed all SA from the samples. Also, the
SA of precipitates approximated to that of the regions before IC were
precipitated. Measurements of IgG in the untreated region and in the
precipitates showed good correlation, and the overall recovery rate of IgG
in precipitates was 93%. Thus, the method of precipitating IC was
effective - IgG in the precipitates could have come only from soluble IC of
region 1. Thus, IC were present in patients with malignant disease
(irrespective of nutritional status), and accounted for some of the SA
detected in cancer plasma. The non-specific nature of the SA of IC has
been demonstrated by the use of autologous and allogeneic cells. From the
results obtained in Section 3.6.3, it is clear that there were other
suppressive factors in the plasma of cancer patients; IC contribute in part
to the increased PSA of cancer patients but not in healthy subjects or
patients with benign disease.
3.8 STUDIES OF REGION 3
Region 3 consisted of fractions with MW between 8 x 105 and 2 x 105
daltons and was the only region to exhibit SA against autologous and
allogeneic lymphocytes in every experimental subject. The amount of SA in
region 3 was relatively constant for subjects within each group; normal and
well nourished subjects with benign disease had relatively little SA in
region 3, whereas well nourished and malnourished cancer patients had
considerable SA associated with this region; the malnourished benign group
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were between these two extremes. The SA in region 3 closely paralleled
that of whole plasma and accounted for the majority of SA of whole plasma
in all subjects. Studies of the eluted plasma fractions with fused rocket
immuno-electrophoresis suggested strongly that the protease inhibitor alpha
2 macroglobulin (A2M) was the principal plasma protein in fractions pooled
to form region 3.
To demonstrate that A2M was responsible for the SA in region 3, A2M
was removed from the region by immuno-specific affinity chromatography
(Section 2.7). SA and A2M concentrations were measured in samples of
(i) whole plasma, (ii) untreated region 3, (iii) elutions from the affinity
chromatography columns, and (iv) the A2M which bound to affinity
chromatography columns.
3.8.1 METHOD
Two affinity chromatography columns were constructed
(Section 2.7.1), one with anti-A2M conjugated to the column matrix and the
other conjugated with normal rabbit serum to act as a control to detect
non-specific binding of proteins. SA was measured against allogeneic
lymphocytes only, as autologous cells were not always obtainable when these
studies were performed.
The volumes of each region 3 applied to the columns were equivalent
to 1.0 ml of plasma, as calculated from the final volumes of region 3
(Appendix 14). If this volume was less than 2.0 ml it was made up to
2.0 ml with Stavitsky's PBS. A2M was removed from the anti-A2M column by
washing the column with 20 ml 3M sodium thiocyanate. The thiocyanate
solution was strongly ionic and eluates containing sodium thiocyanate could
not be assayed for SA in the TEEM test. Therefore, thiocyanate was removed
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by dialysis by placing the thiocyanate eluate in a bag of Visking tubing
which was then sealed; dialysis was performed against Hank's BSS (500 ml
for 10 dialysis bags) for four hours and this was sufficient to remove the
sodium thiocyanate.
3.8.1 (a) Alpha 2 macroglobulin concentration
A2M concentrations were measured by single rocket Immuno¬
electrophoresis (Section 2.6). Plasma dilutions were 1 in 10 and 1 in 20
for A2M measurements of whole plasma. Dilutions of the column elutions
were 1 in 20, a volume equivalent to 1.0 ml of plasma having been applied
to the column, which was washed with 20 ml of Stavitsky's PBS per sample.
Dilutions of the standard A2M antigen were 1 in 10, 1 in 20, 1 in 40 and
1 in 60 for single rocket immuno-electrophoresis plates measuring A2M in
column elutions, and 1 in 5, 1 in 10, 1 in 20 and 1 in 50 for plates
measuring plasma levels of A2M (Appendix 10).
3.8.1 (b) Suppressive activity
The volume of each region 3 used for assay of SA was the volume
which contained the equivalent of 50 ^1 of plasma, made up to 3.0 ml with
Hank's BSS, producing a 1 in 60 dilution as the first dilution for the TEEM
test and allowing serial dilutions (1/120, 1/240 and so on) to be made in
the usual manner. The elution of each sample of region 3 from the affinity
columns was a 1 in 20 dilution of plasma. It was anticipated that removal
of A2M by affinity chromatography would reduce the SA in the column
elutions and so lower dilutions were used to detect SA. The first dilution




3.8.2 (a) Alpha-2-macroglobulin concentration
There was no significant difference in the concentrations of A2M in
plasma or in region 3 between the five experimental groups (Tables 3.22 and
3.23). The range of A2M concentrations in whole* plasma was wide, in
keeping with the wide variation of A2M in normal subjects (Section 1.5.8).
The mean percentage recovery of whole plasma A2M in region 3 was 85%; the
apparent loss of some 15% represents losses due to diluting procedures, the
fractionation method and possible error in the technique of measuring A2M
concentration. Another source of error was the pooling of column fractions
containing A2M into regions 2 and 4; it can be seen from Figures 3.25 and
3.26 that proteins were distributed over a range of several fractions, and
it was inevitable that some A2M at the extremes of its distribution curve
would be included in the two adjacent regions.
The recovery rate of A2M from the control affinity chromatography
column was consistently in the order of 90-95%. A slight loss of A2M
occurred with samples from all groups and may have been due to non-specific
binding to the column.
No A2M was recovered in any elution obtained from the column
conjugated with anti-A2M antibody (Table 3.23). Using dilutions of
standard A2M antigen the lowest concentration of A2M which could be
detected by single rocket immuno-electrophoresis in our laboratory was
0.5 mg/100 ml. Therefore, as A2M was not detected in the elutions, it was
highly unlikely that any significant quantity was present.
3.8.2 (b) Suppressive activity
No SA was detected in region 3 samples after passage through the
anti-A2M affinity chromatography columns, whereas SA in elutions from the
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Table 3.22 Alpha-2-macroglabuliiL concentrations in plasna and in region 3
SUBJECT ALPHA 2 MACROGLOBULIN CONCENTRATION (mg/lOOml)
Plasma Region 3 - % recovery in
region 3
Normal 1 178 125 70
2 115 65 56
3 200 184 92
4 300 274 91
5 213 189 88
Benign well nourished
1 225 201 89
2 307 269 88
3 128 120 94
4 214 150 70
5 198 171 86
Benign malnourished
1 145 120 83
2 317 275 86
3 141 97 69
4 230 200 87
5 345 248 72
Malignant well nourished
1 245 231 94
2 180 164 91
3 150 119 79
4 201 152 76
5 280 215 77
6 160 134 84
Malignant malnourished
1 155 138 89
2 269 249 93
3 301 300 99
4 197 127 65
5 215 179 83
6 237 180 76
Alpha 2 macroglobulin was not detected in elutions from the anti-alpha 2
macroglobulin affinity chromatography columns
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Table 3.23 Alpha-2-macroglobulin concentrations (mean ± 1SD) in plasma and
in region 3 before and after anti-alpha-2-macroglobulin
affinity chromatography
GROUP n ALPHA 2 MACROGLOBULIN CONCENTRATION {mg/JOOml) (mean ± 1SD)
Plasma Region 3 Elution from Thiocyanated
anti-alpha 2 eluate
column
N 5 201.2 167.4 ND ND
±59.8 ±69.8
BWM 5 214.4 182.2 ND ND
±57.3 ±50.8
BMN 5 235.6 188.0 ND ND
±84 . 6 ±69 . 5
MWN 6 202.6 169.2 ND
±46.3 ±40.8
MMN 6 229.0 195.6 ND
±47.5 ±61.2
N = Normal
BWN = Benign well nourished
BMN = Benign malnourished
MWN = Malignant well nourished
MMN = Malignant malnourished
ND = Not detected
D = Detected in very small quantities in some samples only
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control column closely resembled that of untreated region 3 (Tables 3.24
and 3.25). SA was detected in samples eluted from the anti-A2M column with
sodium thiocyanate; these samples were dialysed to remove the thiocyanate
before SA was measured. The values of SA in 'dialysed thiocyanate' eluates
resembled closely those of untreated region 3 and the recovery of SA in
these samples for the five experimental groups was 80.7% - 98.6%. Thus, it
is clear that the use of thiocyanate to remove A2M resulted simply in
uncoupling of antigen from antibody and not denaturation of the A2M
molecule.
3.8.3 THE BIOLOGICAL BEHAVIOUR OF ALPHA-2-MACR0GL0BULIN
The experiments reported in Section 3.8 show that (i) the amounts
of A2M in region 3 of each experimental group were very similar, and
differences between the five groups with respect to A2M concentrations were
not statistically significant (Table 3.22), (ii) the amount of A2M in
region 3 closely matched the A2M concentration in whole plasma for all
samples examined (Table 3.22) and (iii) the SA of region 3 was associated
entirely with A2M, as removal of A2M removed all SA from the region; A2M
was recovered from immunospecific anti-A2M affinity chromatography columns
and was associated with SA, the levels of which were very close to those in
the untreated region 3 (Table 3.24). The amount of SA associated with
region 3 depended on the nature of the experimental group (Table 3.20): SA
was low in normal subjects and well nourished benign patients, increased in
malnourished patients with benign disease and relatively very high in both
groups of cancer patients. As the SA in region 3 of all five subject
groups was associated entirely with A2M, it is clear that the biological
behaviour of A2M in the various subjects was remarkably different: in
normal subjects A2M had little SA whereas A2M was highly suppressive in
215
Table 3.24 Suppressive activity against allogeneic lymphocytes of region 3
before and after affinity chromatography
SUBJECT SUPPRESSIVE ACTIVITY (/il plasma)




1 38.1 37.8 0 39.1
2 38.0 39.0 0 39.0
3 37.2 39.5 0 38.9
4 38.0 38.2 0 38.5
5 35.5 37.0 0 36.3
BWN
1 35.7 37.3 0 54.2
2 40.9 39.6 0 41.6
3 44.2 46.6 0 45.0
4 39.6 39.3 0 42.3
5 40.6 46.6 0 41.7
BMN
1 15.8 20.9 0 14.5
2 35.8 34.9 0 37.2
3 4.2 4.5 0 4.6
4 4.4 4.9 0 4.7
5 4.5 4.8 0 4.6
MWN
1 1.12 1.90 0 1.15
2 2.06 2.10 0 2.60
3 2.09 2.41 0 2.31
4 1.08 1.00 0 2.30
5 1.12 1.32 0 1.22
6 2.22 2.35 0 2.38
MMN
1 4.80 4.95 0 4.88
2 1.22 1.38 0 1.17
3 2.00 2.33 0 2.21
4 1.64 1.76 0 1.87
5 2.35 2.44 0 2.50
6 2.18 2.27 0 2.22
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Table 3.25 Sunmary of suppressive activities against allogeneic
lymphocytes of region 3 before and after affinity
chromatography
GROUP SUPPRESSIVE ACTIVITY (/xl plasma)
(mean ± 1SD)~
















































cancer patients. The differences in behaviour can be quantified by
calculating the amount of A2M from each region 3 of each patient required
to inhibit a standardised allogeneic lymphocyte response, by 50%.
Relatively large amounts of A2M in normal subjects (44.3-176.0 fig)
and well nourished benign patients (45.6 - 226.3-jig) were required to
produce 50% inhibition (Table 3.26). Much smaller amounts of A2M from
malnourished benign patients (8.5 - 183.0 fig), and even smaller quantities
of A2M from cancer patients (well nourished: 2.4 - 4.8 fig;
malnourished: 2.7 - 22.3 ^g) were required for the same degree of
suppression.
3.8.4 DISCUSSION
Region 3 was the only one of the six regions of plasma to exhibit
SA against both autologous and allogeneic lymphocytes in all subjects, an
observation which suggests that the factor responsible for SA in this
region was non-specific and universal. The SA of region 3 accounted for all
(normal, benign well nourished) or most (benign malnourished, malignant) of
the SA of whole plasma, indicating that the factor responsible was the most
important naturally occurring lymphocyte suppressive factor as determined
by the TEEM test assay in these patients. It has been shown clearly that
the SA of region 3 is due entirely to A2M. As levels of A2M in region 3
were similar in all experimental groups, but levels of SA differed greatly,
it is evident that the biological behaviour of A2M was dramatically
different in some of the experimental groups.
The association of a highly suppressive A2M with malignant disease
and tissue catabolism indicates that A2M has an important role in
immunoregulation and the immunosuppression which accompanies some disease
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depression can be achieved by a change in the biological behaviour of the
substance and not an increase in its absolute blood level. This theme will
be discussed further in the context of additional experimental results
(Chapter 6).
3.9 STUDIES OF REGION 4
Only region 4 obtained from cancer patients and from benign
malnourished patients contained SA which was directed against allogeneic
but not autologous lymphocytes. The MW range of region 4 was 2 x 105 to
9 x 104 daltons, and included alpha-l-lipoprotein, caeruloplasmin, lactate
dehydrogenase, IgG, IgA and transferrin. The observation that region 4 SA
was directed against only allogeneic cells suggested that it was due to
immunologically specific molecules. Therefore, the first experiment with
this region aimed to establish an association between the major
immunoglobulin in this region (IgG) and SA.
3.9.1 METHOD
Immunospecific affinity chromatography was used to deplete region 4
of IgG by the method described in Section 2.7. A control column with
adhered rabbit serum was also used. A volume of each region 4 equivalent
to 1.0 ml of plasma was applied to the columns. IgG was eluted from the
columns with 20 ml of 3M sodium thiocyanate which was removed from the
eluate by dialysis against Hank's BSS (Section 3.8.1), and the eluate was
assayed for SA. The SA of IgG-depleted region 4 was assayed against
allogeneic lymphocytes. SA in region 4 was detected only in cancer
patients and benign malnourished patients and so further studies were
performed only with these experimental groups.
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3.9.2 RESULTS
The SA of region 4 accounted for only a small proportion of the SA
of whole plasma (Table 3.27). The SA of the eluate from the control column
closely approximated that of untreated region 4 indicating that minimal
non-specific binding occurred. Virtually no SA was detected in the eluate
from the anti-IgG column: in five patients a 'trace' of SA was detected but
no activity was found in the other 12 patients. The dilution of this
eluate was 1 in 20, as opposed to the usual 1 in 60 dilution. SA was
detected in all dialysed eluates obtained after washing the column with
sodium thiocyanate and the percentage recovery of activity was generally
high (91 - 93%).
3.9.3 DISCUSSION
Depletion of IgG from region 4 resulted in loss of virtually all
lymphocyte SA which was recovered later in the eluate removed from the
column by 3M sodium thiocyanate. The finding that IgG was suppressive is
consistent with the finding that region 4 did not suppress autologous
lymphocytes.
The detection of traces of SA in the regions of some patients after
removal of IgG suggests the presence of other suppressive substances. The
most likely explanation is that A2M (found chiefly in region 3)
contaminated the region. The distributions of A2M and IgG among gel
filtration fractions overlapped to some extent (Figures 3.23 - 3.26) and
contamination of region 4 with small amounts of A2M was inevitable.
The relevance of this suppressive region to the overall immune
depression so frequently observed in cancer and malnourished patients is
open to question because SA was directed against allogeneic lymphocytes
only. It is reasonable to conclude that region 4 (IgG) does not contribute
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Table 3.27 Suppressive activity (allogeneic) of region 4 before and sifter
affinity chromatography
SUBJECT SUPPRESSIVE ACTIVITY (^1 plasma)
Whole
plasma
















































1 0.68 4.5 5.2 T 5.0
2 2.15 34.8 34.2 0 38.3
3 0.94 18.2 18.9 T 20.2
4 0.52 35.1 34.9 0 37.9
5 0.28 18.3 18.0 T 20.2
6 0.97 20.0 19.6 T 21.7












































BMN = Benign malnourished
MWN = Malignant well nourished
MMN = Malignant malnourished
T = Trace amount of suppressive activity detected
SA = Suppressive Activity
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to host lymphocyte suppression. The possible role of IgG in the
immunological escape of tumours has been reviewed in Section 1.5.5 and,
while it is likely that IgG does contribute to tumour advancement in some
situations, it seems unlikely from the present results that the mechanism
is by depression of host lymphocyte reactivity.
It is of interest to speculate upon the origin of the 'suppressive
IgG' in malnourished patients and the fact that IgG was present in normal
and well nourished subjects and yet it did not suppress allogeneic
lymphocytes. It is possible that the former group had subclinical
infections and that the IgG represented a recent or current humoral
response. This finding could alternatively reflect simply levels of IgG in
plasma: IgG may be elevated in malnourished subjects (Section 1.6.1).
3.10 STUDIES OF REGION 6
Suppressive activity against autologous and allogeneic lymphocytes
was detected in region 6 in all of the 12 patients with malignant disease
and in the five malnourished patients with benign diseases. Region 6
contained substances with MW less than 5 x 104 daltons, such as trypsin,
amylase, haptoglobin, alpha-l-antitrypsin, and acidic alpha-l-glycoprotein
(Figures 3.22 - 3.26). Also, small MW immunoglobulin fragments or subunits
may have been present in this fraction of plasma. The possible role of
immunoglobulin fragments in the immunological escape of tumours has been
mentioned in Section 1.5.7(d) and it was decided to investigate the
possibility that Fc subunits of IgG contributed to the lymphocyte SA of
plasma.
3.10.1 METHOD
Only regions (region 6) exhibiting SA were studied, Fc fragments of
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IgG (IgG-Fc) were removed by immunospecific affinity chromatography. An
affinity chromatography column was prepared bearing antibody to the Fc
fraction of IgG, as described in Section 2.7. A control column was used to
detect non-specific antigen binding. The volume of each region 6 applied
to the column was the volume of the region derived from 1.0 ml of the
original plasma sample. SA against allogeneic lymphocytes was measured in
untreated region 6, in the eluate obtained after incubation with the
affinity chromatography columns and in the eluate removed from the columns
by 3M sodium thiocyanate (Section 2.7.2). The percentage of SA lost as a
result of depleting the samples of Fc fragments was calculated by comparing
the SA of paired eluates obtained from the control and anti-Fc columns.
3.10.2 RESULTS
Following depletion of Ig-Fc, SA fell in all samples by 1 - 69%
(Table 3.28). However, SA was detected in the eluate from the anti-Fc
column, indicating that Ig-Fc accounted for only a relatively small
proportion of the SA of the region.
In five patients (numbers 1, 2 and 5 benign malnourished, and
number 1 malignant well nourished, and number 2 malignant malnourished)
depletion of Ig-Fc resulted in reduction of SA by only a few percent,
suggesting that the amount of Ig-Fc in the region was very small.
Previous studies in the laboratory (not reported here) indicated that the
experimental error of the technique was about 4 - 5%, and so it is
conceivable that there were no Fc fragments within this region in some
subjects. The average reductions in SA following Ig-Fc depletion for the
benign malnourished and well nourished and malnourished cancer patients
were 16.8%, 29.5% and 35% respectively. Suppressive activity was difficult
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Table 3.28 Suppressive .activity., against allogeneic lymphocytes of region 6

















1 74.2 74.6 75.7 2% ND
2 73.8 74.2 78.4 5% T
3 35.4 43.0 53.2 18% ND
4 30.1 31.1 62.5 50% ND
5 36.2 36.0 39.6 9% ND
MEAN+1SD 49.9±19.7 50.2±19.8 59.8±16.1 16.8%
MWN
1 9.9 9.8 10.4 6% T
2 20.2 20.8 37.6 47% ND
3 18.6 19.2 38.7 50% ND
4 9.1 9.8 11.8 17% ND
5 34.4 36.7 43.8 16% ND
6 19.6 21.8 36.9 41% ND
MEAN±1SD 18.6+8.3 19.6+9.0 29.9±13.4 29.5%
MMN
1 16.6 19.3 53.5 64% T
2 37.4 36.1 35.8 1% ND
3 8.5 10.2 33.2 69% ND
4 17.0 19.5 36.8 47% ND
5 33.0 53.2 40.6 13% ND
6 49.0 49.6 59.9 17% ND
MEAN+1SD 26.9±14.0 28.3±13.2 43.3+9.9 35%
BMN = Benign malnourished
MWN = Malignant well nourished
MMN = Malignant malnourished
ND Not detected
T Trace amount of suppressive activity detected
SA Suppressive .activity
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to detect in the dialysed eluate removed from the anti-Fc column with
sodium thiocyanate and traces of activity were detected in only three
subjects. It is likely that suppressive substances were either dialysed
out with the sodium thiocyanate or were degraded by this strongly ionic
salt with subsequent loss of SA.
3.10.3 DISCUSSION
The experiment indicates that the SA of region 6 was due only in
part to Fc fragments of IgG and that other substances with suppressive
effects on allogeneic lymphocytes were present in this low MW region. The
importance of Ig-Fc in lymphocyte suppression appeared to differ between
benign and malignant patients. Firstly, three of five benign malnourished
subjects had only marginal reductions of SA after Ig-Fc depletion,
indicating that either Ig-Fc made very little contribution to SA or there
was very little Ig-Fc in the region. However, similar findings occurred in
only two of twelve malignant patients (17%). Secondly, the mean %
reduction of SA after IgG-Fc depletion increased in a step wise fashion,
indicating that Ig-Fc made the largest contribution to SA in the
malnourished malignant group and the least in the malnourished benign
group. These findings could be interpreted as Ig-Fc having an additive
effect in malnutrition and malignancy such that these fragments were most
abundant when the two conditions co-existed.
The potential importance of Fc fragments has been mentioned in the
literature review (Section 1.5.7(b)) and their relevance to mechanisms of
tumour escape will be discussed in Chapter 6.
The importance of the lymphocyte SA of Fc fragments to all patients
with malignant disease and malnutrition secondary to benign disease is
questioned by the inconsistent results in the small number of patients
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studied here. It seems likely that, in some cancer patients at least, Fc
subunits of IgG do have an important inhibitory effect on lymphocyte
reactivity. The origin of the Ig from which the fragments were derived is
unknown. Unfortunately, time did not allow the author to undertake further
studies of the lymphocyte SA of other low MW substances in the region,
although studies were undertaken subsequently in the laboratory by others.
3.11 SUMMARY
The experimental results presented in this chapter show that in 136
subjects who were normal volunteers or patients coming to surgery for
benign or malignant disease:
(i) in vitro lymphocyte reactivity to a recall antigen (PPD) and three
mitogens (PHA, Con A and PWM) was reduced in patients with malignant
disease and to a lesser extent in patients with benign disease, compared
with responses of healthy individuals.
(ii) lymphocyte responses correlated significantly with all parameters
of nutritional assessment (weight for height, weight loss, TSF thickness,
AMC and serum albumin) in patients with benign conditions; lymphocyte
responses to Con A and PWM did not correlate with nutritional parameters in
patients with malignant disease although responses to PPD and PHA
correlated significantly. Generally, the sensitivity of lymphocyte
reactivity was low in patients with malignancy.
(iii) in the absence of nutritional impairment lymphocyte reactivity in
patients with benign conditions did not differ significantly from that of
normal subjects whereas lymphocyte reactivity was reduced in patients who
were adequately nourished but had cancer.
(iv) plasma from all subjects had the ability to suppress the in vitro
227
reactivity of autologous and allogeneic lymphocytes to PPD.
(v) the SA of plasma was significantly increased in patients who were
malnourished because of benign disease, and was much greater in patients
with cancer, irrespective of nutritional status.
(vi) there was no clearly defined relationship between the increase in
plasma SA and the extent or tissue of origin of the malignant disease.
Experiments were performed with plasma obtained from five healthy
volunteers and 22 patients with either benign or malignant diseases:
(vii) within each subject group a consistent pattern of plasma-related
lymphocyte suppression emerged such that fractions of plasma could be
grouped together to form regions of SA.
(viii) in healthy subjects SA was relatively low and was due entirely to
A2M which had SA against autologous and allogeneic lymphocytes.
(ix) the pattern of SA in well nourished patients with benign disease
was the same as in healthy subjects.
(x) SA in malnourished benign patients was associated mainly with A2M
but also with a small MW fraction, and the IgG of these patients had a
suppressive effect on allogeneic lymphocytes.
(xi) SA in all of the cancer patients was associated mainly with A2M
but also with immune complexes, Fc fragments of IgG, small MW substances
and IgG (allogeneic cells).
(xii) the plasma concentrations of A2M in each experimental groups did
not differ significantly whereas the SA associated with A2M did, indicating
that the biological behaviour of the molecule was different in groups with
high SA.
CHAPTER 4
IMMUNOLOGICAL STUDIES OF INTRAVENOUS FLUIDS
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4.1 INTRODUCTION
Acute protein-calorie malnutrition adversely affects the immune
system and reduces the host's ability to launch an effective immune
response against infectious agents (Section 1.6.1). Correction of
nutritional deficiences by enteral feeding has been shown to improve immune
competence in humans and experimental animals (Section 1.7.1). Also, there
is evidence that parenteral nutrition with fat-free intravenous solutions
can improve depressed immune parameters in malnourished humans and that
such improvements are associated with significant clinical benefits
(Section 1.7.2).
Although the effects on the immune system of malnutrition and
subsequent nutritional repletion by total parenteral nutrition (TPN) have
been studied extensively, the effects of the nutrient solutions themselves
are largely unknown. The aims of this study were, firstly, to examine the
effects of five commonly used intravenous nutrient solutions on the
in vitro reactivity of normal lymphocytes, and secondly, to measure the
reactivity of lymphocytes in patients receiving TPN.
4.2 LABORATORY STUDY
4.2.1 METHOD
Five parenteral nutrition solutions were examined (Table 4.1). Two
composite solutions ("A" and "B") were made up so that they would be
suitable for use in a clinical situation; they were almost isocaloric and
contained similar amounts of nitrogen and electrolytes per litre, but
differed in that solution "B" contained a fat emulsion ("Intralipid",
Kabivitrum Ltd., Stockholm, Sweden) which provided approximately half of
the calorie content. The other solutions contained the same amount of
nitrogen (solution "C"), dextrose (solution "D"), and fat emulsion
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Table 4.1 Composition of five test intravenous solutions (contents per
litre)
SOLUTION N Dextrose Fat Na K CI Kilo-
(g) (g) (g) (mraol) (nunol) (mmol) calories
A 4.7 200 0 24.3 20.0 23.3 922
B 4.7 89 44.3 23.0 25.0 21.6 868
C 4.7 0 0 24.3 20.0 23.3 366
D 0 200 0 0 6.0 0 800
E 0 0 44.3 0 0 0 400
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(solution "E") as the composite solutions, and thereby acted as control
solutions for either "A" or "B". Lymphocytes were obtained from five
healthy adult volunteers (Section 2.3.3 (a)). Serial dilutions (1, 1/2,
1/4, 1/8, 1/16, 1/32, 1/64, 1/128) of the five test solutions were made by
addition of Hank's BSS and each dilution was divided equally into five
aliquots which were incubated separately with 0.5 x 106 lymphocytes
(Figure 4.1). After incubation for 30 minutes at 23°C, lymphocytes were
washed three times to remove all traces of the intravenous solutions, and
lymphocyte reactivity to PPD was measured using the TEEM test
(Section 2.3). The Student's t test was used to assess the significance of
differences between results of in vitro lymphocyte reactions following
incubation with the five solutions.
4.2.2 RESULTS
The effect of each dilution of the five test solutions on in vitro
reactivity of normal lymphocytes is shown in Figure 4.2. Solutions "A"
(synthamin and dextrose), "C" (synthamin), and "D" (dextrose) caused
inhibition of lymphocyte reactivity at high concentrations only, and at a 1
in 4 dilution these three solutions had no effect on lymphocyte
responsiveness. In contrast, solutions "B" and "E", which contained a fat
emulsion, initially produced a significant increase in lymphocyte
reactivity (Student's t test, p<0.001). Highly significant inhibition
occurred with 1/4, 1/8, 1/16 and 1/32 dilutions (p<0.001) and the
depressive effect of these fat-containing solutions diminished with further
dilution.
Maximal inhibition of lymphocyte reactivity occurred when the
triglyceride content of the test solution was 0.28 - 1.13 mmol/1 (1/4 -
1/16 dilutions). The recommended infusion rate of "Intralipid" results in
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TEST SOLUTION
1, 1/2, ... 1/128
0.5 x 10 peripheral blood
lymphocytes
Incubate for 30 minutes at 23°C
Wash lymphocytes x 3
Add PPD (100 /*g) in 3.0 ml and incubate for 60 minutes at 30°C
Centrifuge at 500 G for 10 minutes
Supernatant
Add 40 x 106 TSRBC and incubate for 60 minutes at 23°C
Measure electrophoretic mobility of TSRBC in cytopherometer
4.1 Method of measuring the effect of intravenous nutrient



























CON 1 1/2 1/4 1/8 1/16 1/32 1/64 1/128
DILUTION
Figure 4.2 The effect of five intravenous nutrient solutions on in vitro
lymphocyte reactivity to PPD (mean ± 1SD)
Solution A = Synthamin and Dextrose
Solution B = Synthamin, Dextrose and Intralipid
Solution C = Synthamin Solution
Solution D = Dextrose
Solution E = Intralipid
Con = Control
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a plasma triglyceride range of 0.22 - 0.90 mmol/l(333), levels which
coincide closely with the range of maximal inhibition of lymphocyte
reactivity. MacFadyen et al(361) have shown that infusion of 500 ml
Intralipid 10% over four hours into adult patients produces elevated plasma
triglyceride concentrations with peak levels of around 0.44 mmol/1. Thus,
the intravenous infusion of Intralipid for parenteral nutrition may produce
plasma concentrations of triglycerides which correspond almost exactly to
the levels that produce maximum inhibition of lymphocyte reactivity
in vitro.
4.3 CLINICAL STUDY
A clinical study was undertaken to determine whether in vitro
lymphocyte reactivity of patients receiving intravenous nutrient solutions
was affected by the feeding solution.
4.3.1 METHOD
The effect of three intravenous fluid regimes on lymphocyte
reactivity was studied in 15 female patients who had undergone elective
cholecystectomy for radiologically-proven cholelithiasis (Table 4.2). As
nutritional impairment adversely affects lymphocyte reactivity, only well
nourished subjects suitable for a short period of parenteral nutrition were
studied. Informed consent was obtained from each patient.
A central venous catheter was inserted via an antecubital fossa
vein after induction of general anaesthesia. All patients underwent
cholecystectomy without exploration of the common bile duct. A period of
six hours was allowed after operation for haemodynamic stabilisation before
the intravenous feeding regimes were commenced. No patient required a
blood transfusion.
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Table 4.2 Patient details
GROUP 1 GROUP 2 GROUP 3
Age (years) 63.5 64.3 63.8
mean ± 1SD ±7.3 ±2.5 ±5.6
Weight (Kg) 62.5 59.8 64.9
mean ± 1SD ±9.4 ±5.4 ±7.5
PW/IBW (%) 119.6 115.8 122.8
mean ± 1SD ±17.6 ±13.0 ±15.2
TSF (%) 121.3 117.6 128.3
mean ± 1SD ±22.5 ±32.1 ±30.0
AMC (56) 91.6 90.5 99.1
mean ± 1SD ±8.2 ±4.5 ±10.5
Group 1 = Control
Group 2 = Dextrose as principal calorie source
Group 3 = Intralipid in addition to Dextrose
PW/IBW (%) =
TSF (%) = Triceps skin fold thickness as a percentage of standard
(Metropolitan Life Tables)
AMC {%) = Arm muscle circumference as a percentage of standard
Patient's weight expressed as a percentage of ideal body
weight for height.
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Patients were allocated randomly to one of three groups
(Table 4.3). Group 1 received a standard daily maintenance intravenous
fluid regime of 1 litre of 0.9% saline and 2 litres of 5% dextrose for two
days post-operatively, group 2 received a TPN regime of amino acids and
dextrose, and group 3 received a TPN regime which included a 20% fat
emulsion. The amino acid and dextrose solutions were prepared in three
litre polyvinylchloride bags by the hospital pharmacy and were infused
through central venous catheters at a rate controlled by volumetric
infusion pumps. The fat emulsion was given through a 'Y1 connector at a
point just before the central venous catheter penetrated the skin.
Infusions were continued until 48 hours from the commencement of surgery,
during which time patients were allowed to take water by mouth as desired.
Venous blood samples were taken from each patient immediately
before operation (day 0) and on the first, second, third and seventh post¬
operative days. Each sample was divided into two aliquots, one to provide
lymphocytes and the other to provide serum for measurement of triglycerides
and free fatty acids. Lymphocyte reactivity to PPD was measured using the
TEEM test (Section 2.3.3). The Wilcoxon Rank sum test was used for
statistical analysis.
4.3.2 RESULTS
Lymphocyte responses to PPD of the three groups did not differ
significantly before operation (Figure 4.3). The responses of all patients
fell on the first and second post-operative days. Those patients receiving
amino acids, dextrose and fat (group 3) had significantly lower lymphocyte
responses than those receiving physiological saline (group 1) during the
period of infusion (p<0.05). Although the lymphocyte responses of group 3
were lower than those of group 2 on the first and second post-operative
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Contents per 24 hours:
Volume (ml) 3000 3000 3167
Nitrogen (g) 0 14.3 14.3
Kilocalories 400 2766 2766
Sodium (mmol) 150 111 73
Potassium (mmol) 0 60 60
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Figure 4.3 The results of in vitro lymphocyte responses to PPD in patients
receiving either normal saline and dextrose (control) or
parenteral nutrition with either dextrose or fat emulsion.
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days, the differences failed to reach statistical significance at the 5%
level. On the third post-operative day, after cessation of all intravenous
regimes, lymphocyte responses were slightly higher overall than on the
previous day; responses of group 3 were lower than those of groups 1 and 2,
although the differences were not significant." By the seventh day
lymphocyte responses had partly recovered and were approaching pre¬
operative levels.
The serum triglyceride and free fatty acid concentrations are shown
in Tables 4.4 and 4.5 respectively. There was no statistically significant
difference between the serum triglyceride concentrations of the three
groups for any of the days of the study. The serum free fatty acid (FFA)
concentrations in patients receiving the fat emulsion (group 3) increased
significantly during the period of infusion (p<0.001). A similar rise was
not observed in patients who received fat-free solutions (groups 1 and 2).
4.4 DISCUSSION
The study has shown that in vitro lymphocyte reactivity is
impaired, firstly, after short-term incubation with "therapeutic"
concentrations of a fat emulsion, and secondly, in patients who are
receiving a fat emulsion by infusion as part of a short TPN regime. The
results are in keeping with the known effects of fatty acids on in vitro
and in vivo tests of lymphocyte function.
The mechanism of the inhibitory effect of PUFA is not known. As
some fatty acids are precursors of prostaglandins, their inhibitory
activity may be linked closely with that of prostaglandins. If so, PUFA
might exert their influence at cell surface prostaglandin receptors and
activate membrane-bound adenyl cyclase to increase intracellular levels of
adenosine 3'5' cyclic monophosphate (cyclic AMP), which in turn would
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Table 4.4 Serua triglyceride concentration of patients receiving post¬
operative intravenous fluids
GROUP PATIENT SERUM TRIGLYCERIDE CONCENTRATION (mmol/1)
Day
0 1 2 3 7
1 1 0.20 1.12 1.47 1.91 1.67
(Control) 2 2.39 0.79 1.65 1.71 2.38
3 2.69 1.20 1.08 1.00 1.36
4 2.16 0.39 0.24 1.18 1.23
5 1.52 1.30 1.12 0.97 1.41
mean 1.79 0.96 1.11 1.35 1.61
1SD 0.88 0.33 0.48 0.38 0.41
2 1 1.35 0.18 1.06 0.18 1.98
(Dextrose) 2 1.36 0.61 0.98 1.31 0.53
3 1.71 0.86 1.50 2.12 2.77
4 1.74 0.68 0.66 1.11 1.40
5 0.89 0.76 1.29 0.93 1.30
mean 1.41 0.62 1.09 1.13 1.59
1SD 0.30 0.23 0.28 0.62 0.74
3 1 1.41 1.46 1.96 1.03 0.98
(Intralipid) 2 0.96 1.48 1.46 1.98 0.97
3 1.71 0.85 1.51 2.12 2.77
4 1.74 0.68 0.66 0.40 1.41
5 0.89 0.76 1.37 1.00 1.36
mean 1.34 1.05 1.19 1.30 1.49
1SD 0.36 0.35 0.58 0.65 0.66
Reference range: 0.1 - 1.8 mmol/litre.
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Table 4.5 Serum free fatty acid concentrations (aeq/litre) of patients
receiving post-operative intravenous fluids
GROUP PATIENT SERUM FREE FATTY ACID CONCENTRATIONS (meq/1)
Day
**
0 1 2 3 7
1 1 1.45 0.46 0.54 1.08 0.37
(Control) 2 0.72 0.83 0.54 0.92 0.29
3 0.76 2.28 1.40 1.22 0.51
4 0.50 0.27 1.02 0.75 0.83
5 0.90 0.71 0.67 1.33 0.78
mean 0.86 0.91 0.83 1.06 0.56
1SD 0.31 0.71 0.33 0.20 0.22
2 1 0.41 1.91 2.02 2.01 0.39
(Dextrose) 2 0.71 1.38 0.15 1.53 1.50
3 0.77 1.16 1.11 0.81 1.82
4 0.69 0.65 0.40 1.47 0.66
5 0.66 0.54 0.89 0.32 0.59
mean 0.64 1.13 0.91 1.22 0.99
1SD 0.12 0.50 0.65 0.59 0.56
3 1 1.29 1.40 1.22 1.40 0.67
(Intralipid) 2 0.76 1.64 1.63 1.35 0.66
3 0.83 1.81 2.29 0.21 0.48
4 0.46 1.90 2.10 1.48 0.72
5 0.83 1.00 1.06 1.29 1.05
mean 0.83 1.55* 1.66* 1.14 0.72
1SD 0.26 0.32 0.48 0.47 0.19
Reference range: 0.09 - 0.8 meq/litre.
* Day 0 x Day 1, and Day 0 x Day 2: p<0.05 Wilcoxon Rank Sum Test
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activate an intracellular messenger system. Alternatively, PUFA could be
converted rapidly to prostaglandin at the lymphocyte surface by the
membrane-situated prostaglandin synthetase enzyme complex. The study
indicates that suppression can be effected by contact between lymphocytes
and PUFA for a short period of time and so this would tend to favour the
first proposed mechanism of inhibition.
Intralipid significantly inhibited in vitro lymphocyte reactivity
to PPD antigen, a result which is in keeping with that of Mertin et
a2(300,301) possible that the fatty acids were bound to the
lymphocyte cell surface and non-specifically blocked receptor sites for
PPD. Although lymphocytes were washed three times after incubation with
Intralipid, it is possible that PUFA remained on the lymphocyte surface in
spite of washing.
There have been few studies of the in vitro effects of solutions
used for parenteral nutrition. Ota et al^362) studied the effects of 10%
Intralipid on lymphocyte transformation, as measured by incorporation of
H3-thymidine following in vitro stimulation with PHA and Varidase. They
found that at a concentration of 1.15 mg Intralipid per ml (equivalent to
0.6 mg of esterified li-noleic acid per ml) Intralipid significantly
increased lymphocyte reactivity, although two other concentrations
(0.15 mg/ml and 2.3 mg/ml) did not affect lymphocyte function. Ota^362)
also studied the effect of free linoleic acid on lymphocyte transformation
and found that it caused a 75% decrease in transformation, confirming the
findings of Mertin^303^. The experimental system used by Ota differed
markedly from that of the present study. Also, in Ota's transformation
studies, lymphocytes were incubated for three days (PHA) and five days
(Varidase) in the presence of antibiotics and human serum, in addition to
the Intralipid solutions. Closer examination of Ota's results reveals that
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in five of the six experiments some lymphocyte cultures were inhibited by
Intralipid^333) Q^a ^id not attempt to explain his results which are in
disagreement with the known immunosuppressive effects of some of the
components of Intralipid.
The clinical study demonstrated that well nourished females
undergoing elective surgery of moderate severity and receiving post¬
operatively a fat emulsion as a source of calories had significantly lower
lymphocyte reactivity during the period of infusion than two matched groups
of controls. The numbers in each group were small but nevertheless the
differences in lymphocyte reactivity between the groups receiving and not
receiving Intralipid were statistically significant. Although the study
does not allow any conclusions to be drawn regarding possible clinical
sequelae, the demonstration that fat emulsion has non-specific
immunosuppressive properties may have implications for patients who are
candidates for TPN and who are likely to have impaired cellular immunity
before starting therapy. While evidence suggests that restoration of
nutritional status by prolonged TPN with fat-free solutions can improve
immune function, the short-term effects of intravenous fat emulsions appear
to be detrimental to host immunity.
Sepsis has been reported after prolonged treatment with
Intralipid^363) which has also been shown to adversely affect other
immunological mechanisms, such as the bactericidal capacity of
granulocytes(334). Thus, extensive use of fat emulsions with a high
content of fatty acids could result in further impairment of immune
function in already immunocompromised patients and expose them to even
greater risks of septic complications. Further studies are required to
determine the clinical significance of these findings.
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Serum triglyceride levels did not rise in subjects receiving an
intravenous infusion rich in triglycerides because the rate of Intralipid
infusion was less than the potential clearance rate of triglyceride from
the circulation. The infusion rate of triglyceride in the patients
receiving Intralipid was 92.6 nmol triglyceride/minute, which would lead to
an increase in plasma triglyceride concentration of 33.0 /xmol
triglyceride/litre/minute (Appendix 15). This increase is below the rate
of clearance of exogenous lipids from the circulation: in man, exogenous
fats are removed at rates which depend on the concentration of the fat in
plasma: above 1.0 mmol/1 the rate of clearance of triglyceride is
0.07 mmol/1 of plasma/minute, and below this level clearance is slightly
lower at 0.06 mmol/minute(365). Thus, the rate of infusion of triglyceride
was well within its rate of clearance. MacFadyen et al^6^ demonstrated
that triglycerides do accumulate in plasma when their rate of infusion
exceeds their rate of clearance.
Serum FFA concentration rose significantly during infusion of
Intralipid. The reason for this rise is complex and is not due simply to
excessive infusion of FFA, which constitute only 1% of Intralipid. The
particles of an infused fat emulsion are phagocytosed by cells of the
reticulo-endothelial system and in this way are cleared from the blood
stream^366). The intracellular enzyme lipoprotein lipase hydrolyses
triglyceride to FFA and glycerol within the phagocytes. The turnover of FFA
in plasma is rapid^367). FFA are metabolised in the liver to form ketone
bodies and in adipose tissue and peripheral tissues where they form acetyl
CoA which is used in the re-synthesis of fatty acids. Thus, FFA in plasma
following intravenous infusion of fat may be derived from either
triglycerides or infused FFA. In this study FFA were infused at the rate
of 2.82 meq FFA per day. Assuming a plasma volume of 2.79 1 (calculated
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from mean body weight), this infusion would cause a rise in plasma FFA
concentrations after one day of 1.01 meq/1 if there was no FFA clearance
during that time. In addition, the FFA potentially available from
hydrolysis of triglycerides is nearly 100 times the infused quantity.
However, the mean measured increase in plasma FFA after the first 24 hours
of fat infusion was only 0.72 meq/1, indicating that removal of FFA is an
extremely rapid and efficient process.
4.5 SUMMARY
Although nutritional repletion of malnourished individuals may
improve tests of cell-mediated immunity, the effects of intravenous
nutrient solutions themselves on the immune system are largely unknown.
The effects of five parenteral nutrition solutions on in vitro lymphocyte
reactivity were measured by incubating normal human lymphocytes with
dilutions of (a) an amino acid/dextrose solution, (b) an amino
acid/dextrose/fat solution, (c) an amino acid solution, (d) dextrose, and
(e) a fat emulsion, and lymphocyte responses to PPD were measured using the
TEEM test. Lymphocytes were inhibited significantly by the fat emulsion at
concentrations identical to those achieved by therapeutic infusion.
Lymphocyte reactivity was measured in 15 post-operative patients allocated
randomly to receive either simple electrolyte solutions or iso-caloric
parenteral regimes with or without a fat emulsion. In vitro lymphocyte
reactivity was significantly depressed in patients during infusion of fat
emulsion in comparison with controls (p<0.05). The results show that fat
emulsion impairs lymphocyte reactivity and suggest that careful
consideration should be given before using fat emulsions in patients in
whom cell-mediated immunity is impaired already.
CHAPTER 5
PLASMA SUPPRESSIVE ACTIVITY AND TUMOUR GROWTH
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5.1 INTRODUCTION
The studies reported in Chapter 3 showed that lymphocyte SA in
plasma was increased significantly in patients with malignant disease, and
that the increased PSA was due mainly to an alteration in the biological
behaviour of A2M as well as IC and small MW substances. It is likely that
these lymphocyte suppressive factors are directly or indirectly related to
the presence of malignant tissue. The role of these suppressive substances
is speculative but it is proposed by the author that they represent
mechanisms of "immunological escape" and a means by which tumour growth is
enhanced (Section 1.8).
If this hypothesis is correct, then it should be possible to
demonstrate a causal relationship between increased PSA and the presence of
a tumour. The ideal confirmatory study would measure PSA sequentially in a
large number of subjects over a long period of time and compare values in
those who did and did not develop cancer. Clearly, such a study was not
feasible, and so the author turned to an animal model. Secondly, if a high
PSA is beneficial for tumours, manipulation of PSA might be expected to
influence the growth of tumours. This hypothesis was examined in an animal
model also.
The present chapter describes two animal experiments which examined
(a) the causal relationship between tumour growth and PSA, and (b) the
effect of increased PSA on tumour growth.
5.2 METHODS
5.2.1 EXPERIMENTAL ANIMALS
Rats were used as experimental animals because they were easy to
maintain and use, they could support the growth of a readily available
tumour (the growth pattern of which was known), they could be bled
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repeatedly without undue stress, and their MHC types were known. Two in¬
bred rat strains were used: (i) Wistar-Albino-Boots (WAB) rats were used as
recipients of blood transfusions and tumours, and (ii) Portland-Virol-Glaxo
(PVG/C) rats were used as allogeneic blood donors for WAB recipients. MHC
designations are shown in Table 5.1.
All rats were adult females and weighed between 200 - 250 grams.
PVG/C rats tended to be slightly heavier than the WAB rats. PVG/C rats
were white with black 'hoods', while WAB rats were completely white.
Animals were housed four to a cage in an air-conditioned room at 24°C, with
a 12 hour light - 12 hour dark cycle, for one week before and during the
experiments.
5.2.2 TUMOUR
A rat sarcoma was used (gift of Dr. Allan Simpson, Department of
Clinical Biochemistry, Royal Victoria Infirmary, Newcastle Upon Tyne,
England). The sarcoma had been induced in an adult female WAB rat by
subcutaneous injection of 3-methylcholanthrene (5 mg) in trioctanoin and
maintained by subpassage into syngeneic rats of the same sex every two
weeks. The tumour grew rapidly and did not metastasise within the first
three weeks after passage and was highly immunogenic. Baldwin et al^868)
found that WAB rats immunised with the sarcoma, which was subsequently
excised, were able to reject a later challenge with 5 x 106 tumour cells or
whole tumour grafts.
A tumour suspension was made by excising a single sarcoma, removing
the surrounding connective tissue and finely mincing the tumour; the
homogenate was diluted with Hank's BSS containing penicillin 200 units/ml
so that the final concentration was 1 x 107 cells/ml. Cell viability was
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Table 5.1 MHC designations of experimental animals
RAT Ag B H-l MLR Ag C
WAB 2 W 2 2
PVG/C 5 C 5 2
Ag B and H-l : serologically defined antigens
MLR : Antigens defined by mixed lymphocyte reaction
Ag C : red blood cell antigen
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checked by trypan blue exclusion and 90% of cells in the suspension
excluded the dye. The tumour suspension was placed into 1.0 ml sterile
syringes marked with 0.01 ml gradations. Each animal was injected with
0.1 ml of tumour suspension (1 x 106 cells) into the subcutaneous tissue of
the left flank.
Tumours were palpable as small discrete nodules by day six, and
grew as spherical or ovoid lumps in the subcutaneous tissue of the flank,
ideally situated for easy measurement. Tumours were not allowed to grow
beyond 3 x 3 cm, a size which could be attained usually within 21 days of
passage. During this time metastases were not seen. Once a tumour
approximated to 3x3 cm, it was either excised, or the animal was
sacrificed by barbiturate overdose and a thorough necropsy performed to
search for metastases.
5.2.3 ANAESTHETIC
Venepuncture, infusion of saline, blood transfusion, and tumour
passage were performed under general anaesthesia. Animals were placed
individually in a large glass flask which was then covered. The base of
the flask contained a thick pad of cotton wool soaked with ether and rats
became unconscious after 20 - 30 seconds. Anaesthetised animals were
removed from the flask and placed supine on a cork board with each limb
strapped to the board with 1/2 inch adhesive tape. Anaesthesia was
maintained by administering ether on a cotton wool pad at the apex of a
small cone which was placed over the nose. Rats were conscious within a
few minutes of removing the anaesthetic nose cone and were able to walk
around in their cages within 15 - 20 minutes of finishing the anaesthetic.




Animals were bled from the jugular vein under general anaesthesia.
Each rat was placed supine on a cork board and a 1 cm transverse incision
was made on the upper part of the chest on one or other side to expose the
pectoralis muscle. The jugular vein was located beneath the fine layer of
fascia at the upper border of the pectoralis muscle. A sterile 2.0 ml or
5.0 ml plastic syringe was filled with a solution of heparin (1000 units in
1 ml) and then emptied so that there was no heparin within the barrell of
the syringe but some heparin remained in the part which locked into the hub
of the attached 21 gauge needle. The needle was passed through the
uppermost part of the muscle into the jugular vein. In this way, the upper
edge of the muscle covered the point of puncture in the vein and prevented
bleeding after removal of the needle.
Samples of blood (5.0 - 7.0 ml) taken from PVG/C and WAB donor
animals were used immediately for transfusion into recipient animals.
Following removal of more than 4 ml of blood an equal volume of 0.9% saline
was infused into the anaesthetised animal. WAB donor rats were not used
later as recipient animals. Blood samples were taken from WAB recipients
for measurement of lymphocyte reactivity and plasma SA. Aliquots of venous
blood (0.3 ml and 0.7 ml) were placed separately in plastic blood storage
tubes containing lithium heparin before assay by the TEEM test.
After exposure of the vein and venepuncture, each skin wound was
closed with two interrupted black silk sutures. The wounds healed well and
repeated venepunctures could be performed at the same site on each side of
the neck without adverse effects on the animals.
5.2.5 TUMOUR MEASUREMENT
After passage of tumour cells, rats were inspected daily and the
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left flank palpated to detect the presence of a tumour nodule. A small
discrete nodule was present in all animals by the sixth day and was large
enough to measure. Measurements were performed daily from the sixth day
until the tumours were excised.
The aim of sequential measuring was to assess the increase in
tumour mass. However, the mass of a growing tumour cannot be measured
directly in vivo. The net weight of a tumour-bearing animal can be
measured but any change in the animal's weight may reflect factors other
than tumour mass. The growth of an animal tumour is often expressed in
terms of increases in measurable diameters, but although the horizontal and
vertical diameters of a tumour may be measured accurately, the depth or
thickness of a tumour is difficult to measure accurately in situ. Because
of the inaccuracies inherent in measuring three axes of in situ spherical
or ovoid tumours, a method was used whereby tumour volume was calculated
from measurement of two axes of the tumour.
Assuming a fairly constant relationship of tumour mass with tumour
volume, the growth of a tumour can be expressed in terms of increases in
tumour volume. The expression of growth by changes in tumour dimensions,
rather than tumour volume, cannot accurately describe increases in tumour
mass, because increases in the dimensions of an object cause a greater
proportional increase in volume as the dimensions become larger.
The formula used to estimate tumour volume was based on work
performed by Perri et al(369) wk0 found good correlation between calculated
volumes and weights of ovoid-shaped sarcomas in rats using the formula:
V = a b2
where V = calculated volume of tumour
a = the length of the major axis, and
b = the height and width of the minor axes
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However, this formula assumes that the height and width of the
tumour (the minor axes) are equal. Attia et al(373) investigated the
application of this formula to the measurement 122 murine spontaneous
mammary tumours: they measured tumour volume by liquid displacement and
correlated the results with values obtained from the formula of Perri
(V = ab2), calculated from measurements of the tumours in situ immediately
before excision. They found a strong correlation between the measured and
calculated volumes. Their observed regression co-efficient of the
regression equation describing the relationship between measured and
observed volumes was 0.3986. This figure was converted to 0.4 for
practical purposes, and the regression equation formulated by Attia et
al(37°) was:
y = n + mx
y = 0 + 0. 4x
or y = (0.4) (ab2)
where y = measured tumour volume,
n = distance above the abscissa at which the regression line
intercepts the vertical axis. (The value of n was zero as the
regression line passed through the point of interception of the
x and y axes).
m = regression co-efficient, signifying the amount by which a
change in x must be multiplied to give the corresponding change
in y, (in this case m = 0.4).
x = tumour volume calculated from the formula V = ab2.
Attia et al(37°) were able to show that the measured tumour volumes
were very close to tumour volumes (V) calculated from the equation
V = (0.4) (ab2).
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It is apparent, therefore, that the depth dimension of an ovoid
tumour bears a constant relationship to the value of the minor axis (b),
although it may not equal the value of b. The formula of Attia was used to
calculate tumour volumes. Each tumour was measured daily from the sixth
day using calipers. The skin thickness of the riglit flank was measured
daily also, and subtracted from measured diameters of the tumour on the
left flank.
5.3 SEQUENTIAL MEASUREMENT OF PLASMA SUPPRESSIVE ACTIVITY IN
TUMOUR-BEARING RATS
An experiment was performed to examine the relationship between
plasma suppressive activity (PSA) and tumour growth. It has been
demonstrated that a high PSA is present in patients with cancer but the
precise relationship of PSA with tumour growth has not been defined. This
experiment measured PSA in rats before, during and after the growth of a
syngeneic tumour.
5.3.1 METHOD
Twelve WAB rats were studied. Each rat was injected subcutaneously
with 1 x 10® viable cells from a single methyl cholanthrene-induced sarcoma
(Section 5.2.2) on day 1. Tumours were measured daily and were excised
completely under general anaesthetic on day 14. Tumours were cleaned of
surrounding connective tissue and weighed. All animals were allowed to
recover from anaesthesia after the flank wounds had been sutured.
Venepunctures were performed on each animal on days 1 (immediately before
tumour transplantation), 10, 14 (immediately before excision of tumours),
17, 24, 32, 40, 50, 60, 80 and 130. On each occasion 1.0 ml of blood was
obtained and divided into two aliquots, 0.3 ml and 0.7 ml, which were used
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to measure PSA and lymphocyte reactivity to PPD respectively with the TEEM
test.
5.3.2 RESULTS
The PSA values before tumour inoculation, during tumour growth and
after tumour excision are presented in Table 5.2. The results have been
plotted graphically in Figure 5.1 as the log of the microlitre volume of
plasma, and inverted on the vertical axis so that a rise in PSA is shown as
a rise in the points plotted on the graph.
PSA was low before tumour inoculation (day 1) but increased
dramatically during tumour growth (days 10 and 14). Tumours were excised
after venepuncture on day 14 and PSA decreased subsequently to reach pre-
tumour levels by day 32. PSA remained at the relatively low pre-tumour
level thereafter. Local recurrence did not occur in any animal. However,
one rat was observed on day 76 to have a mass at the angle between the left
fore-limb and the chest wall. A blood sample was taken from the animal for
lymphocyte reactivity and PSA estimation, and the rat was sacrificed.
Necropsy revealed that the mass was a tumour nodule and that both lungs
contained multiple metastatic deposits. The PSA of this rat was increased
significantly at 2.2 ^1 plasma, although the PSA had returned to pre-
tumour levels after excision of its flank tumour.
Lymphocyte reactivity was initially high in all animals
(Figure 5.2) but fell markedly after tumour inoculation. Lymphocyte
reactivity recovered slowly following complete excision of the tumours and
returned to pre-tumour levels by day 40, a little later than PSA.
Unfortunately, lymphocytes from the rat which developed lymph node and
pulmonary metastases were lost during preparation before their reactivity
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Table 5.2 Plasma suppressive activity (PSA) before (day 1)., during (days
10 and 14) and after (days 17 - 130) tumour growth
DAY n PSA (fil plasma)
mean ± 1SD
1 12 35.9 ± 1.61
10 12 1.08 ± 0.05
14 12 0.59 ± 0.06
17 12 1.56 ± 0.42
24 12 2.32 ± 0.12
32 12 36.1 ± 0.52
40 12 35.3 ± 0.12
50 11 35.2 ± 0.45
60 11 36.6 ± 1.40
80 10 35.7 ± 0.35
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Figure 5.1 Mean plasma suppressive activity (Log jil plasma) in 12 WAB rats
before, during and after tumour growth.
Open circle represents the rat which developed metastases.
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Figure 5.2 Lymphocyte responses (mean ± 1SD) to PPD in 12 WAB rats before,






This experiment demonstrated that immunosuppressive activity can be
detected in plasma of tumour-bearing WAB rats and that the rise and fall in
PSA accurately paralleled tumour growth in all animals. All animals, except
the one with regional lymph node metastases, remained well and tumour-free
for seven months after excision, suggesting that these rats were "cured" of
their tumours. The case of metastatic spread is the first to be observed
with this tumour in our laboratory. PSA was grossly elevated at the time of
detection of metastases, indicating that a second increase in PSA was a
reliable index of recurrent disease in this animal. Unfortunately, PSA was
not measured frequently enough to detect an increase in PSA before
metastases became obvious.
The fall in PSA after removal of the primary tumours was relatively
slow. The significance of this is uncertain but is may reflect the
elimination of naturally occurring or tumour-induced immunosuppressive
substances from the host.
Although the precise significance of PSA is uncertain, it has been
demonstrated that plasma from a tumour-bearing host is able to suppress the
reactivity of lymphocytes from non-tumourous syngeneic animals. This
indicates that a high PSA associated with a growing tumour contributes to
host immunosuppression. Other cellular immune parameters may be affected
in addition to lymphocyte function. Immune suppression in some animal
tumour models results in increased tumour growth, and it is likely that a
high level of PSA inhibits or suppresses host immune defence mechanisms,
and thereby accelerates tumour growth.
Lymphocyte responses were impaired progressively as tumours
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increased in size. Impairment could have been due to circulating
immunosuppressive factors which caused the increase in PSA or to an
intrinsic defect of the lymphocytes. However, the reduction in lymphocyte
reactivity occurred within a few days of tumour inoculation, within the
life span of a lymphocyte; this would favour an 'extrinsic' cause for the
lymphocyte impairment.
The association of raised PSA with increasing tumour growth was
observed in all animals. The only animal to develop metastases was found
to have a greatly elevated PSA when the metastases were observed. No
conclusions can be drawn from a single animal, but the observation suggests
a direction for future experiments involving sequential measurements of
PSA in an animal model which more closely resembles the human situation,
i.e. using a metastasising tumour.
5.4 MANIPULATION OF PLASMA SUPPRESSIVE ACTIVITY
The previous experiment demonstrated that PSA paralleled tumour
growth, although the significance of increased PSA in terms of benefit to
the tumour is not known with certainty. It can be postulated that the
increase in PSA, which is found in humans and experimental animals with
tumours, benefits tumour growth by way of its suppressive effect on the
host's immune system. If this hypothesis is correct, then the increase in
PSA associated with tumours may be viewed as a mechanism by which tumours
escape from immune destruction. An experiment was performed to assess the
influence of increased PSA on tumour growth.
The aim was to increase PSA artificially and, with appropriate
controls, observe the effect on tumour growth. A method had to be found
whereby PSA could be increased without altering other physiological
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parameters. There are several possible methods. The immunosuppressive
properties of naturally occurring proteins (including the alpha-globulins)
have been reported in pregnancy^371^, uraemia^344), recipients of renal
allografts(37^), diabetes^373) and haemophiliacs who have received blood
transfusions (374). However, there is some physiological or pathological
event taking place in each of these examples to cause the increase in
immunosuppressive activity. It would not have been possible to use a
disease process to induce PSA in an animal model because the disease
process could have altered immunological parameters apart from any effect
on PSA, and also it would have been impossible to regulate a disease
process so that similar levels of PSA were achieved in all experimental
animals. Similarly, a tissue injury could have induced a raised PSA as a
result of increased acute phase reactant proteins, but this method would
have been open to the additional criticism that superadded infection (which
would have been difficult to prevent in an area of tissue necrosis in an
experimental animal) could have interfered with the experimental results.
The use of chemicals or drugs to induce a high PSA was considered but was
thought to be unsuitable as these agents themselves might have a direct
effect on tumour growth.
It was extremely difficult to conceive a means of inducing a high
PSA in an animal while at the same time maintaining its health and
nutritional status. Animal studies(374) performed previously in our
laboratory have shown that transfusion of allogeneic blood results in
significant increases in PSA (the technique had been used extensively in
the investigation of rejection of cardiac allografts in rats). The method
has distinct advantages over the previously described methods, as well as
some disadvantages. These are discussed later. The limitations of the




There were three experimental groups with 12 WAB rats in each:
(1) group 1 ("saline") received intravenous infusions of 0.9% saline.
(2) group 2 ("syngeneic") received intravenously whole blood from
healthy, non-tumour bearing, syngeneic WAB rats.
(3) group 3 ("allogeneic") received intravenously whole blood from
healthy, non-tumour bearing, PVG/C donor rats.
Each infusion (saline) or transfusion (syngeneic or allogeneic) was
2.0 ml in volume. Each recipient animal was given two infusions or
transfusions separated by an interval of three days. Recipient WAB rats
were bled on days 1, 4, 18, 28, 32, 35, 42, 50, 57, 67, 80 and 100. On
each occasion a 1.0 ml blood sample was obtained for measurement of
lymphocyte reactivity and PSA. Immediately after venepuncture on days 1
and 4 the WAB rats received the appropriate infusion of saline or
transfusion of blood. Fourteen days after the second infusion or
transfusion (day 18) each animal received the tumour challenge
subcutaneously in the left flank. The challenge dose was 1.0 x 106 viable
cells. Daily tumour measurements were performed when the tumours were
palpable. Fourteen days after tumour inoculation (day 32) the tumours were
excised completely and weighed immediately. The flank wounds were sutured
and the animals were maintained as described previously. After tumours had
been excised the animals were bled as described above.
The PSA of each blood sample was measured against lymphocytes from
healthy syngeneic rats and lymphocyte reactivity to PPD and a tumour
extract was measured using the TEEM test (Section 2.3). The tumour extract
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was prepared by mechanically slicing a single MC 7 sarcoma from a WAB rat,
pressing the tumour slices through a wire sieve and collecting the tumour
homogenate in Hank's BSS. The final concentration was made up to
1 x 107 cells/ml by adding BSS (Section 5.2.2). Tumour homogenate 0.1 ml
(1 x 106 cells) was incubated with 0.5 x 106 lymphocytes from each animal
in 3.0 ml BSS for 60 minutes at 23°C. The supernatant obtained after
centrifugation was added to TSRBC indicator cells in the usual manner
(Section 2.3.3).
The Student's t test was used for statistical analysis of the
results of PSA and lymphocyte reactivity. The Wilcoxon rank sum test was
used for statistical analysis of tumour volumes and weights.
5.4.2 RESULTS
5.4.2 (a) Plasma suppressive activity
The results have been plotted in Figure 5.3 as the log of the
microlitre volume of plasma required to cause 50% inhibition of the
response of normal syngeneic lymphocytes to PPD (Section 2.3.4) and the
scale of the vertical axis has been inverted so that a rise in PSA (i.e. a
decrease in the microlitre volume of plasma) is seen as a rise in the
points plotted on the graph, and vise versa.
PSA was low in each group before infusion or transfusion (T) .
After the first transfusion of allogeneic blood there was a significant
increase in PSA compared with the pre-transfusion PSA of the allogeneic
group (p<0.001) and the PSA of the saline and syngeneic groups after their
first infusion or transfusion (both p<0.001). There was a further increase
in PSA after the second transfusion of allogeneic blood but PSA remained
unchanged in animals given more syngeneic blood or saline. At the time of
tumour inoculation (I), PSA in the allogeneic group was very high relative
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to the other two groups. Following tumour inoculation, and concurrently
with tumour growth, the PSA of all three groups increased but remained
significantly higher in the allogeneic group. After complete excision of
the tumours (E) , PSA slowly returned towards pre-tumour levels: PSA
returned to pre-tumour ("normal") levels by day 57 in the syngeneic and
saline groups, that is 25 days after excision; PSA had been high before
tumour inoculation in the allogeneic group and the pre-tumour level (or
"day 18" level) was achieved before day 50. Return of PSA to normal or
pre-transfusion levels in the allogeneic group was not achieved until at
least 48 days after excision of the tumour, that is at some time between
days 80 and 100 of the experiment.
5.4.2 (b) Lymphocyte reactivity
The results of in vitro lymphocyte responses to PPD stimulation are
shown in Figure 5.4. On day 1, before any infusion or transfusion (T),
the lymphocyte responses of the three groups to PPD stimulation were not
significantly different. By day 4 the responses of rats given allogeneic
blood had fallen significantly (p<0.001), whereas responses of the saline
and syngeneic groups had not altered. There was a further fall in
lymphocyte reactivity in the allogeneic group following the second
transfusion but not in the other two groups. At the time of tumour
inoculation (I) there was a highly significant difference (p<0.001) in
lymphocyte reactivity to PPD between the allogeneic and the other two
groups but no difference in the responses of lymphocytes from the syngeneic
and saline groups. After tumour inoculation the responses of lymphocytes
from all groups fell markedly. Immediately before tumour excision (E) the
responses in all three groups were very low and were not significantly
different. Following tumour excision lymphocyte reactivity returned
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towards normal levels but at faster rates in the syngeneic and saline
groups than in the allogeneic group. At day 67 the responses of
lymphocytes to PPD of animals which received allogeneic blood were
significantly lower than those of the other two groups (p<0.01) but the
differences were not statistically significant by day 80.
Lymphocyte responses to tumour extract were measured immediately
before tumour inoculation on day 18, immediately before tumour excision on
day 32 and again 10 days later on day 42 (Table 5.3). Responses of
lymphocytes from rats given saline were not statistically significantly
different from those of the syngeneic group but were significantly higher
than responses of animals given allogeneic blood. At the time of tumour
excision lymphocytes in animals from all groups had become sensitised to
tumour tissue, as indicated by the increase in in vitro reactivity to
tumour extract. However, the responses of lymphocytes from animals which
received an allogeneic transfusion were significantly lower than those of
animals given saline (p<0.05) or syngeneic blood (p<0.001). Ten days after
excision of the tumours the lymphocyte responses (mean ± 1SD) to tumour
extract had fallen in the allogeneic group from 17.5% ± 0.3 to 12.3% ± 1.3,
whereas reponses in the saline group had not decreased significantly (19.9%
± 1.9 to 18.4% ± 0.5).
The results indicate that in vitro lymphocyte reactivity measured
by the TEEM test method was suppressed in the recipients of allogeneic
blood but not syngeneic blood or saline. Tumour growth suppressed in vitro
lymphocyte responses in all groups irrespective of pre-treatment, and when
tumours were large (i.e. just prior to excision) the lymphocyte responses
were uniformly low. Lymphocyte reactivity returned slowly to normal after
the removal of the tumour. As these animals were in-bred laboratory
strains it is unlikely that they had been exposed to Mycobacterium
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Table 5.3 Lymphocyte responses to tumour extract expressed as percentage
slowing (mean ± ISD) of TSRBC
GROUP
DAY Saline Syngeneic Allogeneic
18 8.2 ± 1.0 8.6 ± 1.0 5.5 ± 0.8
32 19.9 ± 1.9 21.3 ± 0.5 17.5 ± 0.3
42 18.4 ± 0.5 12.3 ± 1.3
ALLOGENEIC X SALINE (Student's t test):
Day 18 : p < 0.01
Day 32 : p < 0.05
Day 42 : p < 0.001
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tuberculosis and so would not have been sensitised to PPD which may have
been stimulating the lymphocytes in a manner similar to that of a mitogen.
5.4.2 (c) Tumour volume
The mean daily volumes of tumours in animals with a significantly
raised PSA at the time of tumour inoculation were significantly greater
than the volumes of tumours in animals with a low PSA, from day 6 until day
14 when tumours were excised (Table 5.4). At the time of excision tumours
in the high PSA ("allogeneic") group were nearly twice the size of tumours
in the low PSA ("syngeneic" and "saline") groups. Tumours grew in all
animals.
Growth rates of the tumours are plotted in Figure 5.5. At day 6
tumours in the low PSA groups were significantly smaller than tumours in
the high PSA group. Before day 6 tumour growth in the low PSA groups was
obviously less than in the high PSA group even though the tumours were too
small for accurate measurement. However, after days 7 or 8 the growth
lines of the three groups were almost parallel, indicating that after this
time the pattern of growth of each group of tumours was approximately the
same. This suggests that the implanted tumour cells were most susceptible
to whatever host factors differed between the three groups during the first
few days of their growth in the new host, and that as the tumours became
established their growth became less influenced by host factors.
5.4.2 (d) Tumour weight
Tumours were excised completely on day 32, 14 days after
inoculation, and were weighed immediately. There was no significant
difference between the weights of tumours in the two low PSA groups
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Figure 5.5 Mean tumour volumes (log mm3)between the sixth and fourteenth
days of growth. ;
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(Table 5.5). However, tumours from the high PSA group were significantly
heavier than those of the saline (p<0.05) and syngeneic (p<0.05) groups,
which had low PSA values at the time of tumour transplantation.
5.4.3 DISCUSSION
This experiment examined the effect of manipulating PSA on the
growth of a transplantable chemically-induced tumour in in-bred rats and
found that transfusion of allogeneic blood, but not transfusion of
syngeneic blood or infusion of saline, was associated with a significant
rise in the lymphocyte suppressive activity of plasma. The use of normal
syngeneic lymphocytes ensured that the apparent rise in PSA was due to
activity in plasma and not inherently poor lymphocyte reactivity.
Secondly, this experiment showed that tumour growth was associated with a
significant increase in PSA irrespective of whether or not PSA was raised
at the time of tumour inoculation. The rise in PSA was seen in all
experimental groups and appeared to be additive in as much as there were
further significant increases in PSA in animals in which PSA was already
increased. Thirdly, it was shown that tumour growth was increased in
animals in which PSA was greatly increased when the tumours were
transplanted.
A high PSA was induced in WAB rats by transfusion of blood from
allogeneic PVG/C rats. This method of PSA induction has advantages and
disadvantages. The method is simple and readily reproducible, and the
increase in PSA can be controlled accurately by administration of a known
volume of blood. The experimental animals are spared the suffering of a
disease process or tissue injury which might alter physiological and
immunological functions in addition to increasing PSA. The major
disadvantage of the blood transfusion technique is that whole blood
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Table 5.5 Tumour weights
GROUP (n) TUMOUR WEIGHT (grams)
mean ± 1SD
Saline (12) 6.8 ± 2.1
Syngeneic (12) 7.0+1.9
Allogeneic (12) 9.4 ± 3.2
ALLOGENEIC X SYNGENEIC: p < 0.05
(Wilcoxon two sample rank sum test)
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consists of many cellular and humoral elements which have been shown
recently to influence the immune system (Table 5.6). Although this
experiment has demonstrated clearly that allogeneic transfusion leads to an
increase in the lymphocyte SA of plasma in this animal model, it cannot be
said that the increased PSA was the only operative mechanism which could
have caused the increase in tumour growth. It is difficult to conceive of
a direct method of increasing PSA without some accompanying unwanted
physiological disturbance. The transfusion of plasma with high SA might
have provided an indirect method.
The immunological effects of blood transfusion have been
investigated extensively by researchers in the field of organ
transplantation. A full review of this subject is beyond the scope of this
work. However, it is apparent that allogeneic blood transfusions may cause
specific (relative to the immunising antigens) and non-specific suppression
of some immune functions. In an attempt to explain the mechanism or
mechanisms by which blood transfusion benefits subsequent renal allograft
survival, Van Rood(888) has suggested that immunisation of an individual
with allogeneic blood induces suppressor cells which often, but not always,
suppress the formation of anti-HLA antibodies and possibly cytotoxic
lymphocytes, depending on the presence of appropriate Ir genes. This
suppressed state allows the formation of anti-idiotype antibodies which, in
turn, inactivate T cell clones which would have reacted against HLA
antigens present on the immunising cells of the allogeneic blood. If the
blood transfusion donor and a subsequent tissue allograft share antigens,
then the inactivation of the responding clones is optimal. For example,
tumour growth would be accelerated in the case of a tumour allograft and
rejection of a kidney would be impaired in the case of a renal allograft.
Although tumours are known to bear surface antigens which may also
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Table 5.6 Immunological consequences of allogeneic blood transfusion
(from Francis et al^217^)
1. Induction of HLA-independent non-specific suppressor T-lymphocytes
(Lenhard et al (373)).
2. Induction of antigen specific suppressor T-lymphocytes
(Marquet et al (376)).
3. Increased suppressor cell activity (Kerman et al (377)).
4. Reduced natural killer cell activity (Singal et al (378)).
5. Impaired mononuclear phagocytic cell function (Keown et al (37®)).
6. Depletion of phagocytic cells (Van der Linden (38°)).
7. Induction of immune complexes (Benzonna et al (381)).
8. Induction of lymphocyte suppressive activity in plasma (Shenton et
al (344) an(j Francis et al (382)) associated with alpha-2-
macroglobulin (Alomran et al (383)).
9. Increased numbers of circulating IgG-, IgM- and IgA- secreting
cells (Gascon et al (384)).
10. Induction of non-cytotoxic anti-Fc receptor antibodies
(Macleod et al (385)).
11. Induction of anti-idiotypic antibodies (Singal et al (386)).
12. Induction of donor specific lymphocytoxic antibodies
(Ettenger et al (387)).
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be found on normal tissues of the adult host, they also bear neo-antigens
which may be unique to the tumour cells (Section 1.4.1). In particular,
chemically-induced tumours have unique antigens which may not even exhibit
cross-reactivity with tumours of identical histological appearance induced
by the same carcinogen in a syngeneic animal. Thus, while the host may be
rendered specifically unresponsive to antigens shared between the
immunising blood and the tumour, alternative non-specific mechanisms have
to be proposed to explain how allogeneic blood transfusion allows an
accelerated rate of growth of a highly immunogenic tumour bearing unique
surface antigens. One such mechanism is the rise in PSA which accompanies
allogeneic transfusion in humans(344 - 389.) , and experimental animals (as
demonstrated in the present study).
It has been demonstrated that the transfusion of allogeneic blood
increases the immuno-regulatory activity of A2M and that this naturally
occurring globulin acts non-specifically to suppress immune responses of
lymphocytes(374^. A2M has wide ranging immunoregulatory activities against
several types of cells (Section 1.5.8). It is conceivable that the "blood
transfusion effect" demonstrated in this study acts in part by non-specific
suppression of immune activities, including those of lymphocytes.
In spite of the limitations imposed by the use of allogeneic blood
transfusion to increase PSA, the findings are of considerable interest. It
has been shown that both tumour growth and transfusion of allogeneic blood
caused a rise in PSA and that these effects were additive. Even when the
tumours in all three groups were large, the PSA of the syngeneic and saline
groups of rats were not as great as that of the allogeneic group. Also,
the PSA returned to pre-tumour levels after excision of the tumours, a
finding which could be exploited perhaps in the area of clinical oncology.
Perhaps the most significant observation in this experiment is that
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allogeneic blood increased the growth of a transplantable chemically
induced tumour, a finding which is incidential to the aim of the
experiment. The importance of this observation is potentially immense and
is being investigated currently by the author-. Since the present
experimental work was performed and published^332,399)( there has been
considerable interest in the effect of blood transfusion and tumour growth
in humans and experimental animals. The subject has been reviewed recently
by the author(247' 391) ^ although further discussion is beyond the scope of
this thesis.
5.5 DISCUSSION
The first experiment reported in this chapter has shown that a
causal relationship exists between the growth of a tumour and a rise in the
SA in the host's plasma (Section 5.3). Unfortunately, time did not allow
the author to analyse the plasma with increased SA to determine the
responsible substance or substances in the experimental rats. However,
studies described in Chapter 3 indicate that A2M is largely responsible for
the increase in PSA in humans with tumours.
Several naturally occurring immunosuppressive substances have been
described in patients with malignant disease (Section 1.5.7). Sequential
studies of a few of these factors(392-394) and other "tumour markers", such
as carcino-embryonic antigen^393), human chorionic gonadotrophin^39®) and
acute phase reactant proteins(397), have indicated that their serial
measurements may be of value as prognostic indicators following
cytoreductive therapy. However, in many cases poor specificity and
sensitivity have limited the use of such single or multiple marker assays
in clinical practice. An alternative approach would be to measure
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sequentially the immunosuppressive activity in plasma rather than the
concentrations of individual biochemical markers. In contrast to
biochemical assays, measurement of PSA represents a functional assessment
of at least some aspects of immune function. The present study provides
support for the measurement of PSA in longitudinal studies in other tumour
models and, ultimately, in humans.
The close correlation between increased PSA and tumour growth in
rats with primary tumours and in the single case of tumour metastases
supports the hypothesis that the high PSA in tumour-bearing subjects is a
direct consequence of the presence of tumour tissue. The relatively slow
return of PSA to pre-tumour levels after tumour excision may reflect the
slow resolution of factors responsible for the high PSA. There may be
several reasons. Firstly, the human studies indicate that the high PSA in
tumour-bearing subjects is due to several factors and, for example, while
the electrophoretically-fast form of A2M may be eliminated rapidly immune
complexes may be removed at a much slower rate. Secondly, surgery and
anaesthesia have an immunosuppressive effect, as shown by the reduced
lymphocyte responses of patients receiving only crystalloid solutions in
the intravenous fluid study (Section 4.3), and this effect may prolong the
impairment of immune reactivity associated with tumours. Thirdly, it is
possible that the high PSA detected after complete excision of the tumours
was not related directly to the tumour or tumour products but rather was
related to altered metabolic or nutritional states induced by the tumour.
Some support for this view is provided by the studies reported in
Section 3.5.3 in which an increased PSA was found in patients suffering
from malnutrition unrelated to malignancy. Fourthly, it is possible that
the tumours were not removed completely, as would occur with complete local
excision in the presence of distant metastases; however, this scenario is
277
unlikely because the PSA of the single animal which developed metastases
behaved initially in precisely the same manner as that of the other rats
rather than remaining elevated and being unaltered by tumour excision.
The second experiment (Section 5.4) showed' that transfusion of
allogeneic, but not syngeneic, blood produced a significant depression in
lymphocyte reactivity to PPD and a significant increase in PSA, as measured
by the TEEM test, and so provides further evidence of the immuno-modulating
effects of transfusion (Table 5.6). The volume of each of the two
transfusions was 2.0 ml which represents 10 - 15% of the circulating volume
of the rat. The experiment suggested, but did not prove, that the increase
in PSA was beneficial to tumour growth; the method of inducing a high PSA
(transfusion) would have resulted in changes in other immunological
parameters which could have also altered tumour growth. However, the
experimental results were consistent with the hypothesis that PSA is
beneficial for tumour growth.
5.6 SUMMARY
The lymphocyte SA of plasma was measured sequentially in tumour-
bearing rats and was correlated with tumour behaviour. Twelve female adult
WAB rats were inoculated with a methylcholanthrene-induced sarcoma from a
syngeneic animal and bled before, during and after tumour growth. The PSA
increased rapidly with tumour growth and declined slowly following tumour
excision. In animals remaining free of tumour PSA remained at pre-tumour
levels. PSA rose with the occurrence of metastases. The study
demonstrates that PSA closely parallels the growth of primary tumours (as
well as the growth of metastases in a single case), and gives support to
the sequential measurement of PSA in subjects treated for malignant
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disease.
Allogeneic transfusion was associated with significant depression
of in vitro lymphocyte reactivity to PPD and tumour extract, and a
significant increase in PSA, whereas saline infusions and syngeneic blood
were not. Tumour volume and weight were significantly greater in animals
with a high PSA and low lymphocyte reactivity than in animals with
relatively normal PSA and lymphocyte reactivity at the time of tumour
transplantation, suggesting that a high PSA, and impaired lymphocyte




Many aspects of the work have been discussed within the various
sections of the thesis. However, some points concerning the methods and
results require discussion within the overall context of the reviewed
literature.
6.1 METHODS
6.1.1 THE TEEM TEST
The study aimed to examine firstly the intrinsic ability of
lymphocytes to respond.to standardised stimuli, and, secondly the capacity
of plasma and individual plasma components to inhibit lymphocyte
reactivity, and therefore it was necessary to study separate components of
CMI under controlled conditions and to be able to quantify the results. In
particular, it was necessary to assess objectively lymphocyte reactivity in
an environment free of humoral factors. This excluded the use of in vivo
tests (such as CDHR) and in vitro tests which require human or xenogeneic
serum. The problems of standardising and interpreting in vivo tests of CMI
have been discussed (Section 2.3).
The TEEM test was chosen as an in vitro method of quantitatively
assessing lymphocyte reactivity and the suppressive capacity of plasma and
plasma factors. The TEEM test has superceded earlier electrophoretic tests
of CMI, such as the MEM and MOD-MEM tests (Section 2.3.1), and many of the
problems of these older electrophoretic tests have been eliminated by the
use of tanned sheep erythrocytes as indicator particles in the TEEM test.
These cells are inherently stable with respect to their electrophoretic
mobility, and their method of preparation is straight forward. It is
important to emphasise that the TEEM test is a method of detecting and
measuring lymphokine release from lymphocytes in response to antigens or
mitogens; it is not a test for the presence of malignant disease, as has
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been suggested by some proponents of the older electrophoretic tests.
The technique of cytopherometry is very demanding and requires
considerable skill on the part of the operator. A criticism of.
electrophoretic tests is that they are open to operator bias and subjective
interpretation of their results. Consequently, all of the cytopherometry
was undertaken by Dr. Brian Shenton, an internationally recognised expert
in the theory and practise of cytopherometry. Cytopherometry specimens
were coded by the author before being examined by Dr. Shenton and the code
was broken only after the TEEM test had been performed and the results
secured by the author. In this way, samples were tested independently by a
skilled worker in the field without knowledge of their source.
The TEEM test has been found to be highly reproducible. Studies of
reproducibility have been undertaken in our laboratory and have been
reported (British Society of Immunology, London, April 1983). The TEEM
test yields consistent results over a period of time: for example, during
the seven month period of August 1980 to February 1981 the author donated
lymphocytes for control studies on 27 occasions and reactivity to PPD was
measured; during this time the author remained in good health and received
no medications which could have altered lymphocyte reactivity. Reactivity
was measured as percentage slowing of TSRBC (Section 2.3.3(d)) and was
18.6% ± 1.4 (mean ± ISD) with a range of 16.1 to 20.7%.
Comparative studies show that the TEEM test correlates well with
the MEM test^327) and the lymphocyte transformation assay^328). Also,
studies(398) performed in the laboratory have investigated dose-responses
of normal human lymphocytes to the immunosuppressive effects of
hydrocortisone, methyl prednisolone and cyclosporin A, and results with the
TEEM test have been reproducible and have agreed with those of others(399).
The advantage of the TEEM test over more traditional in vitro methods of
assessing lymphocyte reactivity is that it takes only four hours to
perform, thereby allowing assessment of very large numbers of samples
within a relatively short time. This was an essential feature of the study
as several thousand samples of plasma, plasma fractions and lymphocytes
were assayed.
Currie et al^2®) showed that washing lymphocytes from cancer
patients enhanced their specific in vitro cytotoxicity against autologous
and allogeneic tumour cells and believed that the effect was due to removal
of an "inhibitory serum component" from the lymphocyte surface. Thus,
preparation of lymphocytes for this study was meticulous and strictly
standardised to remove this important source of error. Previous studies by
Shenton et al(227) have investigated the effects of washing lymphocytes for
use in the TEEM test, and the method of preparation used in the present
study was the same as that of Shenton et al^34*'344).
6.1.2 SUBJECT GROUPS
It was decided before commencing the project to study patients with
malignant disease of the gastro-intestinal tract and breast. Patients were
typical cases presenting to a general surgical unit for investigation and
treatment. A small group of entirely healthy individuals acted as
controls, being selected only on account of their good health and
availability. A second control group of patients with benign disease was
selected on the basis of age, sex and the site of their disease, with the
aim of eliminating some of the obvious differences between the malignant
and healthy groups. The limitations of such selection are acknowledged. It
is clearly not possible to "match" two disease processes when one is
malignant and the other not, but it is also clear that variables such as
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nutritional status and age can affect immune performance and so attempts
were made to eliminate such variables wherever possible within the
limitations of the available patient population. Comparison of Tables 2.1
and 2.2 indicates that selection of benign patients at times failed to
provide patients with diseases of similar tissues or organs as the
malignant group. However, in many cases the patients' symptoms suggested
that their inclusion in the benign "control" group had clinical relevance.
6.1.3 MALNUTRITION
6.1.3 (a) Measurement
Methods of assessing nutritional status have been discussed
(Section 1.6.1). It is clear that no single method is satisfactory in terms
of sensitivity, specificity or availability. The most accurate method is
measurement of body composition by TBNAA, a technique which was not
available to the author for this study. Therefore, a number of widely used
and well tried methods of assessment were selected, rather than relying on
any single method. The justification for using weight-for-height, weight
loss, arm muscle circumference, triceps skin fold thickness and serum
albumin concentrations is that firstly, these parameters have been regarded
as corner-stones of clinical nutritional assessment protocols for many
years and are used regularly by clinical nutritionalists in hospitals
throughout the world; the five parameters are useful in clinical practice
and were the standard methods of assessment within the hospital where the
study was performed. They are well accepted nutritional parameters.
Secondly, these parameters correlate well with body composition studies
using TBNAA, and although anthropometric and biochemical assays lack the
sensitivity of TBNAA it is reassuring that highly significant and
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reasonably strong correlations have been demonstrated(232)_ Nutritional
parameters become clinically relevant only when they are able to detect
patients who are at risk of serious complications if their nutrition is not
improved and who will benefit from nutritional therapy. The literature
indicates that the above parameters are indeed clinically relevant
(Section 1.6.2), and therefore they were used in the present study.
6.1.3 (b) Standard nutritional data
Patients with nutritional abnormalities are identified by comparing
their nutritional data (anthropometric, biochemical or functional) with
that of normal or 'standard' populations. Thus, "malnutrition" is a
relative definition. The standard population must be relevant to the group
of subjects being assessed, otherwise the sensitivity of the classification
or comparison is open to question. However, standard data were not
available for the local population from which the experimental subjects
came. There have been no epidemiological studies of nutritional status of
the adult population of the north-east of England and so alternative
"standard data" had to be used. The standard data used by clinical
nutritionalists at the Royal Victoria Infirmary, Newcastle-upon-Tyne, at
the time of the study were the Metropolitan Life Insurance Company
tables(400) which have been used widely in nutritional
assessement ^230»238) ^ an(j these were adopted by the author.
The use of these tables was not ideal and is open to criticism.
The Metropolitan Life Insurance Company created body weight standards in
1943 by surveying North American populations, and they were referred to
initially as tables of "ideal weight". They were revised in 1959 and
referred to as "desirable weight" tables for each of three 'frame' types
(small, medium or large), following the realisation that subjects varied in
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skeletal build and that the skeleton made a substantial contribution to
body weight. Measurements of frame type were not made. The inclusion of
body frame type was a considerable advance on the original tables, even
though only three broad categories were included. It has to be accepted,
however, that because of the absence of definitions of frame type^401)
comparisons of individuals with standard data may lead to inaccuracies in
defining underweight subjects: being below an abstract average value does
not necessarily signify that body weight is below "normal" or lower than it
should be for a person's body build, age, sex, height or general state of
health. It was for this reason that '85% of normal' was used as the point
of identification of undernutrition, so that there would be some lee-way in
the definition of malnutrition to account for variations in body type.
It has been recommended that tables of "ideal" or "desirable"
weights-for-height should be replaced by skin fold thickness measurements
appropriate to each body type^40^>403) As stated above, there is still no
satisfactory definition of various body builds, although most investigators
can subjectively categorise most subjects. It is, therefore, inappropriate
to rely on just one method of nutritional assessement, such as body weight-
for-height, and so five criteria were used in the present study. There is,
of course, no way of avoiding the use of normal standard values; "abnormal"
is entirely dependent on "normal".
All so-called 'standard data' are open to these criticisms,
irrespective of whether they are derived from North American or local
populations. Ideally, a nutritional survey of the local population should
have provided the standard data, but that was beyond the scope of the work.
(It could perhaps be argued on sociological grounds that the standards
obtained from such a survey of the north-east of England at the time when
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the experimental work was performed would have been closer to the
Metropolitan Life tables than to present day North American standards).
Support for the contention that the North American data of 1959 is not
greatly different from the local experience comes from the fact that none
of the normal healthy volunteers in the study could be classified as
undernourished by any of the nutritional parameters. The inclusion of this
group of subjects is important, therefore, not only because of the
experimental findings of lymphocyte reactivity, PSA and A2M, but also
because the results of their nutrition assessments add validity to the use
of the Metropolitan Life tables as a source of normal values in the absence
of standards from the local population.
The advantages and disadvantages of functional tests, such as hand
grip dynamometry, have been discussed (Section 1.6.2(d)). As with
anthropometry, standards are required for functional methods of assessment,
but comparative standard tables were not available for the population from
which the experimental subjects came.
6.1.3 (c) Definition
The point of distinction between normal and abnormally low
nutritional measurements was taken as less than 85% of standard values for
anthropometric measurements and less than two standard deviations below the
mean for serum albumin concentrations. As expected from the nature of
methods of assessment and the standard values employed, not all patients
had all five parameters above or below the 85% cut-off point: 62% had less
than two abnormal parameters, 5% had two, and 33% had more than two.
Therefore, it was decided to classify patients as malnourished if the
majority of their parameters were "abnormal" as defined above. The
distribution of normal and abnormal results indicates that there was fairly
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close agreement between the discriminatory powers of the five parameters
based on the 85% cut-off mark. Others(244'404•405) have also used the 85%
cut-off point to define malnourished individuals.
6.2 LYMPHOCYTE REACTIVITY
The complex relationship between nutrition, cancer and
immunological reactivity has been explored by the experiments reported in
Sections 3.2 and 3.3. Lymphocyte reactivity to a recall antigen and to
mitogens, as assessed by an electrophoretic technique, was significantly
lower in well nourished cancer patients than in well nourished patients
with benign conditions or in healthy subjects. Malnutrition adversely
affected lymphocyte reactivity significantly, and malnourished cancer
patients generally had significantly lower lymphocyte responses than
malnourished benign patients.
The results indicate that malnutrition and malignancy both impair
lymphocyte reactivity and that unlike PSA, their effects are cumulative.
Therefore, any investigation of lymphocyte function in cancer patients must
take account of nutritional status. Although it is difficult to
distinguish cause and effect in the relationship between nutrition, cancer
and impaired immuno-competence, it is clear that malnutrition cannot be
ignored as a cause of immunoparesis in cancer patients. Therefore, studies
which correlate the outcome of cancer treatments with tests of immune
competence may merely reflect nutritional consequences of disease or its
treatment rather than any direct effect of therapy itself.
What is the significance of impaired lymphocyte responsiveness?
The reviewed literature emphasises the central role of lymphocytes in the
afferent and efferent limbs of specific immune responses, and so, by
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implication, the immune response against cells exhibiting tumour antigens
would be reduced and tumours would be subjected to weaker immunological
attack if lymphocyte function was impaired. Support for this supposition
has been provided by the animal study in which reduced lymphocyte responses
to PPD, PHA and a tumour extract were associated with increased tumour
growth. Also, circumstantial evidence from clinical transplantation
suggests that impairment of immune function is associated with rapid and
aggressive tumour growth(406). The mechanisms responsible for impairment
of function of lymphocytes and other immune cells are many and varied
(Section 1.5), and a further mechanism has been proposed in this thesis
(Section 1.8).
The use of tests of immune function in assessing malnourished
patients is not accepted generally and the literature concerning their
value is contradictory (Section 1.6.2 (e)). This study showed strong
significant correlations between in vitro lymphocyte reactivity and the
five nutritional parameters in patients with benign disease
(Section 3.2.2), suggesting that lymphocyte reactivity as measured here is
a valuable indicator of malnutrition in these patients. The results in
patients with malignancy were different: correlations between lymphocyte
reactivity and nutritional parameters were generally weaker and 30% were
not statistically significant, indicating, firstly, that lymphocyte
reactivity was a poor index of malnutrition as measured by the five
criteria in these cancer patients, and, secondly, that factors other than
cancer were affecting lymphocyte reactivity adversely. Therefore, it is
reasonable to recommend the use of in vitro lymphocyte reactivity to PPD
and mitogens as a correlate of nutritional status in patients in whom there
are no other factors which adversely affect lymphocyte function.
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6.3 PLASMA SUPPRESSIVE ACTIVITY (PSA)
The study has shown that SA in plasma from cancer patients can be
measured quantitatively by a simple, rapid in vitro technique, a
significant achievement of potential importance in two ways. First,
sequential studies of tumour markers (such as carcino-embryonic antigen and
human chorionic gonadotrophin) indicate that their serial measurement in
some patients is of prognostic significance, although poor specificity and
sensitivity have limited their widespread use in clinical practice. An
alternative approach would be to measure sequentially the immunosuppressive
activity in plasma rather than concentrations of biochemical markers.
Support for this proposal comes from the animal study (Chapter 5) in which
not only was PSA related to tumour growth but PSA returned slowly to pre-
tumour levels following complete tumour removal. Also, PSA was very high
in all cancer patients and, unlike PSA in benign patients, was not
influenced by nutritional status. In contrast to biochemical assays,
measurement of SA represents a functional assessment of immune status, and,
like assays of tumour markers, PSA also represents indirectly a 'tumour
product', as the mechanism of production of an elevated PSA is through the
interaction of tumour products (proteases, antigens) with the host's
response to the tumour (A2M, proteases from immune and inflammatory cells,
antibodies). Therefore, serial measurements of PSA in patients treated for
malignancy may be of value as indices of recurrent or residual disease.
Second, patients with malignancy were distinguishable from healthy
subjects and from benign well nourished patients on the basis of the
ability of their plasma to suppress the activity of allogeneic lymphocytes
(Figure 3.18). This interesting observation has to be interpreted with
caution. The malignant and healthy volunteer groups were not well matched
and the numbers in each were small. PSA is non-specific in that it results
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largely from the indiscriminate uptake and inhibition of virtually all
classes of protease enzymes by a ubiquitous "scavenger" molecule, and
therefore may be elevated by any condition associated with the release or
production of proteases (e.g. ureamia or blood transfusion^374)). The use
of this assay in clinical practice to identify patients with malignancy
could be fraught with problems related to normal values, the exclusion of
perhaps many patients because of other medical problems, and falsely low
values in patients with early tumours. Clearly, many interim studies would
be required before estimation of PSA could be used clinically.
6.3.1 PLASMA SUPPRESSIVE ACTIVITY AND MALNUTRITION
An aim of the present study was to determine whether a correlation
existed between PSA and nutrition parameters (Section 3.5.3). Strong
correlations existed between PSA and all five nutritional parameters in
patients with benign diseases (Table 3.12 and Figures 3.19 and 3.20). The
strongest correlation of PSA against autologous lymphocytes was with serum
albumin concentration (r = 0.83, p < 0.001). The value of autologous PSA
is a reflection of the capacity of a patient's plasma to inhibit the
reactivity of his own lymphocytes; if lymphocytes are intrinsically
suppressed as a result of malnutrition then PSA will be elevated falsely.
The autologous PSA, therefore, is a compounded value, representing the
suppressive capacity of plasma and reactivity of lymphocytes. This latter
factor is removed by the use of lymphocytes from healthy allogeneic donors
which allows measurement of the plasma's SA alone (allogeneic PSA). The
strongest correlation of allogeneic PSA was with TSF thickness (r = 0.84,
p < 0.001).
Correlation of PSA with nutritional status is a new finding which
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supports the use of the five nutritional indices and provides another
nutritional index which can be regarded as a test of immune function.
Measurement of PSA in malnourished patients serves not only to help
classify a patient's nutritional status but also to assess the function of
the immune system. The other abnormalities of immune function secondary to
malnutrition, and the advantages of functional tests over static methods of
nutritional assessment, have been discussed earlier (Section 1.6.2). The
mechanism of the elevation of PSA in malnourished patients is discussed
elsewhere (Section 6.5).
No association existed between PSA and nutritional . status in
patients with malignant diseases although strong correlations were
identified in the benign group. Failure to find an association in
malignant patients may be related to the mechanism by which the high PSA
was produced in these patients. A2M was the predominant factor associated
with PSA; highly suppressive complexes are produced by saturation of A2M
with proteases, and cancer cells and immune cells are plentiful sources of
protease. If the saturation of A2M and removal of A2M-P complexes is as
fast as the turnover of A2M (i.e., the rate at which complexed A2M can be
replaced by free A2M) then the A2M mechanism responsible for producing the
high PSA is maximal and cannot be increased further by production of more
proteases. Of course, PSA could be increased further by way of the other
mechanisms identified by this study or by entirely new mechanisms. It is
known from the findings of the benign group that malnutrition does increase
PSA, and so the failure to find an association between nutrition and PSA in
patients with very high PSA values is consistent with the view that the
mechanism by which malnutrition produces a high PSA (namely, A2M and small
MW peptides) was saturated in the malignant patients.
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6.4 ALPHA-2-MACROGLOBULIN AND MALNUTRITION
Immunosuppressive activity was associated with A2M and small MW
peptides in malnourished patients with benign disease. The amount of SA
associated with A2M in these patients was less than that in well nourished
and malnourished cancer patients but greater than that in normal subjects
and well nourished patients with benign disorders (Table 3.25). These are
new findings which provide, in part, an explanation of the mechanism of
impaired immunocompetence so often recognised in acutely malnourished
individuals.
Malnourished patients with benign disease (benign malnourished,
BMN) suffered mainly from conditions with an inflammatory component causing
release of proteases at local tissue sites. Malnutrition is characterised
by increased muscle (visceral protein) breakdown which provides another
source of protease enzymes. Similarly, unrecognised infection increases
catabolism, stimulates immune responses and leads to tissue necrosis and
further inflammatory reaction. Unfortunately, it is not possible in this
study to separate effects of malnutrition alone from those of inflammation,
albeit localised, because the underlying cause of malnutrition in these
patients, and indeed virtually all hospitalised patients in our society, is
a disease process. Thus, it is not possible to say categorically that
increases in SA associated with A2M and the small MW peptide were due to
tissue catabolism alone. Three of the five patients in the benign well
nourished (BWN) group studied in detail had conditions associated with
inflammation (diverticular disease (2) and duodenal ulcer (1)) but none had
raised PSA. These BWN patients are not adequate controls for the BMN
patients who in all probability had at least mild inflammation associated
with their disease (certainly those with ulcerative colitis (2) and chronic
pancreatitis). There is no satisfactory method of staging or quantifying
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the inflammatory process and it may be that the finding of a raised PSA in
the BMN group was in fact an index of the degree of associated inflammation
rather than a reflection of the malnourished state. Therefore, the results
have to be interpreted cautiously, and although the increase in PSA and
altered biological behaviour of A2M may be due to the metabolic disturbance
in these patients, the possible role of the inflammatory process should not
be forgotten.
The finding of a small MW peptide fraction with suppressive
activity in malnourished subjects is a new finding; its association with
A2M which had increased SA supports the proposal made by Hubbard( 208) in
relation to cancer (Section 1.5.8). Less SA was associated with A2M in
the BMN group than in the malignant group; similarly, less SA was
associated with the small MW peptides from BMN patients than peptides from
cancer patients. However, ratios of SA in region 3 : region 6 after IgG-Fc
depletion were similar in the three groups (Table 6.1), an observation
which supports the hypothesis that there is an association between the
peptide and A2M. This apparent relationship of function says nothing about
a quantitative relationship. It is noted that the ratios are not precisely
the same; differences may simply reflect the small numbers in each group.
Also, it may be incorrect to assume that all SA in region 6 after Fc
depletion was due to the cleavage product of A2M; other molecules, perhaps
released from tumours or tissue catabolism, may have SA and may increase or
decrease the SA assumed to be associated with peptides. However, the
finding that the ratios of SA in region 3 and 6 are similar could be
interpreted as indicating that there is a constant relationship between the
SA of A2M and the peptide fraction, with A2M having much greater SA.
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Table 6.1 Suppressive activity (median and range, fil plasma) associated
with A2M and the small molecular weight peptide fraction after
IgG-Fc depletion.
SUPPRESSIVE ACTIVITY {fil plasma)
(median, range)
A2M Peptide Ratio
BMN 4.5 62.5 1 : 14
(n=5) (4.2 - 35.8) (39.6 - 78.4)
MWN 1.6 37.3 1 : 23
(n=6) (1.1 - 2.2) (10.4 - 43.8)






Malignant well nourished group
Malignant malnourished group
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6.5 IMMUNOLOGICAL ESCAPE AND CIRCULATING NON-SPECIFIC
IMMUNOSUPPRESSIVE FACTORS
A paradox exists within the relationship between a tumour and its
human host. On one hand there is clear evidence of specific immunological'
reactions by the host against his tumour, and, although immune reactivity
in many cancer patients is depressed, it is not entirely paralysed. On
the other hand, tumours which have reached the stage of clinical detection
are able to grow and disseminate, even in the presence of specific
immunological detection and attack, and only very rarely is there evidence
of tumour regression in the absence of cytoreductive therapy. The
recognition of this paradox has led to the concept of immunological escape
of tumours. Several mechanisms exist by which malignant cells are able to
evade immune destruction (Section 1.5): they include host factors, such as
genetic restriction of host immune responses, and the existence of
immunologically inaccessible sites, and factors related to the tumour,
including changes in cell surface antigens to prevent immune recognition
and destruction, shedding of surface antigens so that host antibodies
combine with free antigen rather than antigenic components of tumour cells,
and shedding of surface protease enzymes which can destroy host antibodies
and facilitate growth and spread of malignant cell lines. The role of Ts
lymphocytes as a mechanism of immunological escape is uncertain
(Section 1.3.2). Antibodies formed in response to tumour antigens have
been shown to 'protect' tumours in some respects by stimulating anti¬
idiotype antibodies and masking antigenic specificities after combining
with determinants on the cell surface.
Detection of circulating non-specific immunosuppressive factors
(CN-SIF) in cancer patients suggests yet another mechanism by which tumours
can escape immune destruction. Studies have indicated that the function of
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many immune cells is impaired in some cancer patients but it has not been
ascertained whether impairment is due to intrinsic defects of immune cells
or the existence of circulating immunosuppressive factors. The present
study has shown that lymphocytes from cancer patients had significant
impairment of their in vitro reactivity in comparison with those from
healthy subjects or patients with benign disease, and that plasma from
cancer patients had highly significant increases in SA. The increase in SA
was largely but not entirely non-specific in nature in that it was directed
against autologous and healthy allogeneic lymphocytes and inhibited the
responses of lymphocytes to a recall antigen (PPD) and three mitogens (PHA,
Con A and PWM). The study indicates clearly that CN-SIF are important in
the overall immunological deficit observed in cancer patients.
Unlike other studies of CN-SIF, the present work not only found
that SA in cancer patients was associated with immune complexes (IC),
alpha-2-macroglobulin (A2M), IgG (SA against allogeneic cells only) and Fc
fragments of IgG, but was able to measure PSA quantitatively with the
result that A2M was identified as the major inhibitory factor, while Fc
fragments had slightly higher SA than IC. Other small MW substances (as
yet undefined) were shown to be suppressive also. The importance of this
last group of inhibitory substances is unknown, but the possibility arises
that they may be analogous to the so called "middle molecules" detected in
chronic renal failure patients and may result from the shedding and
catabolism of membrane and intracellular components of abnormal neoplastic
cells. They may include substances derived from the alpha globulins as
observed by Glasgow et al^®8) and Friedman et al^®^ or from A2M as
postulated by Hubbard(208) .
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6.5.1 ALPHA-2-MACROGLOBULIN
The present study identified the protease inhibitor A2M as a
substance with lymphocyte SA in all subjects. The biological behaviour of
A2M was different in patients with malignant disease in that A2M was far
more suppressive than in normal subjects (Section 3.8.3).
The work suggests a new mechanism of immunological escape involving
A2M, and provides further information about the activity of A2M in cancer.
The following model, which is compatible with previous studies of the
structure and function of A2M, is proposed. Tumour cells express a variety
of surface determinants which lead to antibody and cell-mediated immune
responses and a local inflammatory reaction as part of the immune response
following release of lymphokines and other substances from lymphocytes,
macrophages and polymorphonuclear leucocytes. Many of these substances
(histamine, kinins, prostaglandins, complement components, lysosomal
enzymes) depend on protease enzymes for their synthesis, release and
activation. Proteases are generated and released as a result of immune
responses (e.g. from cytotoxic T lymphocytes, polymorphs and killer cells
involved in immune reactions, as a result of target cell lysis, and
following events such as ADCC and complement activation). In addition to
this physiological liberation of proteases, tumour cells carry surface
proteases which are released by shedding, and also, proteases are released
following cell death. However, in contrast to the physiological release of
protease enzymes, proteases from tumour cells are produced unceasingly and
in abundance. A mechanism is required to limit the activity of
physiologically released protease to regulate the protease-dependent
aspects of the immune response, and such a mechanism is provided by
naturally occurring plasma protease inhibitors (PPI), of which A2M is the
most important. The existence of PPI can be regarded as a means of
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feedback control on cells capable of releasing proteases, as not only does
A2M combine with and eliminate proteases rapidly but the A2M-P complex has
inhibitory effects on the immune system. These actions include inhibition
of lymphokine-induced cellular activity by lymphocyte recognition of
antigen, inhibition of B cell activity, inhibition of the chemotactic
activity of lymphokines and enzymes such as kallikrein and plasminogen
activator, and regulation of lymphokine dependent activities of
macrophages. The consequences of A2M combining with protease have been
reviewed (Section 1.5.8), and it has been postulated that the SA of A2M-P
complex is a result of a conformational change in the molecule(^08)
Therefore, a tumour, which stimulates immune responses involving many
cellular elements and which constantly sheds proteases from cell surfaces,
would lead to a high level of complexed A2M. If the hypothesis proposed by
Hubbard(^08) js correct, then the A2M should be highly suppressive. The
present study has demonstrated that the A2M found in cancer patients is
highly suppressive with respect to lymphocyte reactivity, and confirms the
hypothesis. This finding is of great significance because it demonstrates
that, as a result of fulfilling its physiological function of inhibiting
protease enzymes, the A2M molecule is able to suppress the activity of the
immune system to a pathological degree. The importance of this role is
emphasised by the present study which demonstrated clearly that A2M was the
strongest plasma inhibitor of lymphocyte reactivity in all of the subjects
examined.
It is known that the A2M-P complex is removed by cells of the
reticulo-endothelial system following exposure of the receptor recognition
site on the A2M molecule. The interaction of A2M-P and macrophages is
therefore important from the aspect of removing A2M-P from the circulation,
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but it may also be an important mechanism of immune cell suppression.
Macrophages are essential for antigen presentation in immune recognition
and may suppress or augment the immune response of lymphocytes
(Section 1.2). Thus, it is possible that macrophages are a second target
site for A2M-P, in addition to lymphocytes as demonstrated in this study.
It is also attractive to link two apparent functions of macrophages
clearance of A2M-P and initiation of immune suppression as a result of
interaction with A2M-P. Such a mechanism would act as its own inhibitory
feedback loop by reducing immune reactivity and hence protease release from
immune cells. However, with an additional source of proteases
(e.g. release from a tumour) the feedback loop would be 'overloaded' and
excessive or pathological immune inhibition would occur, as demonstrated by
the present work.
Of particular interest to the present work are the studies by
Remold et al^5,26^ who examined the effect of plasma enzyme inhibitors,
including A2M, on the responses of guinea pig macrophages to migration
inhibition factor (MIF), a lymphokine which inhibits the migratory movement
of macrophages. Remold found that the plasma esterase inhibitors A2M,
alpha-l-antitrypsin, Cl-inhibitor, antithrombin-heparin co-factor and
soybean trypsin inhibitor enhanced responses of guinea pig macrophages to
the action of MIF at physiological concentrations when cells were pre-
incubated with the inhibitors before addition of MIF; the inhibitors
themselves did not alter macrophage migration. Remold^2®) concluded that
the presence of serine esterases on the macrophage surface indicated that
either they were inactivators of MIF or they participated in enzymatic
interactions which resulted in activation of macrophages. Thus, it would
appear that protease inhibitors, such as A2M, have an in vitro function in
the regulation of macrophage activities by a complex interaction with
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lymphokines and their inhibitors. If, for example, protease inhibitors
(A2M) came into contact with macrophages at an inflammatory site or site at
which an immunological response occurred then the macrophage response to
lymphokines could be increased and the functional response of macrophages
heightened. Remold's studies(25•26) indicate that A2M and similar plasma
protease inhibitors have an influence on macrophages via lymphokine
activity. The failure of A2M to influence macrophage migration could be
because A2M does not have such a physiological role, or because the A2M
used in the experiments was in the electrophoretically slow or non-
complexed form.
A2M may influence other immune cells in addition to lymphocytes and
macrophages. NK cell activity is impaired following interaction with
proteases and so A2M would be expected to benefit NK activity. However, it
is unknown whether the affinity of proteases for A2M is greater than for
protease - sensitive sites on NK cells, and whether NK activity can be
restored by PPI. Similarly, the effect of complexed A2M-P (as opposed to
free A2M) on NK cells is not known, but the effect may be one of inhibition
if the postulate of a local negative feedback mechanism is correct.
It is clear, then, that the biological behaviour of A2M may vary,
depending on production of proteases. The A2M-P complexes are removed
rapidly from plasma by reticulo-endothelial cells and hepatocytes
(Section 1.5.8), although A2M levels in plasma were not significantly
different in cancer patients and control subjects. Thus, A2M must be
replenished as rapidly as it is removed, indicating that in patients
suffering from conditions associated with the presence of the
immunosuppressive form of A2M (A2M-P, the electrophoretically fast form of
A2M), the turnover of A2M must be increased rapidly. This postulate is
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supported by studies of patients with minor burns, showing significantly
increased A2M turnover but normal serum concentrations^1") . if formation
and removal of A2M-P complexes occurs at a rate faster than the provision
of non-complexed A2M, then eventually all available A2M will be in the form
of A2M-P and a maximal level of inhibitory activity due to A2M will be
achieved. As A2M levels remain approximately constant in all individuals,
the removal of A2M-P must in someway provide a stimulus to the formation
of uncomplexed A2M and increase A2M turnover.
6.5.2 SMALL MOLECULAR WEIGHT PEPTIDE FRACTION
It has been proposed that combination of A2M with proteases causes
or requires cleavage of a small MW peptide from the A2M molecule(183'184).
The function of this peptide is unknown, although Hubbard(208) postulated
that it could act as a messenger rather than being expended after breaking
from the parent molecule. The most obvious function would be related to
control of protease production, i.e. the peptide could have a role in
feedback inhibition of immune responses, which may have led to protease
release initially. Such an action would increase the immunosuppressive
effect of the A2M-P interaction which generates not only the
electrophoretically fast form of A2M but an immunosuppressive peptide. The
present study has not confirmed this propostion directly but has provided
supportive evidence consistent with the postulate. Region 6 had a MW range
of less than 50,000 daltons, and had considerable SA against autologous and
healthy allogeneic lymphocytes when the region was derived from patients
with cancer or who were malnourished. As discussed above, cancer plasma
contained highly suppressive A2M (A2M complexed with proteases), and the
detection of a small MW peptide fraction with SA is consistent with the
postulates of Barrett et al^183,184) and Hubbard^208), and could have been
301
predicted from the results obtained from studying region 3 (Section 3.8).
The present study has demonstrated an association between an A2M moiety
with strong inhibitory activity and a small MW peptide region with
lymphocyte inhibitory activity. Further studies performed in our
laboratory have shown that this peptide fraction liberated by A2M following
interaction with protease does not affect NK cell activity against K562
erythroleukaemic cells or ADCC against Chang liver cell targets(383).
6.5.3 IMMUNE COMPLEXES
Immune complexes (IC) were detected only in plasma from cancer
patients and had SA against autologous and healthy allogeneic lymphocytes.
Further studies of the specificity of antibodies and the nature of antigens
comprising these IC were beyond the scope of this thesis, but, on the basis
of the evidence reviewed (Section 1.5.7(a)), it is reasonable to assume
that IC were formed from anti-tumour antibodies and tumour antigens. The
finding that IC had lymphocyte SA provides further evidence that tumour
antigens and their specific antibodies may be beneficial to a tumour by
causing lymphocyte suppression. Antigen shedding (Section 1.5.3(b)) helps
malignant cells evade immune destruction by preventing attachment of immune
cells and antibodies to surfaces of malignant cells, by producing high
concentrations of antigen locally and thereby "mopping up" anti-tumour
antibody, by reducing tumour cell immunogenicity, and in some cases by
their own inherent immunosuppressive activity. Antibodies may aid tumours
by masking antigenic sites from immune detection and encouraging antigenic
modulation. The present study has identified a further mechanism: antigen
shedding and combination with antibody leads to the formation of complexes
which can circulate freely and inhibit the reactivity of lymphocytes. The
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amount of SA associated with IC was relatively small but nevertheless it
contributed to reduce lymphocyte responsiveness.
IC were detected in all cancer patients analysed in detail in this
study. Others^145) have demonstrated IC in the majority of cancer
patients. Thus, it appears a characteristic of solid tumours that they
shed surface antigens, which combine with host factors hostile to them to
produce substances which reduce the efficiency of the host's anti-tumour
response. The formation of IC can be seen as a mechanism which aids the
immunological escape of tumours.
It is now clear that NK cells have a complex immune function in
addition to their cytotoxic activity. An NK cell subset has been shown to
inhibit B cell production of immunoglobulin, an effect which can be
abrogated by complement-mediated lysis of NK cells(407) . Modulation of the
Fc receptor of NK cells by IC greatly increases inhibition of the antibody
response while at the same time decreasing cytotoxicity against standard
targets of NK cell activity^408). Hence, IC are able to reduce the
activity of cells with inherent cytotoxicity against cancer cells, a
property which may be of direct benefit to cancer cells.
6.5.4 Fc FRAGMENTS
Fc fragments of IgG in the low MW fraction of plasma from cancer
patients have been shown to possess non-specific lymphocyte inhibitory
activity. The specificity of the immunoglobulin from which the Fc
fragments were derived is not known, but the reviewed evidence
(Sections 1.4.2 and 1.5.7) indicates that IgG-Fc could have been derived
from anti-tumour antibodies as a result of the action of tumour surface-
associated protease enzymes(142). Splitting tumour-associated IgG in this
way would leave the Fab portion of the molecule attached to and obscuring
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antigenic determinants on the tumour cell surface and render ineffective
any method of tumour cell destruction which relied on an intact antibody
molecule, such as ADCC and CDL. In addition, free Fc fragments could
attach to Fc receptors on the surface of tumour cells and could possibly
interfere with binding of anti-tumour antibodies.
Lymphocytes, macrophages, polymorphonuclear leukocytes and NK cells
have surface receptors for Fc. Their precise role in some instances is
uncertain, but it is clear that blockade of these surface receptors can
interfere with cellular functions(87). This has been confirmed by the
present study which has shown that Fc fragments impair lymphocyte
reactivity to antigenic and mitogenic stimuli. Fc fragments could inhibit
or regulate other immune activities as well, for example, the Fc moiety of
IC is responsible for inactivation of antigen-sensitive B lymphocytes^407^.
Thus, detection of Fc fragments with non-specific SA can be
interpreted as a further mechanism of immunological escape. Not only is
the tumour cell able to cleave "anti-tumour" immunoglobulin but one of the
cleavage products confers advantage on the tumour cell by reducing the
function of the key cell in the immune system.
6.6 HYPOTHESES
The experimental work has confirmed the hypotheses stated in
Section 1.8. The first hypothesis, that malignant disease is associated
with non-specific immunosuppressive factors, has been confirmed by
demonstrating that plasma from cancer patients inhibits the reactivity of
autologous and healthy allogeneic lymphocytes to antigenic and mitogenic
stimulation. The animal experiments showed that PSA increased with tumour
growth and decreased following tumour removal, indicating that PSA was
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related directly to the presence of tumour tissue. The central role of A2M
in immune regulation has been demonstrated by detailed analysis of plasma
samples. The ability of A2M to change its biological behaviour has been
inferred by comparison of the immunosuppressive activity of A2M in the
various subject groups; studies of A2M and in vitro combination with
protease, and of the immunosuppressive ability of the A2M-P complex, will
further support the hypothesis. The non-specific nature of the role of A2M
has been highlighted by finding that A2M had SA in all subjects and that it
was highly suppressive in all cancer patients irrespective of site or stage
of their primary disease.
The study has shown that malnutrition in hospitalised patients with
benign or malignant disease is associated with increased PSA, which is due
largely to the increased immunosuppressive activity of A2M, and has
confirmed the second hypothesis. In addition, a new functional method of
immunological assessment of malnourished subjects with benign disease has
been defined by the demonstration of a strong, statistically significant
correlation between PSA and conventional methods of nutritional
assessement. The third hypothesis, that TPN fluids containing fat
emulsions will affect immune function adversely, has been proven by
examining lymphocyte reactivity after in vivo and in vitro addition of fat-
free and fat-containing intravenous fluids. The clinical implications of
these observations cannot be ascertained from the present work.
Six experimental aims were given in Section 1.8. The experiments
have fulfilled these aims, although the fifth objective, namely assessment
of the relationship between SA of plasma and tumour growth in an animal
model has not been investigated thoroughly. This is due largely to the
nature of the animal model and the use of blood transfusion to induce high
PSA (Section 5.5). The experiments reported in Chapter 5 are of great
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interest, but strictly speaking, were not able to provide an answer as to
the value of high PSA to tumour growth. Better design of the experiment
could have provided data of greater relevance, although if the blood
transfusion model had not been used, a fascinating area of tumour research
might not have become apparent (viz., the influence of blood transfusion on
tumour growth).
6.7 CONCLUSION
A2M, IC, Ig - Fc and small MW fragments have lymphocyte SA in
cancer patients. These substances or the parent molecules are produced by
the interaction of the host with a tumour. Some are released from tumour
cell surfaces (proteases, antigens, immunoglobulins), and so, logically,
local concentrations of complexed A2M (A2M-P), IC, Fc fragments and
peptides would be greater than concentrations in peripheral blood, and
although the plasma of cancer patients is suppressive, it is likely that
the immediate micro-environment of a tumour is many times more suppressive.
Such a situation would allow the tumour to proliferate in the presence of a
specific immune response: circulating PB immune cells would still exhibit
specific responses to tumour extracts and maintain their reactivity
(although perhaps somewhat reduced), but those cells within the local
environment of the tumour would be paralysed by the relatively high
concentration of naturally occurring immunosuppressive factors. The
concept is supported by the studies of Holmes(96) who demonstrated that the
immune cells obtained from within tumours had a marked "functional
paralysis" in comparison with PB cells in cancer patients. Thus, the study
of naturally occurring immunosuppressive substances provides an explanation
for the apparent paradox of tumour growth in the presence of specific anti-
306
tumour immune responses .
6.8 FUTURE STUDIES
The present study has set a foundation for future studies of
suppressive factors in plasma. Few research projects produce complete
answers in themselves but all should give direction to further work related
to their subject.
Future studies should investigate the suppressive effects of plasma
in other assays of immunological function - in particular, assays of
B lymphocyte activity, other assays of lymphocyte activity (such as
transformation), NK cell activity, ADCC and T lymphocyte cytotoxicity, as
well as macrophage and polymorphonuclear leucocyte activity. Also, A2M
should be obtained from other groups of patients with high and low SA and
its activity measured in these assay systems. It has been suggested in
this thesis that A2M turnover in patients with high PSA may be increased,
and clearly this needs to be verified. It appears that the A2M-P complex
is a highly immunosuppressive substance and this requires confirmation in
other in vitro and in vivo systems.
Undoubtedly, identification of a naturally occurring
immunosuppressive peptide in a number of diverse clinical conditions is an
exciting observation. The range of activity of the peptide, its chemical
composition and purification are being studied currently by others in the
laboratory. The value of this peptide as an immunosuppressant must be
investigated in animal models, with research being directed towards its
possible use as a clinical immunosuppressive agent. Obviously, a
considerable amount of work remains to be done before clinical use can be
contemplated seriously, but even now the advantages of a naturally
occurring immunosuppressive agent in terms of toxicity, activity and
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availability are apparent. The other components of region 6, the small MW
region of plasma, require definition as other immunosuppressive substances
are present within this region and might be suitable for clinical or
experimental purposes. It is conceivable that these naturally occurring
substances could have a role in manipulating immune responses in
circumstances in which they are required for short periods of time
(e.g. exacerbations of auto-immune diseases, acute rejection of organ
allografts or in the treatment of graft versus host disease following bone
marrow transplantation).
It has been suggested that PSA could be used as an indicator of
malignant disease in adequately nourished subjects. This proposal could be
tested by measuring PSA in large populations of patients with malignant and
non-malignant disorders. Large scale testing would require automation of
the TEEM test technique, but is essential to determine the specificity and
sensitivity of the test and its value in clinical practice.
The animal experiments indicate that PSA could be of prognostic
value. The relevance of these studies to humans is unknown at present. A
prospective study has been set up in the Department of Surgery, University
of Newcastle-upon-Tyne, to measure PSA sequentially in patients before and
after 'curative' surgery for malignant disease of the stomach, pancreas,
colon, rectum and breast. Even after years of apparently good health
following cancer surgery, some patients die of disseminated malignancy and
any study assessing the value of a 'marker' of malignant disease must be
extended over a long period of time before conclusions can be stated with
confidence. However, such a study is essential to define the clinical
significance of PSA, if any. Similarly, the use of PSA as a nutritional
index requires further evaluation before it is of value in assessment of
308
malnutrition; it is essential to sequentially observe PSA in subjects
receiving nutritional therapy, and to establish clinical correlates with
changes in lymphocyte reactivity, PSA and A2M behaviour if they are to be
accepted as contributing to patient management.
Perhaps the most important studies will be those involving the
therapeutic manipulation of A2M in cancer patients. If the
immunosuppressive effects of A2M and other naturally occurring substances
can be decreased or the substances themselves reduced quantitatively, then
it is likely that the immune system of cancer patients will be better able
to detect and eliminate malignant tumours. Further work is needed to
identify mechanisms to achieve this, especially within the micro-enviroment
of tumours. Perhaps removal of proteases and other CN-SIF by processes
akin to dialysis or plasmapheresis could be used in conjunction with
conventional cytoreductive therapy. Alternatively, use of synthetic agents
which compete with A2M for proteases would reduce the A2M-P load and reduce
local and systemic tumour-associated immune depression.
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APPENDICES
APPENDIX 1: CLINICAL STAGING OF THE MALIGNANT DISEASES
Clinical staging of breast cancer
Stage T N M
1 1,2 0 0
2 1,2 1 0
3 1-4 2,3 0
4 1-4 0-3 1
Clinical staging of gastric, pancreatic, colonic and rectal cancers
Stage T N M
1 1,2 0 0
2 3,4 0 0
3 1-4 1-3 0
4 1-4 1-3 1
APPENDIX 2: ALSEVERS MEDIUM
1. Dextrose 20.5 g/1
2. Sodium citrate 8.0 g/1
3. Sodium chloride 4.2 g/1
Dissolved in 1.0 litre of deionised water
APPENDIX 3: STAVITSKY'S PHOSPHATE BUFFERED SALINE (PBS)
1. KH2P04 20.41 g/1 (0.15 M)
2. Na2HP04 21.29 g/1 (0.15 M)
Add 119.5 ml 0.15 M KH2P04
380 ml 0.15 M Na2HP04
29.2 g NaCl
500 ml deionised water
Adjusted to pH 7.2
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APPENDIX 4: HANK'S BALANCED SALT SOLUTION (BSS)
1. Na2HP04 0.06 g
2. MgS04 . 7H20 0.2 g
3. KC1 0.4 g
4. NaCl 8.0 g
5. CaCl2 0.14 g
6. KH2P04 0.06 g
7. NaHC03 0.35 g
Dissolved in 1.0 litre of deionised water
APPENDIX 5: TRIS-BUFFER USED FOR GEL FILTRATION COLUMN CHROMATOGRAPHY
1. Tris-hydroxy-methyl-methylamine 12.114 g
2. Sodium chloride 9.0 g
3. Sodium azide 2.0 g
Dissolved in 1.0 litre of deionised water
Adjusted to pH 7.4
APPENDIX 6: DETAILS OF GEL FILTRATION CHROMATOGRAPHY
Gel: Ultrogel AcA 22 (LKB - Produkter AB, Sweden)
Column dimensions: 2.5 cm x 95 cm
Cross-sectional area: X r2 = 3.1415 x (1.25)2 = 4.90 cm2
Gel height: 82 cm
Gel bed volume: 402.5 cm2 (863s of column volume)
Buffer: Tris-hydroxy-methyl-methylamine, pH 7.4, 0.1 M
Packing flow rate: 17.0 cm3 per hour
Fractionation flow rate: 15.0 cm3 per hour
Void volume: 100 - 115 ml (the first 20 -23 fractions)
Fraction volume: 5 ml
Fractions collected: 100
Time for collection of one fraction: 20 minutes
Time for complete separation of plasma sample: 33 1/3 hours
Paper speed of chart recorder: 2 cm per hour
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APPENDIX 7: TRIS-BARBITONE BUFFER (TBB) USED FOR IMMUNOELECTROPHORESIS
STUDIES
1. Tris-hydroxy-methyl-methylamine 44.3 g
2. Sodium barbitone 22.4 g
3. Sodium azide 2.0 g
Dissolved in 1.0 litre of deionised water to produce the stock solution
Adjusted to pH 8.6
Diluted for use with deionised water: buffer + deionised water =1+4
APPENDIX 8: COOMASIE BRILLIANT BLUE SOLUTION
1. Coomasie brilliant blue 5.0
2. Ethanol






1. Ethanol 96% 250 ml
2. Glacial acetic acid 100 ml
3. Deionised water 450 ml
APPENDIX 10: DILUTIONS OF STANDARD REFERENCE PROTEINS AND TEST SERA IN
SINGLE ROCKET ELECTROPHORESIS EXPERIMENTS
Standard proteins
















APPENDIX 11: WALPOLES ACETATE BUFFER
1. Acetic acid 12.0 g/1 (0.2 molar)
2. Sodium acetate 16.4 g/1 (0.2 molar)
Add 44.0 ml of 0.2 M acetic acid
and 6.0 ml of 0.2 M sodium acetate
Adjusted to pH 4.0
APPENDIX 12: CLARK - LUBBS BORATE BUFFER
Solution A
1. Boric acid 6.2 g/1
2. Potassium chloride 7.4 g/1
Solution B
1. Sodium hydroxide 4.0 g/1
Add 50 ml solution A
and 8.5 ml solution B
and 41.5 ml deionised water
Adjusted to pH 8.0




n mean + 1SD
A 30 19.07 + 0.33
B 31 19.15 + 0.60
C 52 19.24 0.78





































































APPENDIX 15: RATE OF TRIGLYCERIDE INFUSION
Infusion rate = 667 ml of 20% Intralipid/day
= 667 ml of 20 g triglyceride/100 ml/day
667 ml of 200 mmol triglyceride/100 ml/day
133.4 mmol triglyceride/day
0.0926 mmol triglyceride/minute
Mean body weight of subjects in group 3 = 64.9 kg
Plasma volume = 43 ml/kg body weight
2.79 litres
Mean increase in plasma triglyceride
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